Submitted URL: http://link.email.empr.com/a/1323/click/66409/2303653/c2e48e4d0c138c0bc1f20aac0a4e1779450f119e/c0822cd9595ecb14dc0410d26b5c...
Effective URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_sour...
Submission: On September 05 via api from US

Summary

This website contacted 47 IPs in 7 countries across 36 domains to perform 240 HTTP transactions. The main IP is 3.225.154.29, located in Ashburn, United States and belongs to AMAZON-AES - Amazon.com, Inc., US. The main domain is www.empr.com.
TLS certificate: Issued by RapidSSL RSA CA 2018 on January 16th 2019. Valid for: 2 years.
This is the only time www.empr.com was scanned on urlscan.io!

urlscan.io Verdict: No classification

Domain & IP information

IP Address AS Autonomous System
1 2 35.238.92.4 15169 (GOOGLE)
34 3.225.154.29 14618 (AMAZON-AES)
24 94.31.29.64 33438 (HIGHWINDS2)
3 2a00:1450:400... 15169 (GOOGLE)
1 93.184.220.113 15133 (EDGECAST)
5 2a00:1450:400... 15169 (GOOGLE)
4 52.217.38.6 16509 (AMAZON-02)
1 2a00:1450:400... 15169 (GOOGLE)
1 2600:9000:205... 16509 (AMAZON-02)
4 2a00:1450:400... 15169 (GOOGLE)
10 216.58.210.2 15169 (GOOGLE)
5 2a00:1450:400... 15169 (GOOGLE)
1 2606:4700::68... 13335 (CLOUDFLAR...)
1 6 2a00:1450:400... 15169 (GOOGLE)
1 13.32.158.202 16509 (AMAZON-02)
1 4 23.5.97.37 16625 (AKAMAI-AS)
3 2a03:2880:f01... 32934 (FACEBOOK)
2 2 52.206.48.92 14618 (AMAZON-AES)
2 2 35.227.248.159 15169 (GOOGLE)
1 34.225.65.223 14618 (AMAZON-AES)
1 13.32.220.210 16509 (AMAZON-02)
67 2606:4700:20:... 13335 (CLOUDFLAR...)
1 34.192.84.248 14618 (AMAZON-AES)
1 13.35.253.105 16509 (AMAZON-02)
4 52.3.171.116 14618 (AMAZON-AES)
2 8 34.247.144.106 16509 (AMAZON-02)
3 2a03:2880:f11... 32934 (FACEBOOK)
1 54.208.174.93 14618 (AMAZON-AES)
1 1 104.111.241.32 16625 (AKAMAI-AS)
2 2 35.190.72.21 15169 (GOOGLE)
2 2 2.18.233.201 16625 (AKAMAI-AS)
1 1 52.215.211.56 16509 (AMAZON-02)
2 3 18.185.83.216 16509 (AMAZON-02)
2 35.227.192.113 15169 (GOOGLE)
1 52.71.111.112 14618 (AMAZON-AES)
4 35.172.78.117 14618 (AMAZON-AES)
4 34.197.62.58 14618 (AMAZON-AES)
4 2600:9000:20b... 16509 (AMAZON-02)
2 143.204.214.75 16509 (AMAZON-02)
1 52.1.34.120 14618 (AMAZON-AES)
6 2a00:1450:400... 15169 (GOOGLE)
4 2600:1f14:e96... 16509 (AMAZON-02)
1 2 2a00:1450:400... 15169 (GOOGLE)
1 4 2600:1f14:e96... 16509 (AMAZON-02)
2 7 2600:1f14:e96... 16509 (AMAZON-02)
1 54.184.16.121 16509 (AMAZON-02)
1 4 2600:1f14:e96... 16509 (AMAZON-02)
2 35.160.22.135 16509 (AMAZON-02)
1 34.219.144.108 16509 (AMAZON-02)
1 18.200.54.67 16509 (AMAZON-02)
1 54.194.184.41 16509 (AMAZON-02)
1 1 2a00:1450:400... 15169 (GOOGLE)
1 2a00:1450:400... 15169 (GOOGLE)
240 47
Apex Domain
Subdomains
Transfer
69 lytics.io
c.lytics.io
api.lytics.io
82 KB
34 empr.com
link.email.empr.com
www.empr.com
3 MB
24 netdna-ssl.com
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
248 KB
23 b2c.com
api.b2c.com
api-54-184-16-121.b2c.com
api-35-160-22-135.b2c.com
api-34-219-144-108.b2c.com
28 KB
11 doubleclick.net
securepubads.g.doubleclick.net
stats.g.doubleclick.net
103 KB
9 ml314.com
ml314.com
in.ml314.com
17 KB
9 haymarketmedia.com
accounts.haymarketmedia.com
subapi.haymarketmedia.com
adtrackapi.haymarketmedia.com
12 KB
8 googlesyndication.com
tpc.googlesyndication.com Failed
pagead2.googlesyndication.com
201 KB
6 spotible.com
ads.spotible.com
cdn1.spotible.com
709 KB
6 google-analytics.com
www.google-analytics.com
40 KB
5 gstatic.com
fonts.gstatic.com
65 KB
5 googletagservices.com
www.googletagservices.com
124 KB
4 medtargetsystem.com
www.medtargetsystem.com
53 KB
4 scorecardresearch.com
sb.scorecardresearch.com
3 KB
4 amazonaws.com
s3.amazonaws.com
2 MB
3 eyeota.net
ps.eyeota.net
1 KB
3 facebook.com
www.facebook.com
251 B
3 sitomobile.com
mt.sitomobile.com
sp.sitomobile.com
2 KB
3 facebook.net
connect.facebook.net
119 KB
3 google.com
adservice.google.com
www.google.com
358 B
3 crwdcntrl.net
tags.crwdcntrl.net
sync.crwdcntrl.net
bcp.crwdcntrl.net
12 KB
3 googleapis.com
fonts.googleapis.com
2 KB
2 mathtag.com
pixel.mathtag.com
1 KB
2 rlcdn.com
idsync.rlcdn.com
440 B
2 adsrvr.org
js.adsrvr.org
insight.adsrvr.org
2 KB
2 tapad.com
pixel.tapad.com
545 B
2 google.de
adservice.google.de
www.google.de
280 B
2 maropost.com
content.maropost.com
mpct1.maropost.com
5 KB
1 infectiousdiseaseadvisor.com
www.infectiousdiseaseadvisor.com
1 MB
1 thecardiologyadvisor.com
www.thecardiologyadvisor.com
612 KB
1 deepintent.com
match.deepintent.com
216 B
1 bluekai.com
tags.bluekai.com
856 B
1 alexametrics.com
certify.alexametrics.com
551 B
1 cloudfront.net
d31qbv1cthcecs.cloudfront.net
2 KB
1 crazyegg.com
script.crazyegg.com
28 KB
1 googletagmanager.com
www.googletagmanager.com
34 KB
240 36
Domain Requested by
67 c.lytics.io 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
c.lytics.io
www.empr.com
33 www.empr.com www.empr.com
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
24 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com www.empr.com
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
10 securepubads.g.doubleclick.net www.googletagservices.com
securepubads.g.doubleclick.net
www.empr.com
9 api-35-160-22-135.b2c.com 2 redirects www.empr.com
8 ml314.com 2 redirects www.empr.com
ml314.com
6 tpc.googlesyndication.com securepubads.g.doubleclick.net
6 www.google-analytics.com 1 redirects www.googletagmanager.com
www.google-analytics.com
www.empr.com
5 api-34-219-144-108.b2c.com 1 redirects www.empr.com
5 api-54-184-16-121.b2c.com 1 redirects www.empr.com
5 fonts.gstatic.com www.empr.com
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
5 www.googletagservices.com www.empr.com
securepubads.g.doubleclick.net
4 api.b2c.com securepubads.g.doubleclick.net
www.empr.com
4 adtrackapi.haymarketmedia.com s3.amazonaws.com
4 ads.spotible.com www.empr.com
ads.spotible.com
4 subapi.haymarketmedia.com s3.amazonaws.com
4 www.medtargetsystem.com www.empr.com
www.medtargetsystem.com
4 sb.scorecardresearch.com 1 redirects www.googletagmanager.com
www.empr.com
4 s3.amazonaws.com www.empr.com
3 ps.eyeota.net 2 redirects www.empr.com
3 www.facebook.com www.empr.com
connect.facebook.net
3 connect.facebook.net www.empr.com
connect.facebook.net
3 fonts.googleapis.com www.empr.com
s3.amazonaws.com
2 pagead2.googlesyndication.com www.empr.com
2 www.google.com 1 redirects securepubads.g.doubleclick.net
2 cdn1.spotible.com www.empr.com
2 api.lytics.io c.lytics.io
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
2 pixel.mathtag.com 2 redirects
2 idsync.rlcdn.com 2 redirects
2 pixel.tapad.com 2 redirects
2 mt.sitomobile.com 2 redirects
1 www.google.de
1 stats.g.doubleclick.net 1 redirects
1 insight.adsrvr.org js.adsrvr.org
1 bcp.crwdcntrl.net tags.crwdcntrl.net
1 www.infectiousdiseaseadvisor.com www.empr.com
1 www.thecardiologyadvisor.com www.empr.com
1 match.deepintent.com www.empr.com
1 sync.crwdcntrl.net 1 redirects
1 tags.bluekai.com 1 redirects
1 in.ml314.com ml314.com
1 certify.alexametrics.com www.empr.com
1 accounts.haymarketmedia.com 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
1 mpct1.maropost.com content.maropost.com
1 js.adsrvr.org www.googletagmanager.com
1 sp.sitomobile.com www.empr.com
1 d31qbv1cthcecs.cloudfront.net www.empr.com
1 script.crazyegg.com www.googletagmanager.com
1 adservice.google.com www.googletagservices.com
1 adservice.google.de www.googletagservices.com
1 content.maropost.com www.empr.com
1 www.googletagmanager.com www.empr.com
1 tags.crwdcntrl.net www.empr.com
1 link.email.empr.com 1 redirects
240 54
Subject Issuer Validity Valid
*.empr.com
RapidSSL RSA CA 2018
2019-01-16 -
2021-01-15
2 years crt.sh
*.netdna-ssl.com
Sectigo RSA Domain Validation Secure Server CA
2019-02-18 -
2020-02-27
a year crt.sh
*.googleapis.com
GTS CA 1O1
2019-08-13 -
2019-11-11
3 months crt.sh
tags.crwdcntrl.net
DigiCert SHA2 Secure Server CA
2019-03-15 -
2021-04-07
2 years crt.sh
*.g.doubleclick.net
GTS CA 1O1
2019-08-13 -
2019-11-11
3 months crt.sh
s3.amazonaws.com
DigiCert Baltimore CA-2 G2
2018-12-03 -
2019-10-25
a year crt.sh
*.google-analytics.com
GTS CA 1O1
2019-08-13 -
2019-11-11
3 months crt.sh
content.maropost.com
Amazon
2018-10-25 -
2019-11-25
a year crt.sh
*.google.com
GTS CA 1O1
2019-08-13 -
2019-11-11
3 months crt.sh
ssl945600.cloudflaressl.com
COMODO ECC Domain Validation Secure Server CA 2
2019-08-20 -
2020-02-26
6 months crt.sh
*.cloudfront.net
DigiCert Global CA G2
2019-07-17 -
2020-07-05
a year crt.sh
*.scorecardresearch.com
COMODO RSA Organization Validation Secure Server CA
2018-11-28 -
2019-12-26
a year crt.sh
*.facebook.com
DigiCert SHA2 High Assurance Server CA
2019-08-24 -
2019-10-19
2 months crt.sh
*.sitomobile.com
RapidSSL RSA CA 2018
2018-01-22 -
2020-07-29
3 years crt.sh
*.adsrvr.org
Trustwave Organization Validation SHA256 CA, Level 1
2019-03-07 -
2021-04-19
2 years crt.sh
*.maropost.com
Go Daddy Secure Certificate Authority - G2
2019-06-10 -
2021-08-09
2 years crt.sh
ssl379818.cloudflaressl.com
COMODO ECC Domain Validation Secure Server CA 2
2019-07-26 -
2020-02-01
6 months crt.sh
accounts.haymarketmedia.com
Amazon
2018-10-26 -
2019-11-26
a year crt.sh
certify.alexametrics.com
Amazon
2019-07-26 -
2020-08-26
a year crt.sh
medtargetsystem.com
Amazon
2018-11-23 -
2019-12-23
a year crt.sh
*.ml314.com
Amazon
2019-03-16 -
2020-04-16
a year crt.sh
*.eyeota.net
Let's Encrypt Authority X3
2019-07-11 -
2019-10-09
3 months crt.sh
*.lytics.io
RapidSSL TLS RSA CA G1
2018-01-26 -
2020-01-06
2 years crt.sh
*.deepintent.com
Go Daddy Secure Certificate Authority - G2
2018-06-08 -
2020-06-08
2 years crt.sh
subapi.haymarketmedia.com
Amazon
2019-06-28 -
2020-07-28
a year crt.sh
*.spotible.com
Go Daddy Secure Certificate Authority - G2
2016-10-16 -
2019-11-06
3 years crt.sh
adtrackapi.haymarketmedia.com
Amazon
2019-03-27 -
2020-04-27
a year crt.sh
*.thecardiologyadvisor.com
RapidSSL RSA CA 2018
2019-02-20 -
2020-02-20
a year crt.sh
*.infectiousdiseaseadvisor.com
RapidSSL RSA CA 2018
2019-02-20 -
2020-02-20
a year crt.sh
tpc.googlesyndication.com
GTS CA 1O1
2019-08-13 -
2019-11-11
3 months crt.sh
*.b2c.com
Amazon
2019-03-24 -
2020-04-24
a year crt.sh
www.google.com
GTS CA 1O1
2019-08-13 -
2019-11-11
3 months crt.sh
*.crwdcntrl.net
Go Daddy Secure Certificate Authority - G2
2019-06-13 -
2021-06-28
2 years crt.sh
www.google.de
GTS CA 1O1
2019-08-13 -
2019-11-11
3 months crt.sh

This page contains 11 frames:

Primary Page: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Frame ID: 2E89357A3DA5B25335ED882B6592D542
Requests: 207 HTTP requests in this frame

Frame: https://www.medtargetsystem.com/beacon/portal/?_url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F&_sid=5b8d02b7-f158-41e3-9fba-b2cbf1939026&_vid=453ff3a7-f142-4d71-811b-f39fbf2222f3&_ak=35-212-8F62AC13&_flash=false&_th=1567665654|1567665654|1
Frame ID: EFFA2FE37CA1C8160C305148D1D517DA
Requests: 1 HTTP requests in this frame

Frame: https://api.lytics.io/api/me/iframe/43bffbce6f25564c8e2145a11836ff9f/_uid/5ddcc1786c2a1805c3a82d291451ce42?segments=true&mergestate=true&ts=1567665654943
Frame ID: 78A0DBB7AE60E74D87D5F560EC66E9A3
Requests: 1 HTTP requests in this frame

Frame: https://www.facebook.com/tr/
Frame ID: AFAC11CDDA5BDE0FF0D6F9EE8E57E96B
Requests: 1 HTTP requests in this frame

Frame: https://www.facebook.com/tr/
Frame ID: 82D2573D6DD91595835F07B8D4BA6787
Requests: 1 HTTP requests in this frame

Frame: https://ads.spotible.com/tag/universal-tag.js
Frame ID: F0368126154B893F0CBBFEED7D357CC8
Requests: 2 HTTP requests in this frame

Frame: https://securepubads.g.doubleclick.net/pcs/view?xai=AKAOjstafsrw89xAr1SULU3OgtW8AFIlb7-P1kyx7T3_jGmidkpJz0jUlqTD2i3IbgC8Jsv6OirxEvM06HgpIRK2Pu2b5WCvwjl3CwyuuUggf4ZanJS2AEdXq_lPQKzo7ZHnFwxZoSzgjGTrfd9C1bzxcYnROzTOKK5nM624z7ER_jvo4oJwF8lMqZDb-Maecx_frNTW0I3zUBDoqOmwUFBagxkPYw8VcQFzguZukd1bs1PRKX_aenCrmJ7wxsLBRTGZw9pebOA7s326AcHoEsYQQxT9FZI&sai=AMfl-YST78OzqQ8AOoavY5sFrl9bQp3BfV5mmdfjyh9ZORO5CO0vdcZMIQLK4ScbYRY1ynutYGCY6YVsDEZhbwZr-Gv7qKKjPoIUc07zn3Uljw&sig=Cg0ArKJSzC_BVmAD0r1PEAE&adurl=
Frame ID: 45FFAE89665AC8236E828E3A480841A0
Requests: 11 HTTP requests in this frame

Frame: https://securepubads.g.doubleclick.net/pcs/view?xai=AKAOjssZw4qbjnhrGnHl5kmoFButqZJRw-SiW23K2b8AdA_eOtAPjp8BDOlIRPE8KEFrFzKIB5fQ6GAXB1GxAw5kOGMEEdKrGzz5x5sl-6DeWsLhAG3U7upAgy4lhxa4s7snqChlHH6cQ3c1Jh-pk9dSx3rYW0345kblkiY3gEoAo52Jy5LVyYy9lRhTQNIE4ShGPEnF6n7givCQDz9xcYxXBkGtt2cVlfmO3Co3_V0Vorw5kaR7mmq850xeIfXgBlpQlze6epCOCOG3&sig=Cg0ArKJSzDd3wzYxlaouEAE&adurl=
Frame ID: 7ABAF2EE0F5FE65EC707F4BBBD6523D1
Requests: 11 HTTP requests in this frame

Frame: https://securepubads.g.doubleclick.net/pcs/view?xai=AKAOjsshMeFRAHxbB497GiiQC7KDZaz_16puvICoRQeJXe3xH4FTeVdEdnsFB1_IL0wjH1La2_IU-na9TsUMXmS1mzNFyBTV-DZkN7g3m3fkw-DDhQQN_AIVST_PT8lnzuqfH8G78LciUPu7eAt0JWUIXx2lx6wbAWvqvlabxYd2-O-NScVhofdGMIrbqs1sqd2O2z6ngA8tPeNXDV6_D_t_DfM2N7ncekJBagEtgwPhX5JVHeqWMjW6UcSEYAJ_gqQ3oNiomq7nvL_N&sig=Cg0ArKJSzLXInGypNbDKEAE&adurl=
Frame ID: B52CAC033F0C761C8EF768B737925963
Requests: 11 HTTP requests in this frame

Frame: https://bcp.crwdcntrl.net/5/c=14413/rand=231707015/pv=y/ver=1.4/int=%23OpR%2396858%23Total%20Site%20Traffic%20%3A%20www.empr.com/int=%23OpR%2396859%23www.empr.com%20%3A%20Site%20Section%20%3A%20home/int=%23OpR%2396860%23www.empr.com%20%3A%20Site%20Section%20%3A%20home%20%20%3A%20news/int=%23OpR%2397492%23www.empr.com%20%3A%20Site%20Section%20%3A%20home%20%3A%20news%20%3A%20ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/med=%23OpR%2397539%23Article%20Tags%20%3A%20Miscellaneous%20Musculoskeletal%20Disorders%2CMusculoskeletal%20Disorders/rb=%7B%22url%22%3A%22https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653%22%7D/rt=ifr
Frame ID: 65989944DC84154F5018D8A57751D091
Requests: 1 HTTP requests in this frame

Frame: https://insight.adsrvr.org/track/up?adv=wxli9bh&ref=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&upid=7fhq4wn&upv=1.1.0
Frame ID: 77BF2791BBC9A0458BFF998992E8ED1D
Requests: 1 HTTP requests in this frame

Screenshot


Page URL History Show full URLs

  1. http://link.email.empr.com/a/1323/click/66409/2303653/c2e48e4d0c138c0bc1f20aac0a4e1779450f119e/c0822cd9... HTTP 302
    https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-s... Page URL

Detected technologies

Overall confidence: 100%
Detected patterns
  • headers link /rel="https:\/\/api\.w\.org\/"/i

Overall confidence: 100%
Detected patterns
  • headers link /rel="https:\/\/api\.w\.org\/"/i

Overall confidence: 100%
Detected patterns
  • headers link /rel="https:\/\/api\.w\.org\/"/i

Overall confidence: 100%
Detected patterns
  • headers server /nginx(?:\/([\d.]+))?/i

Overall confidence: 100%
Detected patterns
  • script /script\.crazyegg\.com\/pages\/scripts\/\d+\/\d+\.js/i

Overall confidence: 100%
Detected patterns
  • script /\/\/connect\.facebook\.net\/[^\/]*\/[a-z]*\.js/i

Overall confidence: 100%
Detected patterns
  • script /google-analytics\.com\/(?:ga|urchin|analytics)\.js/i

Overall confidence: 100%
Detected patterns
  • html /googletagmanager\.com\/ns\.html[^>]+><\/iframe>/i
  • html /<!-- (?:End )?Google Tag Manager -->/i

Page Statistics

240
Requests

100 %
HTTPS

38 %
IPv6

36
Domains

54
Subdomains

47
IPs

7
Countries

7920 kB
Transfer

10269 kB
Size

11
Cookies

Page URL History

This captures the URL locations of the websites, including HTTP redirects and client-side redirects via JavaScript or Meta fields.

  1. http://link.email.empr.com/a/1323/click/66409/2303653/c2e48e4d0c138c0bc1f20aac0a4e1779450f119e/c0822cd9595ecb14dc0410d26b5c760172252a25&amp HTTP 302
    https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653 Page URL

Redirected requests

There were HTTP redirect chains for the following requests:

Request Chain 49
  • https://mt.sitomobile.com/sync/ta?aid=136&sid=hmm&val=12 HTTP 302
  • https://pixel.tapad.com/idsync/ex/push?partner_id=2822&partner_url=https%3A%2F%2Fmt.sitomobile.com%2Fsync%2Ftacb%3Fexid%3D%24%7BTA_DEVICE_ID%7D%26aid%3D136%26sid%3Dhmm%26val%3D12 HTTP 302
  • https://pixel.tapad.com/idsync/ex/push/check?partner_id=2822&partner_url=https%3A%2F%2Fmt.sitomobile.com%2Fsync%2Ftacb%3Fexid%3D%24%7BTA_DEVICE_ID%7D%26aid%3D136%26sid%3Dhmm%26val%3D12 HTTP 302
  • https://mt.sitomobile.com/sync/tacb?exid=1c41f211-cfa8-11e9-a5ed-92685282a72d&aid=136&sid=hmm&val=12 HTTP 302
  • https://sp.sitomobile.com/i?tna=sito&p=mob&e=ue&ue_px=eyJzY2hlbWEiOiJpZ2x1OmNvbS5zbm93cGxvd2FuYWx5dGljcy5zbm93cGxvdy91bnN0cnVjdF9ldmVudC9qc29uc2NoZW1hLzEtMC0wIiwiZGF0YSI6eyJzY2hlbWEiOiJpZ2x1OmNvbS5zaXRvbW9iaWxlLnNub3dwbG93L2Nvb2tpZV9zeW5jL2pzb25zY2hlbWEvMS0wLTAiLCJkYXRhIjp7InBhcnRuZXJJZCI6InRhcGFkIn19fQ%3D%3D&cx=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
Request Chain 51
  • https://sb.scorecardresearch.com/b?c1=2&c2=21948019&ns__t=1567665654597&ns_c=UTF-8&c8=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&c7=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&c9= HTTP 302
  • https://sb.scorecardresearch.com/b2?c1=2&c2=21948019&ns__t=1567665654597&ns_c=UTF-8&c8=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&c7=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&c9=
Request Chain 71
  • https://tags.bluekai.com/site/20486?limit=0&id=5978151494658009684&redir=https://ml314.com/csync.ashx%3Ffp=$_BK_UUID%26person_id=5978151494658009684%26eid=50056 HTTP 302
  • https://ml314.com/csync.ashx?fp=h8Q0vx9999eydUO5&person_id=5978151494658009684&eid=50056
Request Chain 72
  • https://idsync.rlcdn.com/395886.gif?partner_uid=5978151494658009684 HTTP 307
  • https://idsync.rlcdn.com/1000.gif?memo=CO6UGBIeChoIARCuXxoTNTk3ODE1MTQ5NDY1ODAwOTY4NBAAGg0I9tvC6wUSBQjoBxAAQgBKAA HTTP 307
  • https://ml314.com/csync.ashx?fp=&person_id=5978151494658009684&eid=50082
Request Chain 73
  • https://pixel.mathtag.com/sync/img?redir=https://ml314.com/csync.ashx%3Ffp=[MM_UUID]%26person_id=5978151494658009684%26eid=50220 HTTP 302
  • https://pixel.mathtag.com/sync/img?redir=https://ml314.com/csync.ashx%3Ffp=[MM_UUID]%26person_id=5978151494658009684%26eid=50220&mm_bnc&mm_bct&UUID=f1105d70-a70e-4300-b780-b092317bc17d HTTP 302
  • https://ml314.com/csync.ashx?fp=f1105d70-a70e-4300-b780-b092317bc17d&person_id=5978151494658009684&eid=50220
Request Chain 74
  • https://sync.crwdcntrl.net/map/c=6985/tp=BOMB?https://ml314.com/csync.ashx%3Ffp%3D%24%7Bprofile_id%7D%26eid%3D50146%26person_id%3D5978151494658009684 HTTP 302
  • https://ml314.com/csync.ashx?fp=d181d062f9136b1a46437f8e5d5c9661&eid=50146&person_id=5978151494658009684
Request Chain 75
  • https://ps.eyeota.net/pixel?pid=r8hrb20&t=gif HTTP 302
  • https://ps.eyeota.net/pixel/bounce/?pid=r8hrb20&t=gif HTTP 302
  • https://ml314.com/utsync.ashx?eid=50052&et=0&fp=2oIyXwjj-X6VZW1iQUtVzwZ0k1V2I2JX7iHWeuvGCrPQ&gdpr=1&gdpr_consent=&return=https%3A%2F%2Fps.eyeota.net%2Fmatch%3Fbid%3Dr8hrb20%26uid%3Dnil HTTP 302
  • https://ml314.com/csync.ashx?fp=2oIyXwjj-X6VZW1iQUtVzwZ0k1V2I2JX7iHWeuvGCrPQ&person_id=5978151494658009684&eid=50052&return=https%3a%2f%2fps.eyeota.net%2fmatch%3fbid%3dr8hrb20%26uid%3dnil HTTP 302
  • https://ps.eyeota.net/match?bid=r8hrb20&uid=nil
Request Chain 225
  • https://api-54-184-16-121.b2c.com/api/x?sEaYTw0KJW1qVIzS$bmF2aWdhdGlvbi10eXBlJDYkbmF2aWdhdGUiLCJnbG9iYWxzLXRpbWUkOSQwLjUzIiwiZ2xvYmFscyQxMCRhMzc1MjVhMyIsImRvY3VtZW50LXRpbWUkMTIkMC42NCIsImRvY3VtZW50JDEzJDljOTc5ODUyIiwiY29ubmVjdGlvbiQxMyQiLCJkb3dubGlua01heCQxMyQiLCJnZXRVc2VyTWVkaWEkMTMkMiIsImNsb2NrJDE3JDM0MjkiLCJiYXR0ZXJ5JDIwJDEgMSAwIEluZmluaXR5IiwiYXVkaW9jb250ZXh0JDIxJGFmZTRmOWM0IiwiaW50ZXJzZWN0aW9uLXNpemUkMjIkMTU4NXgxMjAwIiwiaW50ZXJzZWN0aW9uLWVudGVyJDIyJDAuNXgwIDcyOHgwIiwiaW50ZXJzZWN0aW9uJDIyJDEwMCIsInNvcnQkNzIkMzIuMDc1IiwiZnJhbWVyYXRlJDEyNSQ3MA HTTP 302
  • https://api-54-184-16-121.b2c.com:444/api/4?sEaYTw0KJW1qVIzS
Request Chain 228
  • https://api-35-160-22-135.b2c.com/api/x?gDQiv1XKhstcG1lx$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 HTTP 302
  • https://api-35-160-22-135.b2c.com:444/api/4?gDQiv1XKhstcG1lx
Request Chain 230
  • https://api-34-219-144-108.b2c.com/api/x?ScvvlpZwtOqCJZY7$bmF2aWdhdGlvbi10eXBlJDIkbmF2aWdhdGUiLCJnbG9iYWxzLXRpbWUkNSQwLjQwNSIsImdsb2JhbHMkNSRhMzc1MjVhMyIsImRvY3VtZW50LXRpbWUkNyQwLjU2IiwiZG9jdW1lbnQkNyQ5Yzk3OTg1MiIsImNvbm5lY3Rpb24kNyQiLCJkb3dubGlua01heCQ3JCIsImdldFVzZXJNZWRpYSQ3JDIiLCJjbG9jayQxMSQ1MDUyIiwiYmF0dGVyeSQxNCQxIDEgMCBJbmZpbml0eSIsImludGVyc2VjdGlvbi1zaXplJDE0JDE1ODV4MTIwMCIsImludGVyc2VjdGlvbi1lbnRlciQxNCQwLjV4MCAzMDB4MCIsImludGVyc2VjdGlvbiQxNCQxMDAiLCJhdWRpb2NvbnRleHQkMTUkYWZlNGY5YzQiLCJzb3J0JDUwJDE2LjQ2IiwiZnJhbWVyYXRlJDExNCQ4MA HTTP 302
  • https://api-34-219-144-108.b2c.com:444/api/4?ScvvlpZwtOqCJZY7
Request Chain 237
  • https://www.google-analytics.com/r/collect?v=1&_v=j79&a=927312587&t=event&ni=1&_s=1&dl=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&ul=en-us&de=UTF-8&dt=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&sd=24-bit&sr=1600x1200&vp=1585x1200&je=0&ec=lytics_refresh&ea=undefined&_u=aCjAAAAjQ~&jid=1401154439&gjid=1015605570&cid=1629988481.1567665651&tid=UA-1290429-2&_gid=1250147468.1567665658&_r=1&gtm=2wg8l25XFK9V6&cd20=ga_med_nomycme%2Cga_med_nht_false%2Call%2Cga_med_known&cd21=&cd22=&cd23=&cd24=&cd25=&cd26=&cd27=&cd28=&cd29=&cd30=Normal%20(68%20segments%20found)&z=688796880 HTTP 302
  • https://stats.g.doubleclick.net/r/collect?v=1&aip=1&t=dc&_r=3&tid=UA-1290429-2&cid=1629988481.1567665651&jid=1401154439&_gid=1250147468.1567665658&gjid=1015605570&_v=j79&z=688796880 HTTP 302
  • https://www.google.com/ads/ga-audiences?v=1&aip=1&t=sr&_r=4&tid=UA-1290429-2&cid=1629988481.1567665651&jid=1401154439&_v=j79&z=688796880 HTTP 302
  • https://www.google.de/ads/ga-audiences?v=1&aip=1&t=sr&_r=4&tid=UA-1290429-2&cid=1629988481.1567665651&jid=1401154439&_v=j79&z=688796880&slf_rd=1&random=1803167192
Request Chain 244
  • https://api-35-160-22-135.b2c.com/api/x?sPGeg3fTMwdLiuIi$dGltZS1kb21haW5Mb29rdXBFbmQkNyQyNTAiLCJ0aW1lLWNvbm5lY3RTdGFydCQ3JDI1MCIsInRpbWUtY29ubmVjdEVuZCQ3JDI1MCIsInRpbWUtcmVxdWVzdFN0YXJ0JDckMjUxIiwidGltZS1yZXNwb25zZVN0YXJ0JDckNjI3IiwidGltZS1yZXNwb25zZUVuZCQ3JDYzMCIsInRpbWUtZG9tTG9hZGluZyQ3JDYzNiIsInRpbWUtZG9tSW50ZXJhY3RpdmUkNyQ5MTkiLCJ0aW1lLWRvbUNvbnRlbnRMb2FkZWRFdmVudFN0YXJ0JDckMTQ1NCIsInRpbWUtZG9tQ29udGVudExvYWRlZEV2ZW50RW5kJDckMTQ4NyIsInRpbWUtZG9tQ29tcGxldGUkNyQ0MjM0IiwidGltZS1sb2FkRXZlbnRTdGFydCQ3JDQyMzQiLCJ0aW1lLWxvYWRFdmVudEVuZCQ3JDQyNDMiLCJuYXZpZ2F0aW9uLXJlZGlyZWN0Q291bnQkNyQwIiwibmF2aWdhdGlvbi10eXBlJDckbmF2aWdhdGUiLCJnbG9iYWxzLXRpbWUkMTQkMC44MSIsImdsb2JhbHMkMTQkYTM3NTI1YTMiLCJkb2N1bWVudC10aW1lJDE5JDAuOTc1IiwiZG9jdW1lbnQkMTkkOWM5Nzk4NTIiLCJjb25uZWN0aW9uJDE5JCIsImRvd25saW5rTWF4JDE5JCIsImdldFVzZXJNZWRpYSQxOSQyIiwiY2xvY2skMjUkMzI5NSIsImJhdHRlcnkkMjYkMSAxIDAgSW5maW5pdHkiLCJpbnRlcnNlY3Rpb24tc2l6ZSQyOSQxNTg1eDEyMDAiLCJpbnRlcnNlY3Rpb24kMjkkMjkiLCJhdWRpb2NvbnRleHQkMzEkYWZlNGY5YzQiLCJzb3J0JDU4JDEwLjg0NSIsImZyYW1lcmF0ZSQxMzQkOTAiLCJhZGJsb2NrJDE5NyQw HTTP 302
  • https://api-35-160-22-135.b2c.com:444/api/4?sPGeg3fTMwdLiuIi

240 HTTP transactions

Resource
Path
Size
x-fer
Type
MIME-Type
Primary Request /
www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/
Redirect Chain
  • http://link.email.empr.com/a/1323/click/66409/2303653/c2e48e4d0c138c0bc1f20aac0a4e1779450f119e/c0822cd9595ecb14dc0410d26b5c760172252a25&amp
  • https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_m...
100 KB
22 KB
Document
General
Full URL
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
6ecd0e1420a6ff10cc5ffb6c3b05ff12cd38902568bee252d6dcaaa86d725265

Request headers

:method
GET
:authority
www.empr.com
:scheme
https
:path
/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
pragma
no-cache
cache-control
no-cache
upgrade-insecure-requests
1
user-agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
sec-fetch-site
none
accept-encoding
gzip, deflate, br
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

status
200
server
nginx
date
Thu, 05 Sep 2019 06:40:54 GMT
content-type
text/html; charset=UTF-8
vary
Accept-Encoding Accept-Encoding Accept-Encoding,Cookie,X-WPENGINE-SEGMENT
x-distributor
yes
x-pingback
https://www.empr.com/xmlrpc.php
link
<https://www.empr.com/wp-json/>; rel="https://api.w.org/" <https://www.empr.com/?p=122761>; rel=shortlink
wpe-backend
apache
x-wpe-loopback-upstream-addr
127.0.0.1:6783
x-cacheable
SHORT
cache-control
max-age=600, must-revalidate
x-cache
MISS
x-pass-why
x-cache-group
normal
x-wpengine-segment
NONHT
content-encoding
gzip

Redirect headers

Content-Type
text/html; charset=utf-8
Transfer-Encoding
chunked
Connection
keep-alive
Status
302 Found
Cache-Control
no-cache
X-XSS-Protection
1; mode=block
X-Request-Id
ce8621de-209f-42e2-a168-442dc8d46be3
Location
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
X-Runtime
0.024214
X-Frame-Options
SAMEORIGIN
X-Content-Type-Options
nosniff
Date
Thu, 05 Sep 2019 06:40:53 GMT
Set-Cookie
_session_id=b0fc35301015cf866e82149efff38369; path=/; expires=Thu, 05 Sep 2019 18:40:53 -0000; HttpOnly
X-Powered-By
Phusion Passenger 5.3.4
Server
nginx/1.14.0 + Phusion Passenger 5.3.4
style.min.css
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/css/dist/block-library/
29 KB
5 KB
Stylesheet
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/css/dist/block-library/style.min.css?ver=5.2.2
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
4b8fe5c3d0e5ef7a6582185cbf5c535b5d369c8df1da98c03ed69833e55f474d

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Mon, 22 Apr 2019 12:40:04 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5cbdb624-726f"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
text/css
access-control-allow-origin
*
cache-control
public, max-age=2592000
shared-style.min.css
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/
48 KB
7 KB
Stylesheet
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/shared-style.min.css?ver=1553589230
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
33fe4fe8214760f15a5fdd753b5c396ee5b916e5d6f66f79d4765ed260706723

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5c99e3ee-c05a"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
text/css
access-control-allow-origin
*
cache-control
public, max-age=2592000
style.min.css
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/
240 KB
32 KB
Stylesheet
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/style.min.css?ver=1567085297
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
f1e3884dae2f0ddd32795c0c1ac83e9f9a8c7dce35dbd784bdc3c9872196bb1c

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Thu, 29 Aug 2019 13:28:17 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d67d2f1-3bfb4"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
text/css
access-control-allow-origin
*
cache-control
public, max-age=2592000
css
fonts.googleapis.com/
8 KB
825 B
Stylesheet
General
Full URL
https://fonts.googleapis.com/css?family=Lato:400,400i,700,700i|Roboto+Slab:400,400i,700,700i
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:80b::200a Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
ESF /
Resource Hash
bb4c48e63332f312f4d1945747e9e319247d26592eec54e38fe75eff833eb130
Security Headers
Name Value
Strict-Transport-Security max-age=31536000
X-Frame-Options SAMEORIGIN
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=31536000
content-encoding
br
last-modified
Thu, 05 Sep 2019 06:40:54 GMT
server
ESF
link
<https://fonts.gstatic.com>; rel=preconnect; crossorigin
status
200
date
Thu, 05 Sep 2019 06:40:54 GMT
x-frame-options
SAMEORIGIN
content-type
text/css; charset=utf-8
access-control-allow-origin
*
cache-control
private, max-age=86400, stale-while-revalidate=604800
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
x-xss-protection
0
expires
Thu, 05 Sep 2019 06:40:54 GMT
lytics.min.css
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/
39 KB
3 KB
Stylesheet
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/lytics.min.css?ver=1567085297
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
6944e75951f2e7bf00121eea502e7d952a833e811e13a1f28fb077df6af721f3

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Thu, 29 Aug 2019 13:28:17 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d67d2f1-9de9"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
text/css
access-control-allow-origin
*
cache-control
public, max-age=2592000
css
fonts.googleapis.com/
825 B
466 B
Stylesheet
General
Full URL
https://fonts.googleapis.com/css?family=Bree+Serif&ver=0.1.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:80b::200a Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
ESF /
Resource Hash
19aa6c614f72f6bb67cb17a6169ca551686c2bab5475293c95880f5f32cd830e
Security Headers
Name Value
Strict-Transport-Security max-age=31536000
X-Frame-Options SAMEORIGIN
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=31536000
content-encoding
br
last-modified
Thu, 05 Sep 2019 06:40:54 GMT
server
ESF
link
<https://fonts.gstatic.com>; rel=preconnect; crossorigin
status
200
date
Thu, 05 Sep 2019 06:40:54 GMT
x-frame-options
SAMEORIGIN
content-type
text/css; charset=utf-8
access-control-allow-origin
*
cache-control
private, max-age=86400, stale-while-revalidate=604800
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
x-xss-protection
0
expires
Thu, 05 Sep 2019 06:40:54 GMT
autosuggest.min.css
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/elasticpress/dist/css/
766 B
580 B
Stylesheet
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/elasticpress/dist/css/autosuggest.min.css?ver=3.0.3
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
8689484e31c0c85e3e074f0b59348974f5de4b2eec412e388e2ea32924a41478

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Wed, 10 Jul 2019 08:59:26 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d25a8ee-2fe"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
text/css
access-control-allow-origin
*
cache-control
public, max-age=2592000
jquery.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/jquery/
95 KB
34 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/jquery/jquery.js?ver=1.12.4-wp
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
1db21d816296e6939ba1f42962496e4134ae2b0081e26970864c40c6d02bb1df

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Fri, 17 May 2019 17:08:53 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5cdeeaa5-17a69"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
jquery-migrate.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/jquery/
10 KB
4 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=1.4.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
48eb8b500ae6a38617b5738d2b3faec481922a7782246e31d2755c034a45cd5d

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Fri, 20 May 2016 06:11:28 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"573eaa90-2748"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
cookie.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/mu-plugins/cookie-controller/js/
2 KB
1 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/mu-plugins/cookie-controller/js/cookie.min.js?ver=1.2
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
e828282e92509efc0f7bc57888382c5816bd403e0abbb685eda5c4372cc7daa5

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5c99e3ee-834"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
cc.js
tags.crwdcntrl.net/c/14413/
38 KB
11 KB
Script
General
Full URL
https://tags.crwdcntrl.net/c/14413/cc.js?ver=1.4&ns=_cc14413
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
93.184.220.113 London, United Kingdom, ASN15133 (EDGECAST - MCI Communications Services, Inc. d/b/a Verizon Business, US),
Reverse DNS
Software
ECS (fcn/40E9) /
Resource Hash
3c0c418574419249b3fff12c4cdb9a2ad6ddc191fa025ea56d4027552487e78c

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Tue, 13 Aug 2019 19:05:38 GMT
server
ECS (fcn/40E9)
etag
"5d530a02-98ef+gzip"
vary
Accept-Encoding
x-cache
HIT
content-type
application/javascript
status
200
cache-control
max-age=86400
content-length
11304
expires
Fri, 06 Sep 2019 06:40:54 GMT
digest.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/hm-npi-manager/js/
16 KB
5 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/hm-npi-manager/js/digest.min.js?ver=2.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
b3c617e4ee00489d6fb85a53bd88cb1e1f5e71ae5244c54a7fea6b6e7d9921ad

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Wed, 22 May 2019 09:37:40 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5ce51864-3fc1"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
UtilityMove-custom.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/vendor/
2 KB
1 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/vendor/UtilityMove-custom.min.js?ver=1553589230
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
cffef365e4b53f1a6e9d33a7d42c0d1542b573360f774069589240f75f0e84f1

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5c99e3ee-751"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
polyfill.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/js/frontend/
102 KB
35 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/js/frontend/polyfill.min.js?ver=1553589230
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
59173f786dd1f3802f7ab26fd339aac4099dc10c6cb54a6a92213e6af277592a

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5c99e3ee-19873"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
gpt.js
www.googletagservices.com/tag/js/
39 KB
12 KB
Script
General
Full URL
https://www.googletagservices.com/tag/js/gpt.js
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:824::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
f4ce67688b22d141487d3064c9e540ec1626002af53a3ba58fcee3e622445f10
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
sffe
etag
"269 / 816 of 1000 / last-modified: 1567440284"
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
private, max-age=900, stale-while-revalidate=3600
timing-allow-origin
*
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43,39",quic=":443"; ma=2592000; v="46,43,39"
content-length
12518
x-xss-protection
0
expires
Thu, 05 Sep 2019 06:40:54 GMT
adtracking.js
s3.amazonaws.com/haymarket-adtracking-js/prod/
19 KB
19 KB
Script
General
Full URL
https://s3.amazonaws.com/haymarket-adtracking-js/prod/adtracking.js
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.217.38.6 Ashburn, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
s3-1.amazonaws.com
Software
AmazonS3 /
Resource Hash
822847109c3aaf484affe599900514bcf4167ceda17fcca7a97b691d780dae25

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:55 GMT
Last-Modified
Tue, 15 Jan 2019 22:54:19 GMT
Server
AmazonS3
x-amz-request-id
2EA8825D7E03A351
ETag
"dc289fc811d6d3a62b068bfcda1f8f30"
Content-Type
application/javascript
x-amz-version-id
MlU6AsBGwcOjZYgQIgNYntESpQyo9BbN
Accept-Ranges
bytes
Content-Length
19158
x-amz-id-2
QHPBqyCAY1HZkUyIBHCSOaRPVf6lpuUnID/4FC+I7hvJhKvCCPkDe6b4EZmVBqdVT9FFMMSFiXY=
head.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/
43 KB
13 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/head.min.js?ver=1567085297
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
70c5977dcbb02566149a292768c9c22cd169b38e54d3275bfa29b5c7547905e9

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Thu, 29 Aug 2019 13:28:17 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d67d2f1-ac53"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
MPR-logo_website.png
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2018/12/
16 KB
16 KB
Image
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2018/12/MPR-logo_website.png
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
9c9401c3de840fa118289641c41b6125ca5825612d110a20584d2ba32036a1cf

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
etag
"452a9f099947d43a38734d72a92e9193"
last-modified
Wed, 20 Mar 2019 21:55:07 GMT
server
NetDNA-cache/2.2
x-amz-server-side-encryption
AES256
x-cache
HIT
content-type
image/png
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
16492
expires
Fri, 20 Sep 2019 11:33:34 GMT
gtm.js
www.googletagmanager.com/
135 KB
34 KB
Script
General
Full URL
https://www.googletagmanager.com/gtm.js?id=GTM-5XFK9V6
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:819::2008 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
Google Tag Manager /
Resource Hash
6f825d61e0e6b9d1ef30ffe0d989d6463ccc0c59b353ebd20106f0a76ceb494a
Security Headers
Name Value
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
br
last-modified
Thu, 05 Sep 2019 06:00:00 GMT
server
Google Tag Manager
access-control-allow-headers
Cache-Control
status
200
vary
Accept-Encoding
content-type
application/javascript; charset=UTF-8
access-control-allow-origin
http://www.googletagmanager.com
cache-control
private, max-age=900
access-control-allow-credentials
true
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
34383
x-xss-protection
0
expires
Thu, 05 Sep 2019 06:40:54 GMT
Park_Brian-150x150.jpg
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2019/05/
15 KB
15 KB
Image
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2019/05/Park_Brian-150x150.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
de709acbe98dba4f2f3fc3204a09a5add553a366b33501d54f78b5f263775785

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
last-modified
Thu, 08 Aug 2019 13:51:38 GMT
server
NetDNA-cache/2.2
status
200
etag
"5d4c28ea-3a49"
vary
Accept-Encoding
x-cache
HIT
content-type
image/jpeg
access-control-allow-origin
*
cache-control
max-age=2592000, public, max-age=2592000
accept-ranges
bytes
content-length
14921
expires
Sat, 07 Sep 2019 16:47:26 GMT
ankylosingspondylitisg87379_1497821.jpg
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2018/12/
14 KB
14 KB
Image
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2018/12/ankylosingspondylitisg87379_1497821.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
f431ee593d1222adae2d17c930ea1832d2e6ced7b15ea0fefef2a3314b99210d
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
etag
"4584396b5a5d374d06199325cc90d319"
last-modified
Wed, 20 Mar 2019 21:41:19 GMT
server
NetDNA-cache/2.2
x-amz-server-side-encryption
AES256
x-frame-options
SAMEORIGIN
x-cache
MISS
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
13993
expires
Sat, 05 Oct 2019 06:40:54 GMT
300x100mprsub-300x105.gif
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2019/01/
13 KB
14 KB
Image
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2019/01/300x100mprsub-300x105.gif
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
f0341fe392815f4fedec6d94398334b176ce2fb0eafebc391a82afcb3cc5fef0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
etag
"fb86d90a5bcf340b8bd64802ec39a7a5"
last-modified
Wed, 20 Mar 2019 09:05:43 GMT
server
NetDNA-cache/2.2
x-amz-server-side-encryption
AES256
x-cache
HIT
content-type
image/gif
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
13667
expires
Fri, 20 Sep 2019 12:01:48 GMT
spinner.svg
www.empr.com/wp-content/themes/haymarket/assets/svg/src/
694 B
630 B
Image
General
Full URL
https://www.empr.com/wp-content/themes/haymarket/assets/svg/src/spinner.svg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
abb1dd7905b3797711e15609800d43cabead4c0358dc0030a1932a20e82a37d7

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
nginx
status
200
etag
W/"5c99e3ee-2b6"
vary
Accept-Encoding, Accept-Encoding, Accept-Encoding
content-type
image/svg+xml
access-control-allow-origin
*
cache-control
public, max-age=2592000
96ac8580a54c3864c4ba15ff4a38efdcb7084985-v2.js
content.maropost.com/uploads/1323/websites/5/
3 KB
3 KB
Script
General
Full URL
https://content.maropost.com/uploads/1323/websites/5/96ac8580a54c3864c4ba15ff4a38efdcb7084985-v2.js?ver=1.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:9000:2057:aa00:1b:fadc:b780:93a1 , United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
AmazonS3 /
Resource Hash
3b8eec5229515f9e95a68b635aba1d27d7d91f2e1b726302c53124fe18cefd20

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Wed, 04 Sep 2019 10:44:21 GMT
via
1.1 d07eabeb1ed60c06da1457f35fb5c8c5.cloudfront.net (CloudFront)
last-modified
Thu, 27 Sep 2018 21:48:02 GMT
server
AmazonS3
age
71794
etag
"ff4375eccda3ca6bc54ed96c5d77d9bb"
x-cache
Hit from cloudfront
status
200
x-amz-cf-pop
FRA6-C1
accept-ranges
bytes
content-length
2622
x-amz-cf-id
vY--rSC9uG_oLRrhI1o2b4rjbCVvheFRzoSfz3DBpNpkbTK9W-ZBrA==
blocks.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/
7 KB
3 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/blocks.min.js?ver=1567085297
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
3ed3de3fd0fabc795d8b96ada205998944ff3157366f20b70d5d10b099b63120

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Thu, 29 Aug 2019 13:28:17 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d67d2f1-1b42"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
local-storage-lib.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/hm-npi-manager/js/
1 KB
917 B
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/hm-npi-manager/js/local-storage-lib.js?ver=2.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
693d39f8b27d78f2a570672b862512cb8e3dee72e8f641cf95ada2d81bac720b

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Wed, 17 Jul 2019 13:03:16 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d2f1c94-591"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
npi-manager.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/hm-npi-manager/js/
3 KB
1 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/hm-npi-manager/js/npi-manager.js?ver=2.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
43a5ba666207ae3718ce7fe6b4015c58043b4ac4dfdacae285d5d8574d80fdf6

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Thu, 29 Aug 2019 13:28:17 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d67d2f1-b3b"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
hmi-registration-ui.manifest.js
s3.amazonaws.com/haymarket-reg-js/develop/production/
799 B
1 KB
Script
General
Full URL
https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.manifest.js?ver=0.1.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.217.38.6 Ashburn, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
s3-1.amazonaws.com
Software
AmazonS3 /
Resource Hash
4d3e9dbf75d761b4fc344b3be601971eb517ce533c7ce46e093539e03349616e

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:55 GMT
Last-Modified
Thu, 29 Aug 2019 20:10:10 GMT
Server
AmazonS3
x-amz-request-id
BB9816F1AD631B89
ETag
"6878a8fbe72bde4a3f8ecf5b16523972"
Content-Type
application/javascript
x-amz-version-id
csLBKnYjTffo31CifRF6x383B2E_amuJ
Accept-Ranges
bytes
Content-Length
799
x-amz-id-2
ne8hy6JX1D7JXwb+QRt1ExAEP9hHkpyo2nS/rgUcCxiznlhrob7AOhvhRa8c8mArpjiAFnDmeho=
hmi-registration-ui.vendor.js
s3.amazonaws.com/haymarket-reg-js/develop/production/
357 KB
357 KB
Script
General
Full URL
https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.vendor.js?ver=0.1.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.217.38.6 Ashburn, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
s3-1.amazonaws.com
Software
AmazonS3 /
Resource Hash
2673f6b0416b9a9f7488ee96f384f5badfa04acb14499c92ae52e394b7572f1f

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:55 GMT
Last-Modified
Thu, 29 Aug 2019 20:10:10 GMT
Server
AmazonS3
x-amz-request-id
A08580E846F69522
ETag
"dfdfd93abc9eec4ff346a12a61df7c41"
Content-Type
application/javascript
x-amz-version-id
6ACuZZ4Fakkhaw3IL9mD952B0XZGZK4Q
Accept-Ranges
bytes
Content-Length
365119
x-amz-id-2
3NBhzs+33XVNfcG7XKhfP69c0kVXxZmuHKN9niW0atfuvd6WAmOTmto7m0xfGEK9qI5gxIcFiwk=
hmi-registration-ui.bundle.js
s3.amazonaws.com/haymarket-reg-js/develop/production/
1 MB
1 MB
Script
General
Full URL
https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.bundle.js?ver=0.1.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.217.38.6 Ashburn, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
s3-1.amazonaws.com
Software
AmazonS3 /
Resource Hash
4eef9cbbcb01ac2538e54c45514c0560e686abf17070adfba489fd1b3b86455a

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:55 GMT
Last-Modified
Thu, 29 Aug 2019 20:10:10 GMT
Server
AmazonS3
x-amz-request-id
89A7903992607DA8
ETag
"8f47379688c3f5980d42b891fcaea0eb"
Content-Type
application/javascript
x-amz-version-id
1g9qbXhjK6v_p1EyiVTzg_c7stFBXUFD
Accept-Ranges
bytes
Content-Length
1225121
x-amz-id-2
wWynDYiV+0pwu784QLYf4f1VbqTdWhW1MecxQFx93ssTjTq7qp8Zpl5uYsg77UcBdFrADnjdtcQ=
autosuggest.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/elasticpress/dist/js/
4 KB
2 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/elasticpress/dist/js/autosuggest.min.js?ver=3.0.3
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
c93e697d8038c51fe0e5002d6ff046cfe3497e03a47c302684292b3f1eeb6c46

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Wed, 10 Jul 2019 08:59:26 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d25a8ee-117d"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
frontend.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/
147 KB
39 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1567085297
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
3b5a3ea636e4cd5a2bf556bff258470249c0267744de25cd28f173354ffe0239

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Thu, 29 Aug 2019 13:28:17 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d67d2f1-24c7e"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
iab.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/
8 KB
2 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/iab.min.js?ver=1567085297
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
6463301e10c71f76fc14bb977dfa9097b5633ed4a3ee4119abccf2ead9aa9e29

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Thu, 29 Aug 2019 13:28:17 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d67d2f1-1ecd"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
wp-embed.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/
1 KB
1003 B
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/wp-embed.min.js?ver=5.2.2
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
2152557cac69e2bd7d6debef5037a9f554f9209cc305b8141b3329acb10c42b7

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Thu, 30 Aug 2018 12:40:26 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5b87e5ba-57b"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=2592000
integrator.js
adservice.google.de/adsid/
109 B
171 B
Script
General
Full URL
https://adservice.google.de/adsid/integrator.js?domain=www.empr.com
Requested by
Host: www.googletagservices.com
URL: https://www.googletagservices.com/tag/js/gpt.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81b::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
0482a98d09daebc18a0d2e1ed8f748da5b0179e61223ed541101df1f4699f073
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

timing-allow-origin
*
date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
cafe
p3p
CP="This is not a P3P policy! See http://support.google.com/accounts/answer/151657 for more info."
status
200
cache-control
private, no-cache, no-store
content-disposition
attachment; filename="f.txt"
content-type
application/javascript; charset=UTF-8
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43,39",quic=":443"; ma=2592000; v="46,43,39"
content-length
104
x-xss-protection
0
integrator.js
adservice.google.com/adsid/
109 B
171 B
Script
General
Full URL
https://adservice.google.com/adsid/integrator.js?domain=www.empr.com
Requested by
Host: www.googletagservices.com
URL: https://www.googletagservices.com/tag/js/gpt.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81b::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
0482a98d09daebc18a0d2e1ed8f748da5b0179e61223ed541101df1f4699f073
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

timing-allow-origin
*
date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
cafe
p3p
CP="This is not a P3P policy! See http://support.google.com/accounts/answer/151657 for more info."
status
200
cache-control
private, no-cache, no-store
content-disposition
attachment; filename="f.txt"
content-type
application/javascript; charset=UTF-8
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43,39",quic=":443"; ma=2592000; v="46,43,39"
content-length
104
x-xss-protection
0
pubads_impl_2019082701.js
securepubads.g.doubleclick.net/gpt/
158 KB
58 KB
Script
General
Full URL
https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019082701.js
Requested by
Host: www.googletagservices.com
URL: https://www.googletagservices.com/tag/js/gpt.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
216.58.210.2 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra16s07-in-f2.1e100.net
Software
sffe /
Resource Hash
d1d597a740d4b09db2d6491af33397944f7dddc5d7e21d95cb33066f2e747ca8
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
x-content-type-options
nosniff
last-modified
Tue, 27 Aug 2019 11:19:55 GMT
server
sffe
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
private, immutable, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
59715
x-xss-protection
0
expires
Thu, 05 Sep 2019 06:40:54 GMT
src.svg
www.empr.com/wp-content/themes/haymarket/assets/svg/
33 KB
10 KB
Other
General
Full URL
https://www.empr.com/wp-content/themes/haymarket/assets/svg/src.svg?ver=1553589230
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
866e74600600f8647c979414828f3538d646101dc8504de84c2ed00e30460811

Request headers

Sec-Fetch-Mode
same-origin
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
nginx
status
200
etag
W/"5c99e3ee-8317"
vary
Accept-Encoding, Accept-Encoding, Accept-Encoding
content-type
image/svg+xml
access-control-allow-origin
*
cache-control
public, max-age=2592000
S6uyw4BMUTPHjx4wXiWtFCc.woff2
fonts.gstatic.com/s/lato/v16/
14 KB
14 KB
Font
General
Full URL
https://fonts.gstatic.com/s/lato/v16/S6uyw4BMUTPHjx4wXiWtFCc.woff2
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81d::2003 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
036d841b132c14046e26d8f2da1bc634c6ad34885ed1295660694a91c98933a6
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://fonts.googleapis.com/css?family=Lato:400,400i,700,700i|Roboto+Slab:400,400i,700,700i
Origin
https://www.empr.com
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Mon, 26 Aug 2019 13:36:09 GMT
x-content-type-options
nosniff
last-modified
Tue, 23 Jul 2019 03:45:55 GMT
server
sffe
age
839085
status
200
content-type
font/woff2
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
14044
x-xss-protection
0
expires
Tue, 25 Aug 2020 13:36:09 GMT
chevron-right-white.svg
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/svg/src/
190 B
399 B
Image
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/svg/src/chevron-right-white.svg
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/vendor/UtilityMove-custom.min.js?ver=1553589230
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
8e0da2e2d764c1a202d33dd39287784df8ac6bc20c7401ea14f2d62001292856

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/style.min.css?ver=1567085297
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5c99e3ee-be"
vary
Accept-Encoding
x-cache
HIT
content-type
image/svg+xml
access-control-allow-origin
*
cache-control
public, max-age=2592000
BngRUXZYTXPIvIBgJJSb6u92w7CGwR2oefDo.woff2
fonts.gstatic.com/s/robotoslab/v9/
11 KB
11 KB
Font
General
Full URL
https://fonts.gstatic.com/s/robotoslab/v9/BngRUXZYTXPIvIBgJJSb6u92w7CGwR2oefDo.woff2
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/vendor/UtilityMove-custom.min.js?ver=1553589230
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81d::2003 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
4901c9453014d8e210b2f62189f68c2d7964543517e1fc8447924de7d542058a
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://fonts.googleapis.com/css?family=Lato:400,400i,700,700i|Roboto+Slab:400,400i,700,700i
Origin
https://www.empr.com
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Mon, 26 Aug 2019 13:27:01 GMT
x-content-type-options
nosniff
last-modified
Mon, 22 Jul 2019 19:27:03 GMT
server
sffe
age
839633
status
200
content-type
font/woff2
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
11388
x-xss-protection
0
expires
Tue, 25 Aug 2020 13:27:01 GMT
BngMUXZYTXPIvIBgJJSb6ufN5qWr4xCC.woff2
fonts.gstatic.com/s/robotoslab/v9/
11 KB
11 KB
Font
General
Full URL
https://fonts.gstatic.com/s/robotoslab/v9/BngMUXZYTXPIvIBgJJSb6ufN5qWr4xCC.woff2
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/vendor/UtilityMove-custom.min.js?ver=1553589230
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81d::2003 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
c68d891f07355e5d0807b4a4f18ac8f16f6e9088277be3134c7efa570022ab2d
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://fonts.googleapis.com/css?family=Lato:400,400i,700,700i|Roboto+Slab:400,400i,700,700i
Origin
https://www.empr.com
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Mon, 02 Sep 2019 15:53:22 GMT
x-content-type-options
nosniff
last-modified
Mon, 22 Jul 2019 19:19:23 GMT
server
sffe
age
226052
status
200
content-type
font/woff2
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
11272
x-xss-protection
0
expires
Tue, 01 Sep 2020 15:53:22 GMT
S6u9w4BMUTPHh6UVSwiPGQ3q5d0.woff2
fonts.gstatic.com/s/lato/v16/
14 KB
14 KB
Font
General
Full URL
https://fonts.gstatic.com/s/lato/v16/S6u9w4BMUTPHh6UVSwiPGQ3q5d0.woff2
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81d::2003 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
9baad10e85c5be8d5697086479983b6b477197103bf8f0f11817b1bdfb9a7451
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://fonts.googleapis.com/css?family=Lato:400,400i,700,700i|Roboto+Slab:400,400i,700,700i
Origin
https://www.empr.com
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Wed, 21 Aug 2019 21:19:20 GMT
x-content-type-options
nosniff
last-modified
Tue, 23 Jul 2019 03:45:54 GMT
server
sffe
age
1243294
status
200
content-type
font/woff2
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
14176
x-xss-protection
0
expires
Thu, 20 Aug 2020 21:19:20 GMT
S6u8w4BMUTPHjxsAXC-qNiXg7Q.woff2
fonts.gstatic.com/s/lato/v16/
15 KB
15 KB
Font
General
Full URL
https://fonts.gstatic.com/s/lato/v16/S6u8w4BMUTPHjxsAXC-qNiXg7Q.woff2
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81d::2003 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
fe4bbdad1d6dff75cde79f8afc07f29502bd4708cb0ce5f552083c3d81ba8382
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://fonts.googleapis.com/css?family=Lato:400,400i,700,700i|Roboto+Slab:400,400i,700,700i
Origin
https://www.empr.com
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Mon, 02 Sep 2019 10:53:04 GMT
x-content-type-options
nosniff
last-modified
Tue, 23 Jul 2019 03:45:51 GMT
server
sffe
age
244070
status
200
content-type
font/woff2
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
14864
x-xss-protection
0
expires
Tue, 01 Sep 2020 10:53:04 GMT
7341.js
script.crazyegg.com/pages/scripts/0034/
88 KB
28 KB
Script
General
Full URL
https://script.crazyegg.com/pages/scripts/0034/7341.js?435462
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtm.js?id=GTM-5XFK9V6
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700::6813:9308 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
9657fb8a0a588adb91904cc27ad6112de087dfc6d0f606e3a0581ab3f11f820d

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
via
1.1 9a736972b021a4b2382c29923f73ce8b.cloudfront.net (CloudFront)
cf-cache-status
HIT
age
9350
cf-polished
origSize=90069
x-cache
Hit from cloudfront
status
200
content-encoding
gzip
last-modified
Tue, 20 Aug 2019 14:00:23 GMT
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
vary
Accept-Encoding
content-type
application/x-javascript
cache-control
private, max-age=300
x-amz-cf-pop
VIE50-C1
cf-ray
511636e549f88c7a-VIE
x-amz-cf-id
J7QwyhXsonf7d1177jXu8wtqkhS-sLVbVCFHj43GjSOMEZA2Us7R6Q==
cf-bgj
minify
analytics.js
www.google-analytics.com/
43 KB
17 KB
Script
General
Full URL
https://www.google-analytics.com/analytics.js
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtm.js?id=GTM-5XFK9V6
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81a::200e Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
Golfe2 /
Resource Hash
dbb67c620eaabf6679a314db18d3ae43037aef71ab27422e6feec08ee987cc0a
Security Headers
Name Value
Strict-Transport-Security max-age=10886400; includeSubDomains; preload
X-Content-Type-Options nosniff

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=10886400; includeSubDomains; preload
content-encoding
gzip
x-content-type-options
nosniff
last-modified
Mon, 19 Aug 2019 17:22:41 GMT
server
Golfe2
age
7041
date
Thu, 05 Sep 2019 04:43:33 GMT
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
public, max-age=7200
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
17803
expires
Thu, 05 Sep 2019 06:43:33 GMT
atrk.js
d31qbv1cthcecs.cloudfront.net/
4 KB
2 KB
Script
General
Full URL
https://d31qbv1cthcecs.cloudfront.net/atrk.js
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
13.32.158.202 Seattle, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
server-13-32-158-202.fra56.r.cloudfront.net
Software
AmazonS3 /
Resource Hash
90451ba3e82cd9db02f0ca76bd45d0ab5ef7e90a49da4215903cb7f08471e2e7

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Sun, 05 May 2019 01:24:34 GMT
Content-Encoding
gzip
Connection
keep-alive
Last-Modified
Sat, 16 Mar 2019 16:01:33 GMT
Server
AmazonS3
Age
10646181
Vary
Accept-Encoding
X-Cache
Hit from cloudfront
Content-Type
text/javascript
Via
1.1 617456b5ad99c756ee702b235ecfe148.cloudfront.net (CloudFront)
Cache-Control
max-age=26920000
Transfer-Encoding
chunked
X-Amz-Cf-Pop
FRA56
X-Amz-Cf-Id
eGSDJOhL9irJoZtGF9dVXZ06oPWbhW5hy_mHI5M0sKTiXOdHfIIDOg==
gg.js
sb.scorecardresearch.com/rs/pt/
2 KB
1 KB
Script
General
Full URL
https://sb.scorecardresearch.com/rs/pt/gg.js
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtm.js?id=GTM-5XFK9V6
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
23.5.97.37 , Netherlands, ASN16625 (AKAMAI-AS - Akamai Technologies, Inc., US),
Reverse DNS
a23-5-97-37.deploy.static.akamaitechnologies.com
Software
/
Resource Hash
d0e90581c7b707bcad9f78f9b066371e6b1377d993ff03cbdee7193d6068ac78

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Content-Encoding
gzip
Connection
keep-alive
X-N
S
Content-Length
1246
Vary
Accept-Encoding
Content-Type
application/x-javascript
fbevents.js
connect.facebook.net/en_US/
121 KB
31 KB
Script
General
Full URL
https://connect.facebook.net/en_US/fbevents.js
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a03:2880:f01c:8012:face:b00c:0:3 , Ireland, ASN32934 (FACEBOOK - Facebook, Inc., US),
Reverse DNS
Software
/
Resource Hash
14d88b3a27f0e6de034f86ad42d6411081e9467daf754147f2f16bcb20782177
Security Headers
Name Value
Content-Security-Policy default-src * data: blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net *.google-analytics.com *.virtualearth.net *.google.com 127.0.0.1:* *.spotilocal.com:* 'unsafe-inline' 'unsafe-eval' blob: data: 'self';style-src data: blob: 'unsafe-inline' *;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net *.spotilocal.com:* wss://*.facebook.com:* https://fb.scanandcleanlocal.com:* attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self';
Strict-Transport-Security max-age=31536000; preload; includeSubDomains
X-Content-Type-Options nosniff
X-Frame-Options DENY
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=31536000; preload; includeSubDomains
content-encoding
gzip
x-content-type-options
nosniff
status
200
content-length
31604
x-xss-protection
0
pragma
public
x-fb-debug
CCh0xzl1PL78AT/qMnXNqQ7dTb/An9NNFjdItrqixwTPkGyTT3m9FZ1lKdRLTFH3yQ+d9gktS7LUHH2v55V0uw==
x-fb-trip-id
194532234
x-frame-options
DENY
date
Thu, 05 Sep 2019 06:40:54 GMT
vary
Accept-Encoding
content-type
application/x-javascript; charset=utf-8
cache-control
public, max-age=1200
content-security-policy
default-src * data: blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net *.google-analytics.com *.virtualearth.net *.google.com 127.0.0.1:* *.spotilocal.com:* 'unsafe-inline' 'unsafe-eval' blob: data: 'self';style-src data: blob: 'unsafe-inline' *;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net *.spotilocal.com:* wss://*.facebook.com:* https://fb.scanandcleanlocal.com:* attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self';
expires
Sat, 01 Jan 2000 00:00:00 GMT
i
sp.sitomobile.com/
Redirect Chain
  • https://mt.sitomobile.com/sync/ta?aid=136&sid=hmm&val=12
  • https://pixel.tapad.com/idsync/ex/push?partner_id=2822&partner_url=https%3A%2F%2Fmt.sitomobile.com%2Fsync%2Ftacb%3Fexid%3D%24%7BTA_DEVICE_ID%7D%26aid%3D136%26sid%3Dhmm%26val%3D12
  • https://pixel.tapad.com/idsync/ex/push/check?partner_id=2822&partner_url=https%3A%2F%2Fmt.sitomobile.com%2Fsync%2Ftacb%3Fexid%3D%24%7BTA_DEVICE_ID%7D%26aid%3D136%26sid%3Dhmm%26val%3D12
  • https://mt.sitomobile.com/sync/tacb?exid=1c41f211-cfa8-11e9-a5ed-92685282a72d&aid=136&sid=hmm&val=12
  • https://sp.sitomobile.com/i?tna=sito&p=mob&e=ue&ue_px=eyJzY2hlbWEiOiJpZ2x1OmNvbS5zbm93cGxvd2FuYWx5dGljcy5zbm93cGxvdy91bnN0cnVjdF9ldmVudC9qc29uc2NoZW1hLzEtMC0wIiwiZGF0YSI6eyJzY2hlbWEiOiJpZ2x1OmNvbS5...
43 B
388 B
Script
General
Full URL
https://sp.sitomobile.com/i?tna=sito&p=mob&e=ue&ue_px=eyJzY2hlbWEiOiJpZ2x1OmNvbS5zbm93cGxvd2FuYWx5dGljcy5zbm93cGxvdy91bnN0cnVjdF9ldmVudC9qc29uc2NoZW1hLzEtMC0wIiwiZGF0YSI6eyJzY2hlbWEiOiJpZ2x1OmNvbS5zaXRvbW9iaWxlLnNub3dwbG93L2Nvb2tpZV9zeW5jL2pzb25zY2hlbWEvMS0wLTAiLCJkYXRhIjp7InBhcnRuZXJJZCI6InRhcGFkIn19fQ%3D%3D&cx=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
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.225.65.223 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-34-225-65-223.compute-1.amazonaws.com
Software
Apache-Coyote/1.1 /
Resource Hash
f4eef8263281c0b26486637831251059757bc3fdc4c3a48045a8ef8646b36e8f

Request headers

Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Server
Apache-Coyote/1.1
Connection
keep-alive
P3P
policyref="/w3c/p3p.xml", CP="NOI DSP COR NID PSA OUR IND COM NAV STA"
Content-Length
43
Content-Type
image/gif

Redirect headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Server
nginx/1.12.1
X-Powered-By
Express
Vary
Accept
Content-Type
text/plain; charset=utf-8
Location
https://sp.sitomobile.com/i?tna=sito&p=mob&e=ue&ue_px=eyJzY2hlbWEiOiJpZ2x1OmNvbS5zbm93cGxvd2FuYWx5dGljcy5zbm93cGxvdy91bnN0cnVjdF9ldmVudC9qc29uc2NoZW1hLzEtMC0wIiwiZGF0YSI6eyJzY2hlbWEiOiJpZ2x1OmNvbS5zaXRvbW9iaWxlLnNub3dwbG93L2Nvb2tpZV9zeW5jL2pzb25zY2hlbWEvMS0wLTAiLCJkYXRhIjp7InBhcnRuZXJJZCI6InRhcGFkIn19fQ%3D%3D&cx=eyJzY2hlbWEiOiJpZ2x1OmNvbS5zbm93cGxvd2FuYWx5dGljcy5zbm93cGxvdy9jb250ZXh0cy9qc29uc2NoZW1hLzEtMC0wIiwiZGF0YSI6W3sic2NoZW1hIjoiaWdsdTpjb20uc2l0b21vYmlsZS5zbm93cGxvdy90YXBhZF9jb250ZXh0L2pzb25zY2hlbWEvMS0wLTAiLCJkYXRhIjp7InRhcGFkSWQiOiIxYzQxZjIxMS1jZmE4LTExZTktYTVlZC05MjY4NTI4MmE3MmQifX0seyJzY2hlbWEiOiJpZ2x1OmNvbS5zaXRvbW9iaWxlLnNub3dwbG93L3NpdG9fY2FtcGFpZ25fY29udGV4dC9qc29uc2NoZW1hLzEtMC0wIiwiZGF0YSI6eyJhZHZlcnRpc2VySWQiOiIxMzYiLCJjYW1wYWlnbklkIjoiIiwibGluZUl0ZW1JZCI6IiJ9fSx7InNjaGVtYSI6ImlnbHU6Y29tLnNpdG9tb2JpbGUuc25vd3Bsb3cvc2VnbWVudF9jb250ZXh0L2pzb25zY2hlbWEvMS0wLTAiLCJkYXRhIjp7InNlZ21lbnRJZCI6ImhtbSIsInNlZ21lbnRWYWwiOiIxMiJ9fV19
Connection
keep-alive
Content-Length
972
up_loader.1.1.0.js
js.adsrvr.org/
6 KB
2 KB
Script
General
Full URL
https://js.adsrvr.org/up_loader.1.1.0.js
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtm.js?id=GTM-5XFK9V6
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
13.32.220.210 Seattle, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
server-13-32-220-210.fra56.r.cloudfront.net
Software
AmazonS3 /
Resource Hash
7e98e381189d908e1981b6e535bcdd7f3edceafdb0e7095f3e04292e8aac6a0c

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Wed, 04 Sep 2019 19:46:50 GMT
Content-Encoding
gzip
Last-Modified
Wed, 17 Jul 2019 18:26:10 GMT
Server
AmazonS3
Age
41939
Vary
Accept-Encoding
X-Cache
Hit from cloudfront
Content-Type
application/x-javascript
Via
1.1 1136b0fc7377c6211173282a3992a814.cloudfront.net (CloudFront)
Connection
keep-alive
Transfer-Encoding
chunked
X-Amz-Cf-Pop
FRA56
X-Amz-Cf-Id
zNSY9KcQA9n_EhESWpEc7Hgvxrs8mC_Uq-Y_UvhDo7QpamdX7Wm8ww==
b2
sb.scorecardresearch.com/
Redirect Chain
  • https://sb.scorecardresearch.com/b?c1=2&c2=21948019&ns__t=1567665654597&ns_c=UTF-8&c8=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&c7=https%3A%2F%2...
  • https://sb.scorecardresearch.com/b2?c1=2&c2=21948019&ns__t=1567665654597&ns_c=UTF-8&c8=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&c7=https%3A%2F%...
0
248 B
Image
General
Full URL
https://sb.scorecardresearch.com/b2?c1=2&c2=21948019&ns__t=1567665654597&ns_c=UTF-8&c8=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&c7=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&c9=
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
23.5.97.37 , Netherlands, ASN16625 (AKAMAI-AS - Akamai Technologies, Inc., US),
Reverse DNS
a23-5-97-37.deploy.static.akamaitechnologies.com
Software
/
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:54 GMT
Cache-Control
private, no-cache, no-cache=Set-Cookie, no-store, proxy-revalidate
Connection
keep-alive
Content-Length
0
Expires
Mon, 01 Jan 1990 00:00:00 GMT

Redirect headers

Location
https://sb.scorecardresearch.com/b2?c1=2&c2=21948019&ns__t=1567665654597&ns_c=UTF-8&c8=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&c7=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&c9=
Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:54 GMT
Cache-Control
private, no-cache, no-cache=Set-Cookie, no-store, proxy-revalidate
Connection
keep-alive
Content-Length
0
Expires
Mon, 01 Jan 1990 00:00:00 GMT
96ac8580a54c3864c4ba15ff4a38efdcb7084985.js
mpct1.maropost.com/accounts/1323/websites/5/track/
4 KB
3 KB
Script
General
Full URL
https://mpct1.maropost.com/accounts/1323/websites/5/track/96ac8580a54c3864c4ba15ff4a38efdcb7084985.js?contact_id=2303653&campaign_id=66409&title=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&url=https%3A%2F%2Fempr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F&parent_url=&version=2&&&&funnel[0][name]=&funnel[0][status]=started&funnel[0][time_out]=40&
Requested by
Host: content.maropost.com
URL: https://content.maropost.com/uploads/1323/websites/5/96ac8580a54c3864c4ba15ff4a38efdcb7084985-v2.js?ver=1.1
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
35.238.92.4 , United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
4.92.238.35.bc.googleusercontent.com
Software
nginx/1.14.0 + Phusion Passenger 5.3.4 / Phusion Passenger 5.3.4
Resource Hash
163f3d649858ad6a44fbf02a7e93e1b638cd88ef3d58c7c562740861de2e0f16
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Frame-Options SAMEORIGIN
X-Xss-Protection 1; mode=block

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Content-Encoding
gzip
X-Content-Type-Options
nosniff
X-Powered-By
Phusion Passenger 5.3.4
Transfer-Encoding
chunked
Status
200 OK
Connection
keep-alive
Vary
Accept-Encoding
X-XSS-Protection
1; mode=block
X-Request-Id
93521091-9ee3-405e-8a7f-e8e5f612f240
X-Runtime
0.023657
Server
nginx/1.14.0 + Phusion Passenger 5.3.4
ETag
W/"b3d75c2ae5a8ca45cfb6f0ebc774211e"
X-Frame-Options
SAMEORIGIN
Content-Type
text/javascript; charset=utf-8
Cache-Control
max-age=0, private, must-revalidate
js
www.google-analytics.com/gtm/
56 KB
21 KB
Script
General
Full URL
https://www.google-analytics.com/gtm/js?id=GTM-T8P2ZZ9&t=gtm1&cid=1629988481.1567665651
Requested by
Host: www.google-analytics.com
URL: https://www.google-analytics.com/analytics.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81a::200e Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
Google Tag Manager /
Resource Hash
ae394306e5316947f122edbb7df5fee120e1674b344dec604e09e779e2312434
Security Headers
Name Value
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
br
server
Google Tag Manager
access-control-allow-headers
Cache-Control
status
200
vary
Accept-Encoding
content-type
application/javascript; charset=UTF-8
access-control-allow-origin
http://www.googletagmanager.com
cache-control
private, max-age=900
access-control-allow-credentials
true
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
21574
x-xss-protection
0
expires
Thu, 05 Sep 2019 06:40:54 GMT
1073716492693685
connect.facebook.net/signals/config/
307 KB
78 KB
Script
General
Full URL
https://connect.facebook.net/signals/config/1073716492693685?v=2.9.4&r=stable
Requested by
Host: connect.facebook.net
URL: https://connect.facebook.net/en_US/fbevents.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a03:2880:f01c:8012:face:b00c:0:3 , Ireland, ASN32934 (FACEBOOK - Facebook, Inc., US),
Reverse DNS
Software
/
Resource Hash
93c4a8cc5d4782ed85c9a7661ce68d1e7e7e6d4a91a57219f649f77564617460
Security Headers
Name Value
Content-Security-Policy default-src * data: blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net *.google-analytics.com *.virtualearth.net *.google.com 127.0.0.1:* *.spotilocal.com:* 'unsafe-inline' 'unsafe-eval' blob: data: 'self';style-src data: blob: 'unsafe-inline' *;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net *.spotilocal.com:* wss://*.facebook.com:* https://fb.scanandcleanlocal.com:* attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self' chrome-extension://boadgeojelhgndaghljhdicfkmllpafd chrome-extension://dliochdbjfkdbacpmhlcpmleaejidimm;
Strict-Transport-Security max-age=31536000; preload; includeSubDomains
X-Content-Type-Options nosniff
X-Frame-Options DENY
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=31536000; preload; includeSubDomains
content-encoding
gzip
x-content-type-options
nosniff
status
200
content-length
79754
x-xss-protection
0
pragma
public
x-fb-debug
MVd+ZcliU9u7IJ/FXDdkozao+usGNe0jYOeAecY03rTp0B5Ys1nXh8V6hHDK8r1kZEibPpbAdL01BKQM+l2vpg==
x-fb-trip-id
194532234
x-frame-options
DENY
date
Thu, 05 Sep 2019 06:40:54 GMT
vary
Origin, Accept-Encoding
access-control-allow-methods
OPTIONS
content-type
application/x-javascript; charset=utf-8
access-control-allow-origin
https://connect.facebook.net
access-control-expose-headers
X-FB-Debug, X-Loader-Length
cache-control
public, max-age=1200
access-control-allow-credentials
true
content-security-policy
default-src * data: blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net *.google-analytics.com *.virtualearth.net *.google.com 127.0.0.1:* *.spotilocal.com:* 'unsafe-inline' 'unsafe-eval' blob: data: 'self';style-src data: blob: 'unsafe-inline' *;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net *.spotilocal.com:* wss://*.facebook.com:* https://fb.scanandcleanlocal.com:* attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self' chrome-extension://boadgeojelhgndaghljhdicfkmllpafd chrome-extension://dliochdbjfkdbacpmhlcpmleaejidimm;
expires
Sat, 01 Jan 2000 00:00:00 GMT
lio.js
c.lytics.io/api/tag/43bffbce6f25564c8e2145a11836ff9f/
45 KB
11 KB
Script
General
Full URL
https://c.lytics.io/api/tag/43bffbce6f25564c8e2145a11836ff9f/lio.js
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1567085297
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
803e3ba42413340bcc0c185e1b5f40bfcc115ed3a52832ffcdf7827cbf239be0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

cf-ray
511636e5bf84599a-VIE
date
Thu, 05 Sep 2019 06:40:54 GMT
via
1.1 google
cf-cache-status
HIT
server
cloudflare
age
997
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
vary
Accept-Encoding
content-type
application/javascript
status
200
cache-control
public, max-age=7200
content-encoding
br
expires
Thu, 05 Sep 2019 08:40:54 GMT
most-widget
www.empr.com/wp-json/haymarket/v1/
4 KB
2 KB
XHR
General
Full URL
https://www.empr.com/wp-json/haymarket/v1/most-widget?id=most-5
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1567085297
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
a8fede43f9790aecd26ca16535327c0d479d116f9c1cf760a993c227c405c8d4
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
x-content-type-options
nosniff
x-cacheable
SHORT
x-cache
HIT: 1
status
200
x-wpengine-segment
NONHT
x-cache-group
normal
access-control-allow-headers
Authorization, Content-Type
allow
GET
wpe-backend
apache
server
nginx
vary
Accept-Encoding, Accept-Encoding, Accept-Encoding,Cookie
content-type
application/json; charset=UTF-8
access-control-expose-headers
X-WP-Total, X-WP-TotalPages
cache-control
max-age=600, must-revalidate
x-distributor
yes
x-robots-tag
noindex
link
<https://www.empr.com/wp-json/>; rel="https://api.w.org/"
x-pass-why
122761
www.empr.com/wp-json/haymarket/v1/infinite-scroll/
6 KB
2 KB
XHR
General
Full URL
https://www.empr.com/wp-json/haymarket/v1/infinite-scroll/122761
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1567085297
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
ede2582f7205eb8ebd7d87d7bf6eaae4e6b80cf11a8f7f8652ecf44507be6342
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
x-content-type-options
nosniff
x-cacheable
SHORT
x-cache
MISS
status
200
x-wpengine-segment
NONHT
x-cache-group
normal
access-control-allow-headers
Authorization, Content-Type
allow
GET
wpe-backend
apache
server
nginx
vary
Accept-Encoding, Accept-Encoding, Accept-Encoding,Cookie
content-type
application/json; charset=UTF-8
x-wpe-loopback-upstream-addr
127.0.0.1:6783
access-control-expose-headers
X-WP-Total, X-WP-TotalPages
cache-control
max-age=600, must-revalidate
x-distributor
yes
x-robots-tag
noindex
link
<https://www.empr.com/wp-json/>; rel="https://api.w.org/"
x-pass-why
partial-login
www.empr.com/wp-json/haymarket/v1/
634 B
854 B
XHR
General
Full URL
https://www.empr.com/wp-json/haymarket/v1/partial-login?subid=&subemail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1567085297
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
ad16911f49d3e72d789bfe438841576129e86d69f42bcaddf489d3523ed69951
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
content-encoding
gzip
x-content-type-options
nosniff
x-cacheable
SHORT
x-cache
HIT: 2
status
200
x-wpengine-segment
NONHT
x-cache-group
normal
access-control-allow-headers
Authorization, Content-Type
allow
GET
wpe-backend
apache
server
nginx
vary
Accept-Encoding, Accept-Encoding, Accept-Encoding,Cookie
content-type
application/json; charset=UTF-8
access-control-expose-headers
X-WP-Total, X-WP-TotalPages
cache-control
max-age=600, must-revalidate
x-distributor
yes
x-robots-tag
noindex
link
<https://www.empr.com/wp-json/>; rel="https://api.w.org/"
x-pass-why
/
accounts.haymarketmedia.com/sso/check/
45 B
440 B
XHR
General
Full URL
https://accounts.haymarketmedia.com/sso/check/?gn=101
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1567085297
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.192.84.248 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-34-192-84-248.compute-1.amazonaws.com
Software
Microsoft-IIS/8.5 / ASP.NET
Resource Hash
916b46685de3064525220ba828d946e60ab332f5e65c62d7df5fe9877f9c54b2

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
x-aspnetmvc-version
4.0
server
Microsoft-IIS/8.5
x-aspnet-version
4.0.30319
x-powered-by
ASP.NET
status
200
content-type
application/json; charset=utf-8
access-control-allow-origin
https://www.empr.com
cache-control
private
access-control-allow-credentials
true
content-length
45
atrk.gif
certify.alexametrics.com/
43 B
551 B
Image
General
Full URL
https://certify.alexametrics.com/atrk.gif?frame_height=1200&frame_width=1600&iframe=0&title=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&time=1567665654685&time_zone_offset=-120&screen_params=1600x1200x24&java_enabled=0&cookie_enabled=1&ref_url=&host_url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&random_number=8766306238&sess_cookie=7df5c7ee16d00278b9cd5aee9cd&sess_cookie_flag=1&user_cookie=7df5c7ee16d00278b9cd5aee9cd&user_cookie_flag=1&dynamic=true&domain=empr.com&account=gujPp1NErb205V&jsv=20130128&user_lang=en-US
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
13.35.253.105 Seattle, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
server-13-35-253-105.fra6.r.cloudfront.net
Software
AmazonS3 /
Resource Hash
89fe0ee6020314794fc2cfeacf3d10c31050cfe56f8ebddf1ed0a33fbe941fa7

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 05:27:11 GMT
Via
1.1 a350f357b825293e306b1b0a2cb490c1.cloudfront.net (CloudFront)
Last-Modified
Mon, 17 Jan 2011 20:41:40 GMT
Server
AmazonS3
Age
25018
ETag
"221d8352905f2c38b3cb2bd191d630b0"
X-Cache
Hit from cloudfront
Content-Type
image/gif
Connection
keep-alive
Accept-Ranges
bytes
X-Amz-Cf-Pop
FRA6-C1
x-amz-meta-alexa-last-modified
20110117123941
Content-Length
43
X-Amz-Cf-Id
mBgSju3o0yipNXQGVdh43IlMD1J1y82Afs_86tNgbmEANunhNvZZQw==
io.min.js
c.lytics.io/static/v2/
13 KB
6 KB
Script
General
Full URL
https://c.lytics.io/static/v2/io.min.js
Requested by
Host: c.lytics.io
URL: https://c.lytics.io/api/tag/43bffbce6f25564c8e2145a11836ff9f/lio.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
b2435070f04e40c2666a729a016c60355b2025c969c3b7857489b7c8b2755bc2

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

cf-ray
511636e5ef92599a-VIE
date
Thu, 05 Sep 2019 06:40:54 GMT
via
1.1 google
cf-cache-status
HIT
last-modified
Wed, 26 Jun 2019 19:48:45 GMT
server
cloudflare
age
2371
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
vary
Accept-Encoding
content-type
application/javascript
status
200
cache-control
public, max-age=7200
content-encoding
br
expires
Thu, 05 Sep 2019 08:40:54 GMT
beacon.js
www.medtargetsystem.com/javascript/
176 KB
52 KB
Script
General
Full URL
https://www.medtargetsystem.com/javascript/beacon.js?v2.5.12
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.3.171.116 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-3-171-116.compute-1.amazonaws.com
Software
Apache/2.4.7 (Ubuntu) /
Resource Hash
17d16dea2b5b8f1be932ad9db03660a4ba13edd7d25da10b57fb225bba8c9389

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Content-Encoding
gzip
Last-Modified
Thu, 15 Aug 2019 18:31:28 GMT
Server
Apache/2.4.7 (Ubuntu)
ETag
"2c024-5902c14f34000-gzip"
Vary
X-Forwarded-Proto,Accept-Encoding
Content-Type
application/javascript
Connection
keep-alive
Accept-Ranges
bytes
Content-Length
52900
linkid.js
www.google-analytics.com/plugins/ua/
2 KB
932 B
Script
General
Full URL
https://www.google-analytics.com/plugins/ua/linkid.js
Requested by
Host: www.google-analytics.com
URL: https://www.google-analytics.com/analytics.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81a::200e Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
92fca55833f48b4289ac8f1cedd48752b580fce4ec4b5d81670b8193d6e51b54
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:17:19 GMT
content-encoding
gzip
x-content-type-options
nosniff
last-modified
Thu, 21 Apr 2016 03:17:22 GMT
server
sffe
age
1415
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
public, max-age=3600
accept-ranges
bytes
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
856
x-xss-protection
0
expires
Thu, 05 Sep 2019 07:17:19 GMT
tag.aspx
ml314.com/
26 KB
12 KB
Script
General
Full URL
https://ml314.com/tag.aspx?582019
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.247.144.106 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-247-144-106.eu-west-1.compute.amazonaws.com
Software
Microsoft-IIS/10.0 / ASP.NET
Resource Hash
390a28be2ca4bcea5b71fe050295281a1a8fc99175690cdd62de378190400acb

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Content-Encoding
gzip
Last-Modified
Thu, 05 Sep 2019 05:49:13 GMT
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Vary
Accept-Encoding
Content-Type
application/javascript; charset=utf-8
Cache-Control
public, max-age=83298
Connection
keep-alive
Content-Length
11933
Expires
Fri, 06 Sep 2019 05:49:13 GMT
inferredEvents.js
connect.facebook.net/signals/plugins/
35 KB
10 KB
Script
General
Full URL
https://connect.facebook.net/signals/plugins/inferredEvents.js?v=2.9.4
Requested by
Host: connect.facebook.net
URL: https://connect.facebook.net/en_US/fbevents.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a03:2880:f01c:8012:face:b00c:0:3 , Ireland, ASN32934 (FACEBOOK - Facebook, Inc., US),
Reverse DNS
Software
/
Resource Hash
b4e9e9bef19c34422f55a7fdb9d10c4db5e39cff24b8c98a0be0e09b2ee6ac2b
Security Headers
Name Value
Content-Security-Policy default-src * data: blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net *.google-analytics.com *.virtualearth.net *.google.com 127.0.0.1:* *.spotilocal.com:* 'unsafe-inline' 'unsafe-eval' blob: data: 'self';style-src data: blob: 'unsafe-inline' *;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net *.spotilocal.com:* wss://*.facebook.com:* https://fb.scanandcleanlocal.com:* attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self';
Strict-Transport-Security max-age=31536000; preload; includeSubDomains
X-Content-Type-Options nosniff
X-Frame-Options DENY
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=31536000; preload; includeSubDomains
content-encoding
gzip
x-content-type-options
nosniff
status
200
content-length
10218
x-xss-protection
0
pragma
public
x-fb-debug
6miGlSIsslxhf+Qr5LSawx4nWDbIdKwFJkHdXobt2GzLbzZcnkcRE/kuG8/96ktIKeeAw4ZIEEq2Jceqfu5dgA==
x-fb-trip-id
194532234
x-frame-options
DENY
date
Thu, 05 Sep 2019 06:40:54 GMT
vary
Accept-Encoding
content-type
application/x-javascript; charset=utf-8
cache-control
public, max-age=1200
content-security-policy
default-src * data: blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net *.google-analytics.com *.virtualearth.net *.google.com 127.0.0.1:* *.spotilocal.com:* 'unsafe-inline' 'unsafe-eval' blob: data: 'self';style-src data: blob: 'unsafe-inline' *;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net *.spotilocal.com:* wss://*.facebook.com:* https://fb.scanandcleanlocal.com:* attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self';
expires
Sat, 01 Jan 2000 00:00:00 GMT
collect
www.google-analytics.com/
35 B
103 B
Image
General
Full URL
https://www.google-analytics.com/collect?v=1&_v=j79&a=927312587&t=pageview&_s=1&dl=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&ul=en-us&de=UTF-8&dt=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&sd=24-bit&sr=1600x1200&vp=1585x1200&je=0&_u=SCCAAAAjQ~&jid=&gjid=&cid=1629988481.1567665651&tid=UA-1290429-2&_gid=244612982.1567665655&gtm=2wg8l25XFK9V6&cd1=122761%3A0&cd2=miscellaneous%20musculoskeletal%20disorders%2Cmusculoskeletal%20disorders&cd3=&cd4=&cd5=post&cd6=&cd7=home&cd8=news&cd9=ixekizumab%20gains%20fda%20approval%20for%20treatment%20of%20active%20ankylosing%20spondylitis&cd11=omn&cd12=13&cd14=false&cd15=&cd16=false&cd17=&cd18=0&cd19=&cd31=&cd32=&cd33=&cd34=Brian%20Park%2C%20PharmD&cd35=MPR%20Drug%20News&cd36=pcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019&cd37=undefined&cd38=undefined&cd39=undefined&cd40=&cd41=&cd42=&cd43=&cd46=&cd48=&cd50=&cd52=&cd53=home&cd54=&cd55=&cd56=9&cd57=&cd58=&cd62=false&cd63=2019-08-26&cd64=325&cd67=&cd68=undef&cd71=false&cd78=false&cd79=false&cd80=false&cd93=news&z=126819679
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81a::200e Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
Golfe2 /
Resource Hash
8337212354871836e6763a41e615916c89bac5b3f1f0adf60ba43c7c806e1015
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 29 Aug 2019 04:25:33 GMT
x-content-type-options
nosniff
last-modified
Sun, 17 May 1998 03:00:00 GMT
server
Golfe2
age
612921
status
200
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
35
expires
Mon, 01 Jan 1990 00:00:00 GMT
4
c.lytics.io/cid/
77 B
201 B
Script
General
Full URL
https://c.lytics.io/cid/4?callback=jQuery112406199277181627068_1567665654482&_=1567665654483
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/jquery/jquery.js?ver=1.12.4-wp
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6217fe39a2355a292c610752ddbfce68086b7c68e58a52b07ea3dd3f747d4a0a

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

cf-ray
511636e64ff2599a-VIE
pragma
no-cache
date
Thu, 05 Sep 2019 06:40:54 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
text/javascript
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
content-encoding
br
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
expires
0
/
www.facebook.com/tr/
44 B
251 B
Image
General
Full URL
https://www.facebook.com/tr/?id=1073716492693685&ev=PageView&dl=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&rl=&if=false&ts=1567665654760&sw=1600&sh=1200&v=2.9.4&r=stable&ec=0&o=30&fbp=fb.1.1567665654759.1997912015&it=1567665654659&coo=false&rqm=GET
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a03:2880:f11c:8083:face:b00c:0:25de , Ireland, ASN32934 (FACEBOOK - Facebook, Inc., US),
Reverse DNS
Software
proxygen-bolt /
Resource Hash
10d8d42d73a02ddb877101e72fbfa15a0ec820224d97cedee4cf92d571be5caa
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:54 GMT
last-modified
Fri, 21 Dec 2012 00:00:01 GMT
server
proxygen-bolt
strict-transport-security
max-age=31536000; includeSubDomains
content-type
image/gif
status
200
cache-control
no-cache, must-revalidate, max-age=0
content-length
44
expires
Thu, 05 Sep 2019 06:40:54 GMT
utsync.ashx
ml314.com/
793 B
2 KB
Script
General
Full URL
https://ml314.com/utsync.ashx?pub=&adv=&et=0&eid=740&ct=js&pi=&fp=&clid=&if=0&ps=&cl=&mlt=&data=&&cp=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&pv=1567665654762_44rn5jh3l&bl=en-us&cb=4354583&return=&ht=&d=&dc=&si=1567665654762_44rn5jh3l&cid=&s=1600x1200&rp=
Requested by
Host: ml314.com
URL: https://ml314.com/tag.aspx?582019
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.247.144.106 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-247-144-106.eu-west-1.compute.amazonaws.com
Software
Microsoft-IIS/10.0 / ASP.NET
Resource Hash
85efad507808b3debbb8fee7cedbc33112ecc8f5230066dc91cdad0f5f09680a

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:54 GMT
Content-Encoding
gzip
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Vary
Accept-Encoding
p3P
CP="NON DSP COR ADMo PSAo DEVo BUS COM UNI NAV DEM STA"
Cache-Control
private
Connection
keep-alive
Content-Type
application/javascript; charset=utf-8
Content-Length
486
Expires
0
ud.ashx
in.ml314.com/
20 B
698 B
Script
General
Full URL
https://in.ml314.com/ud.ashx?topiclimit=&cb=582019
Requested by
Host: ml314.com
URL: https://ml314.com/tag.aspx?582019
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
54.208.174.93 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-54-208-174-93.compute-1.amazonaws.com
Software
Microsoft-IIS/8.5 / ASP.NET
Resource Hash
d0e4a6372d6fb5ffe9505dbe9e94aee8f1b9b96ec8e5e20684cce8b4c5a88fa7

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Content-Encoding
gzip
Server
Microsoft-IIS/8.5
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Vary
Accept-Encoding
Content-Type
application/javascript; charset=utf-8
Cache-Control
public, no-cache="set-cookie"
Connection
keep-alive
Content-Length
138
Expires
Fri, 06 Sep 2019 06:40:54 GMT
csync.ashx
ml314.com/
Redirect Chain
  • https://tags.bluekai.com/site/20486?limit=0&id=5978151494658009684&redir=https://ml314.com/csync.ashx%3Ffp=$_BK_UUID%26person_id=5978151494658009684%26eid=50056
  • https://ml314.com/csync.ashx?fp=h8Q0vx9999eydUO5&person_id=5978151494658009684&eid=50056
43 B
312 B
Image
General
Full URL
https://ml314.com/csync.ashx?fp=h8Q0vx9999eydUO5&person_id=5978151494658009684&eid=50056
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.247.144.106 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-247-144-106.eu-west-1.compute.amazonaws.com
Software
Microsoft-IIS/10.0 / ASP.NET
Resource Hash
b1442e85b03bdcaf66dc58c7abb98745dd2687d86350be9a298a1d9382ac849b

Request headers

Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Content-Type
image/gif
Cache-Control
private
Connection
keep-alive
Content-Length
43
Expires
Fri, 06 Sep 2019 02:40:55 GMT

Redirect headers

Location
https://ml314.com/csync.ashx?fp=h8Q0vx9999eydUO5&person_id=5978151494658009684&eid=50056
Date
Thu, 05 Sep 2019 06:40:55 GMT
Connection
keep-alive
Content-Length
0
BK-Server
3d03
P3P
CP="NOI DSP COR CUR ADMo DEVo PSAo PSDo OUR SAMo BUS UNI NAV", policyref="http://tags.bluekai.com/w3c/p3p.xml"
csync.ashx
ml314.com/
Redirect Chain
  • https://idsync.rlcdn.com/395886.gif?partner_uid=5978151494658009684
  • https://idsync.rlcdn.com/1000.gif?memo=CO6UGBIeChoIARCuXxoTNTk3ODE1MTQ5NDY1ODAwOTY4NBAAGg0I9tvC6wUSBQjoBxAAQgBKAA
  • https://ml314.com/csync.ashx?fp=&person_id=5978151494658009684&eid=50082
43 B
312 B
Image
General
Full URL
https://ml314.com/csync.ashx?fp=&person_id=5978151494658009684&eid=50082
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.247.144.106 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-247-144-106.eu-west-1.compute.amazonaws.com
Software
Microsoft-IIS/10.0 / ASP.NET
Resource Hash
b1442e85b03bdcaf66dc58c7abb98745dd2687d86350be9a298a1d9382ac849b

Request headers

Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Content-Type
image/gif
Cache-Control
private
Connection
keep-alive
Content-Length
43
Expires
Fri, 06 Sep 2019 02:40:55 GMT

Redirect headers

date
Thu, 05 Sep 2019 06:40:54 GMT
via
1.1 google
status
307
p3p
CP="NOI DSP COR NID CURa ADMa DEVa PSAa PSDa OUR BUS COM INT OTC PUR STA"
location
https://ml314.com/csync.ashx?fp=&person_id=5978151494658009684&eid=50082
cache-control
no-cache, no-store
timing-allow-origin
*
alt-svc
clear
content-length
0
csync.ashx
ml314.com/
Redirect Chain
  • https://pixel.mathtag.com/sync/img?redir=https://ml314.com/csync.ashx%3Ffp=[MM_UUID]%26person_id=5978151494658009684%26eid=50220
  • https://pixel.mathtag.com/sync/img?redir=https://ml314.com/csync.ashx%3Ffp=[MM_UUID]%26person_id=5978151494658009684%26eid=50220&mm_bnc&mm_bct&UUID=f1105d70-a70e-4300-b780-b092317bc17d
  • https://ml314.com/csync.ashx?fp=f1105d70-a70e-4300-b780-b092317bc17d&person_id=5978151494658009684&eid=50220
43 B
312 B
Image
General
Full URL
https://ml314.com/csync.ashx?fp=f1105d70-a70e-4300-b780-b092317bc17d&person_id=5978151494658009684&eid=50220
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.247.144.106 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-247-144-106.eu-west-1.compute.amazonaws.com
Software
Microsoft-IIS/10.0 / ASP.NET
Resource Hash
b1442e85b03bdcaf66dc58c7abb98745dd2687d86350be9a298a1d9382ac849b

Request headers

Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Content-Type
image/gif
Cache-Control
private
Connection
keep-alive
Content-Length
43
Expires
Fri, 06 Sep 2019 02:40:54 GMT

Redirect headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Server
MT3 1684 2519bb0 master zrh-pixel-x22
P3P
CP="NOI DSP COR NID CURa ADMa DEVa PSAa PSDa OUR BUS COM INT OTC PUR STA"
Location
https://ml314.com/csync.ashx?fp=f1105d70-a70e-4300-b780-b092317bc17d&person_id=5978151494658009684&eid=50220
Cache-Control
no-cache
Connection
keep-alive
Content-Type
image/gif
Content-Length
0
Expires
Thu, 05 Sep 2019 06:40:53 GMT
csync.ashx
ml314.com/
Redirect Chain
  • https://sync.crwdcntrl.net/map/c=6985/tp=BOMB?https://ml314.com/csync.ashx%3Ffp%3D%24%7Bprofile_id%7D%26eid%3D50146%26person_id%3D5978151494658009684
  • https://ml314.com/csync.ashx?fp=d181d062f9136b1a46437f8e5d5c9661&eid=50146&person_id=5978151494658009684
43 B
312 B
Image
General
Full URL
https://ml314.com/csync.ashx?fp=d181d062f9136b1a46437f8e5d5c9661&eid=50146&person_id=5978151494658009684
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.247.144.106 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-247-144-106.eu-west-1.compute.amazonaws.com
Software
Microsoft-IIS/10.0 / ASP.NET
Resource Hash
b1442e85b03bdcaf66dc58c7abb98745dd2687d86350be9a298a1d9382ac849b

Request headers

Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Content-Type
image/gif
Cache-Control
private
Connection
keep-alive
Content-Length
43
Expires
Fri, 06 Sep 2019 02:40:54 GMT

Redirect headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:54 GMT
P3P
CP=NOI DSP COR NID PSAa PSDa OUR UNI COM NAV
Location
https://ml314.com/csync.ashx?fp=d181d062f9136b1a46437f8e5d5c9661&eid=50146&person_id=5978151494658009684
Cache-Control
no-cache
X-Server
10.45.9.239
Connection
keep-alive
Content-Length
0
Expires
0
match
ps.eyeota.net/
Redirect Chain
  • https://ps.eyeota.net/pixel?pid=r8hrb20&t=gif
  • https://ps.eyeota.net/pixel/bounce/?pid=r8hrb20&t=gif
  • https://ml314.com/utsync.ashx?eid=50052&et=0&fp=2oIyXwjj-X6VZW1iQUtVzwZ0k1V2I2JX7iHWeuvGCrPQ&gdpr=1&gdpr_consent=&return=https%3A%2F%2Fps.eyeota.net%2Fmatch%3Fbid%3Dr8hrb20%26uid%3Dnil
  • https://ml314.com/csync.ashx?fp=2oIyXwjj-X6VZW1iQUtVzwZ0k1V2I2JX7iHWeuvGCrPQ&person_id=5978151494658009684&eid=50052&return=https%3a%2f%2fps.eyeota.net%2fmatch%3fbid%3dr8hrb20%26uid%3dnil
  • https://ps.eyeota.net/match?bid=r8hrb20&uid=nil
70 B
171 B
Image
General
Full URL
https://ps.eyeota.net/match?bid=r8hrb20&uid=nil
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
18.185.83.216 Frankfurt am Main, Germany, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-18-185-83-216.eu-central-1.compute.amazonaws.com
Software
/
Resource Hash
de9d3fd0eb948bd294477d0eda60a73b85caff1794803530d0463193a113da98

Request headers

Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Content-Length
70
Content-Type
image/gif

Redirect headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Content-Type
text/html; charset=utf-8
Location
https://ps.eyeota.net/match?bid=r8hrb20&uid=nil
Cache-Control
private
Connection
keep-alive
Content-Length
168
Expires
Fri, 06 Sep 2019 02:40:54 GMT
Cookie set /
www.medtargetsystem.com/beacon/portal/ Frame EFFA
0
0
Document
General
Full URL
https://www.medtargetsystem.com/beacon/portal/?_url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F&_sid=5b8d02b7-f158-41e3-9fba-b2cbf1939026&_vid=453ff3a7-f142-4d71-811b-f39fbf2222f3&_ak=35-212-8F62AC13&_flash=false&_th=1567665654|1567665654|1
Requested by
Host: www.medtargetsystem.com
URL: https://www.medtargetsystem.com/javascript/beacon.js?v2.5.12
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.3.171.116 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-3-171-116.compute-1.amazonaws.com
Software
Apache/2.4.7 (Ubuntu) / PHP/7.0.19-1+deb.sury.org~trusty+2
Resource Hash

Request headers

Host
www.medtargetsystem.com
Connection
keep-alive
Pragma
no-cache
Cache-Control
no-cache
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
Sec-Fetch-Site
cross-site
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Accept-Encoding
gzip, deflate, br
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653

Response headers

Cache-Control
no-store, no-cache, must-revalidate
Content-Encoding
gzip
Content-Type
text/html; charset=UTF-8
Date
Thu, 05 Sep 2019 06:40:54 GMT
Expires
Thu, 19 Nov 1981 08:52:00 GMT
P3P
CP="IDC DSP COR ADM DEVi TAIi PSA PSD IVAi IVDi CONi HIS OUR IND CNT"
Pragma
no-cache
Server
Apache/2.4.7 (Ubuntu)
Set-Cookie
DMDSESSID=4cc14t64i54ggsi12o5f777944; path=/; HttpOnly
Vary
X-Forwarded-Proto,Accept-Encoding
X-Powered-By
PHP/7.0.19-1+deb.sury.org~trusty+2
Content-Length
6988
Connection
keep-alive
collect.gif
www.medtargetsystem.com/analytics/
0
313 B
Image
General
Full URL
https://www.medtargetsystem.com/analytics/collect.gif?e=1&aid=&vid=453ff3a7-f142-4d71-811b-f39fbf2222f3&sid=5b8d02b7-f158-41e3-9fba-b2cbf1939026&vh=1&vt=1567665654&pt=1567665654&u=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&r=&t=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&p=1154.57&pm=&ab=&ak=35-212-8F62AC13
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.3.171.116 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-3-171-116.compute-1.amazonaws.com
Software
Apache/2.4.7 (Ubuntu) / PHP/7.0.19-1+deb.sury.org~trusty+2
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:54 GMT
Server
Apache/2.4.7 (Ubuntu)
Connection
keep-alive
X-Powered-By
PHP/7.0.19-1+deb.sury.org~trusty+2
Content-Length
0
Vary
X-Forwarded-Proto
Content-Type
text/html; charset=UTF-8
5ddcc1786c2a1805c3a82d291451ce42
api.lytics.io/api/me/iframe/43bffbce6f25564c8e2145a11836ff9f/_uid/ Frame 78A0
0
0
Document
General
Full URL
https://api.lytics.io/api/me/iframe/43bffbce6f25564c8e2145a11836ff9f/_uid/5ddcc1786c2a1805c3a82d291451ce42?segments=true&mergestate=true&ts=1567665654943
Requested by
Host: c.lytics.io
URL: https://c.lytics.io/api/tag/43bffbce6f25564c8e2145a11836ff9f/lio.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
35.227.192.113 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
113.192.227.35.bc.googleusercontent.com
Software
lytics.io 910393fbafbb08c3ef4e7267ee4b5e65ce7f6385 /
Resource Hash

Request headers

:method
GET
:authority
api.lytics.io
:scheme
https
:path
/api/me/iframe/43bffbce6f25564c8e2145a11836ff9f/_uid/5ddcc1786c2a1805c3a82d291451ce42?segments=true&mergestate=true&ts=1567665654943
pragma
no-cache
cache-control
no-cache
upgrade-insecure-requests
1
user-agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
sec-fetch-mode
nested-navigate
accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
sec-fetch-site
cross-site
referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
accept-encoding
gzip, deflate, br
cookie
__cfduid=dcf459a426b67ab43f0d78e598b2e25b31567665654; seerid=5ddcc1786c2a1805c3a82d291451ce42
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653

Response headers

status
200
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Authorization, Cookie, *
access-control-allow-methods
GET
access-control-allow-origin
content-encoding
gzip
content-type
text/html
server
lytics.io 910393fbafbb08c3ef4e7267ee4b5e65ce7f6385
date
Thu, 05 Sep 2019 06:40:55 GMT
content-length
294
via
1.1 google
alt-svc
clear
store
match.deepintent.com/usersync/114/
0
216 B
Image
General
Full URL
https://match.deepintent.com/usersync/114/store?id=UNK&ext1=5b8d02b7-f158-41e3-9fba-b2cbf1939026
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.71.111.112 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-71-111-112.compute-1.amazonaws.com
Software
nginx /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

status
200
date
Thu, 05 Sep 2019 06:40:55 GMT
server
nginx
content-type
image/gif
content-length
0
p3p
policyref='http://cdn.deepintent.com/p3p.xml', CP='NON CUR DEV TAI'
css
fonts.googleapis.com/
1 KB
488 B
Stylesheet
General
Full URL
https://fonts.googleapis.com/css?family=Lato:400,900
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.bundle.js?ver=0.1.1
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:80b::200a Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
ESF /
Resource Hash
4bd7ab38b940371c161b19f0cf34bdfdeaac480eda86b13c29591ed01ed67c36
Security Headers
Name Value
Strict-Transport-Security max-age=31536000
X-Frame-Options SAMEORIGIN
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=31536000
content-encoding
br
last-modified
Thu, 05 Sep 2019 06:40:55 GMT
server
ESF
link
<https://fonts.gstatic.com>; rel=preconnect; crossorigin
status
200
date
Thu, 05 Sep 2019 06:40:55 GMT
x-frame-options
SAMEORIGIN
content-type
text/css; charset=utf-8
access-control-allow-origin
*
cache-control
private, max-age=86400, stale-while-revalidate=604800
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
x-xss-protection
0
expires
Thu, 05 Sep 2019 06:40:55 GMT
truncated
/
5 KB
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
d9593473fc4d73446eac1a620bb1bbe590fc80d61d8909484dfee64ae522b787

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/png
13
subapi.haymarketmedia.com/newsletter/
3 KB
4 KB
XHR
General
Full URL
https://subapi.haymarketmedia.com/newsletter/13
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.vendor.js?ver=0.1.1
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
35.172.78.117 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-35-172-78-117.compute-1.amazonaws.com
Software
/ Express
Resource Hash
dc33184388cdcf8d8744da89db61d1633ff8219cc2a82f5c16758ff51a6ef531

Request headers

Accept
application/json, text/plain, */*
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
cors

Response headers

date
Thu, 05 Sep 2019 06:40:55 GMT
x-powered-by
Express
etag
W/"d3e-V8fKzUWOVMxpQEouMHWsycPY5EQ"
status
200
access-control-allow-methods
GET, POST, OPTIONS
content-type
text/html; charset=utf-8
access-control-allow-origin
*
access-control-allow-credentials
true
access-control-allow-headers
Content-Type, Connection, Keep-Alive, Content-Length
content-length
3390
13
subapi.haymarketmedia.com/newsletter/
3 KB
4 KB
XHR
General
Full URL
https://subapi.haymarketmedia.com/newsletter/13
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.vendor.js?ver=0.1.1
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
35.172.78.117 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-35-172-78-117.compute-1.amazonaws.com
Software
/ Express
Resource Hash
dc33184388cdcf8d8744da89db61d1633ff8219cc2a82f5c16758ff51a6ef531

Request headers

Accept
application/json, text/plain, */*
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
cors

Response headers

date
Thu, 05 Sep 2019 06:40:55 GMT
x-powered-by
Express
etag
W/"d3e-V8fKzUWOVMxpQEouMHWsycPY5EQ"
status
200
access-control-allow-methods
GET, POST, OPTIONS
content-type
text/html; charset=utf-8
access-control-allow-origin
*
access-control-allow-credentials
true
access-control-allow-headers
Content-Type, Connection, Keep-Alive, Content-Length
content-length
3390
truncated
/
24 KB
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
65f72bc49f7e243cf332df6eb265d987e4c6e997e7aecd813ceace591f805071

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/gif
collect.gif
www.medtargetsystem.com/analytics/
0
245 B
Image
General
Full URL
https://www.medtargetsystem.com/analytics/collect.gif?e=1&aid=&vid=453ff3a7-f142-4d71-811b-f39fbf2222f3&sid=5b8d02b7-f158-41e3-9fba-b2cbf1939026&vh=2&vt=1567665654&pt=1567665655&u=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&r=&t=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&p=1486.44&pm=&ab=&ak=35-212-8F62AC13
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.3.171.116 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-3-171-116.compute-1.amazonaws.com
Software
Apache/2.4.7 (Ubuntu) / PHP/7.0.19-1+deb.sury.org~trusty+2
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:55 GMT
Server
Apache/2.4.7 (Ubuntu)
Connection
keep-alive
X-Powered-By
PHP/7.0.19-1+deb.sury.org~trusty+2
Content-Length
0
Vary
X-Forwarded-Proto
Content-Type
text/html; charset=UTF-8
truncated
/
82 KB
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
ad9d820f1802abd0f80d4e260c43cd6c92d643c926732a00296821182ae3f9c7

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/svg+xml
/
www.facebook.com/tr/ Frame AFAC
0
0
Document
General
Full URL
https://www.facebook.com/tr/
Requested by
Host: connect.facebook.net
URL: https://connect.facebook.net/en_US/fbevents.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a03:2880:f11c:8083:face:b00c:0:25de , Ireland, ASN32934 (FACEBOOK - Facebook, Inc., US),
Reverse DNS
Software
proxygen-bolt /
Resource Hash
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains

Request headers

:method
POST
:authority
www.facebook.com
:scheme
https
:path
/tr/
content-length
12038
pragma
no-cache
cache-control
no-cache
origin
https://www.empr.com
upgrade-insecure-requests
1
content-type
application/x-www-form-urlencoded
user-agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
sec-fetch-mode
nested-navigate
accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
sec-fetch-site
cross-site
referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
accept-encoding
gzip, deflate, br
cookie
fr=0Rwt8jbow4KjEJ5xy..BdcK32...1.0.BdcK32.
Origin
https://www.empr.com
Upgrade-Insecure-Requests
1
Content-Type
application/x-www-form-urlencoded
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653

Response headers

status
200
content-type
text/plain
access-control-allow-origin
https://www.empr.com
access-control-allow-credentials
true
strict-transport-security
max-age=31536000; includeSubDomains
content-length
0
server
proxygen-bolt
date
Thu, 05 Sep 2019 06:40:55 GMT
registration-profession
subapi.haymarketmedia.com/
589 B
876 B
XHR
General
Full URL
https://subapi.haymarketmedia.com/registration-profession?countryCode=US
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.vendor.js?ver=0.1.1
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
35.172.78.117 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-35-172-78-117.compute-1.amazonaws.com
Software
/ Express
Resource Hash
808e5dda9ebf9cae0ae42a7f53c8c335e6f2951724c8a58c15658d0fdd49b61f

Request headers

Accept
application/json, text/plain, */*
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
cors

Response headers

date
Thu, 05 Sep 2019 06:40:55 GMT
x-powered-by
Express
etag
W/"24d-pNT5lZLPsLHhX4AYX72K6qXLTk4"
status
200
access-control-allow-methods
GET, POST, OPTIONS
content-type
application/json; charset=utf-8
access-control-allow-origin
*
access-control-allow-credentials
true
access-control-allow-headers
Content-Type, Connection, Keep-Alive, Content-Length
content-length
589
registration-specialty
subapi.haymarketmedia.com/
2 KB
2 KB
XHR
General
Full URL
https://subapi.haymarketmedia.com/registration-specialty?countryCode=US
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.vendor.js?ver=0.1.1
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
35.172.78.117 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-35-172-78-117.compute-1.amazonaws.com
Software
/ Express
Resource Hash
2ccc2d6a6ce64b8e30228624183547c2456f8d9597ca456d147f47e95f4fe443

Request headers

Accept
application/json, text/plain, */*
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
cors

Response headers

date
Thu, 05 Sep 2019 06:40:55 GMT
x-powered-by
Express
etag
W/"686-ZUbw46JA9hG3Fv9uXg61Vkj0+q0"
status
200
access-control-allow-methods
GET, POST, OPTIONS
content-type
application/json; charset=utf-8
access-control-allow-origin
*
access-control-allow-credentials
true
access-control-allow-headers
Content-Type, Connection, Keep-Alive, Content-Length
content-length
1670
truncated
/
88 B
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
65af014c9562d3ef38dbb4638bef464aa19d2c5899e1872b6ec96da9046168e5

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/svg+xml;charset=utf-8
/
www.facebook.com/tr/ Frame 82D2
0
0
Document
General
Full URL
https://www.facebook.com/tr/
Requested by
Host: connect.facebook.net
URL: https://connect.facebook.net/en_US/fbevents.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a03:2880:f11c:8083:face:b00c:0:25de , Ireland, ASN32934 (FACEBOOK - Facebook, Inc., US),
Reverse DNS
Software
proxygen-bolt /
Resource Hash
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains

Request headers

:method
POST
:authority
www.facebook.com
:scheme
https
:path
/tr/
content-length
3708
pragma
no-cache
cache-control
no-cache
origin
https://www.empr.com
upgrade-insecure-requests
1
content-type
application/x-www-form-urlencoded
user-agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
sec-fetch-mode
nested-navigate
accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
sec-fetch-site
cross-site
referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
accept-encoding
gzip, deflate, br
cookie
fr=0Rwt8jbow4KjEJ5xy..BdcK32...1.0.BdcK32.
Origin
https://www.empr.com
Upgrade-Insecure-Requests
1
Content-Type
application/x-www-form-urlencoded
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653

Response headers

status
200
content-type
text/plain
access-control-allow-origin
https://www.empr.com
access-control-allow-credentials
true
strict-transport-security
max-age=31536000; includeSubDomains
content-length
0
server
proxygen-bolt
date
Thu, 05 Sep 2019 06:40:55 GMT
pathfora.min.js
c.lytics.io/static/
98 KB
20 KB
Script
General
Full URL
https://c.lytics.io/static/pathfora.min.js
Requested by
Host: c.lytics.io
URL: https://c.lytics.io/api/tag/43bffbce6f25564c8e2145a11836ff9f/lio.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
4215e6200c04a4874f3d23c78af23fcd22b5bc3bc916237fd95c108aaae38735

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

cf-ray
511636ea7a5b599a-VIE
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
cf-cache-status
HIT
last-modified
Wed, 03 Jul 2019 23:03:58 GMT
server
cloudflare
age
1880
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
vary
Accept-Encoding
content-type
application/javascript
status
200
cache-control
public, max-age=7200
content-encoding
br
expires
Thu, 05 Sep 2019 08:40:55 GMT
43bffbce6f25564c8e2145a11836ff9f
c.lytics.io/c/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f?_ts=1567665655399&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_e=pv&utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&_sesstart=1&_tz=2&_ul=en-US&_sz=1600x1200&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ea7a5c599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
43bffbce6f25564c8e2145a11836ff9f
c.lytics.io/c/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f?publicationId=13&channel=home&pagetype=post&tags=miscellaneous%20musculoskeletal%20disorders%2Cmusculoskeletal%20disorders&categories=news&pagename=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&author=Brian%20Park%2C%20PharmD&section=home%3Anews%3Aixekizumab%20gains%20fda%20approval%20for%20treatment%20of%20active%20ankylosing%20spondylitis&email=nguyentt%40sutterhealth.org&user_id=0&cpn=pcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019&login=nguyentt%40sutterhealth.org&userstate=CA&userspecialty=&userprofession=Physician&_ts=1567665655400&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ea7a5e599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?gtm.start=1567665654441&event=gtm.js&gtm.uniqueEventId=15&_ts=1567665655401&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ea7a5f599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.AdBlocking=&_ts=1567665655401&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ea7a60599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.NHTFlag=false&_ts=1567665655401&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ea7a61599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
94 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.ArticleId=122761%3A0&_ts=1567665655402&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ea9a66599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
173 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.ArticleType=MPR%20Drug%20News&_ts=1567665655402&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636eb5ac1599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
94 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.MetaData=&_ts=1567665655403&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636eb5ac3599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Type=post&_ts=1567665655403&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636eb5ac4599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.ScrollDepth=&_ts=1567665655404&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636eb5ac5599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.cmeActivityId=&_ts=1567665655404&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636eb5ac6599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
231 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.PrintSource=&_ts=1567665655404&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636eb7ad4599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.SEOScore=&_ts=1567665655404&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ec4b2e599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Site.Prefix=omn&_ts=1567665655405&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ec4b2f599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Site.PublicationId=13&_ts=1567665655405&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ec4b30599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.Author=Brian%20Park%2C%20PharmD&_ts=1567665655405&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ec4b32599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Novo.PremiumMonograph=&_ts=1567665655406&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ec4b35599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Novo.Geolocation=&_ts=1567665655406&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ec5b3c599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Activity.Name=&_ts=1567665655406&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ed2ba3599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.GenericEvents=&_ts=1567665655407&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ed2ba5599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?eComm.CurrencyCode=&_ts=1567665655407&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ed2ba6599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
104 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?eComm.OrderId=&_ts=1567665655407&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ed2ba9599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
94 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Drug.CompanyName=&_ts=1567665655407&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ed2baa599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Novo.IsPremiumMonograph=false&_ts=1567665655408&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ed3baf599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.GatingType=post%3Anone&_ts=1567665655408&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ee1c09599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
116 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.Company=&_ts=1567665655408&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ee1c0a599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.Discipline=&_ts=1567665655409&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ee1c0b599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.Asset=&_ts=1567665655410&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ee1c0d599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.PublishDate=2019-08-26&_ts=1567665655410&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ee1c0e599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.Curation=false&_ts=1567665655410&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ee1c0f599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
189 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.WordCount=325&_ts=1567665655411&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ef0c8a599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
95 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?MyCME.CreditType=&_ts=1567665655411&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ef0c8d599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
95 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?MyCME.ActivityResult=&_ts=1567665655411&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ef0c8e599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
95 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.NumberofAdCalls=9&_ts=1567665655411&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ef0c8f599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
95 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?eComm.ProductsInCart=&_ts=1567665655412&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ef0c90599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
95 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Section1=home&_ts=1567665655412&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636ef0c91599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Section2=home%3Anews&_ts=1567665655412&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f00d20599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Section3=home%3Anews%3Aixekizumab%20gains%20fda%20approval%20for%20treatment%20of%20active%20ankylosing%20spondylitis&_ts=1567665655413&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f00d23599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Section4=&_ts=1567665655413&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f00d24599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Tags=miscellaneous%20musculoskeletal%20disorders%2Cmusculoskeletal%20disorders&_ts=1567665655413&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f00d26599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Categories=news&_ts=1567665655414&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f00d28599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.LoggedIn=false&_ts=1567665655414&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f00d29599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.Login=&_ts=1567665655415&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f0fdbc599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.SocSSN=&_ts=1567665655415&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f0fdbe599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.SSO=3&_ts=1567665655415&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f0fdbf599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.SubscriberId=0&_ts=1567665655416&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f0fdc0599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.Source=&_ts=1567665655416&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f0fdc1599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.Profession=Physician&_ts=1567665655416&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f0fdc2599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.Specialty=&_ts=1567665655417&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f1ee50599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.SubProfession=&_ts=1567665655417&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f1ee51599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.SubSpecialty=&_ts=1567665655417&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f1ee52599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
101 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.JobTitle=&_ts=1567665655418&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f1ee53599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
94 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.CampaignCodes=pcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019&_ts=1567665655418&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f1ee54599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
94 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.Country=&_ts=1567665655418&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f1ee55599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.Company=&_ts=1567665655418&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f2ceec599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.CompanySize=&_ts=1567665655419&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f2deed599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
231 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.IsHaymarket=false&_ts=1567665655419&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f2deee599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.IsTracked=true&_ts=1567665655419&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f2deef599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.IsFromAim=false&_ts=1567665655420&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f2def0599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.NpiNumber=1619909975&_ts=1567665655420&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f2def7599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
116 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?gtm.start=1567665654654&event=gtm.js&gtm.uniqueEventId=3&_ts=1567665655420&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&_uid=5ddcc1786c2a1805c3a82d291451ce42&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:57 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
511636f3af92599a-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
5ddcc1786c2a1805c3a82d291451ce42
api.lytics.io/api/content/recommend/43bffbce6f25564c8e2145a11836ff9f/user/_uid/
176 KB
28 KB
XHR
General
Full URL
https://api.lytics.io/api/content/recommend/43bffbce6f25564c8e2145a11836ff9f/user/_uid/5ddcc1786c2a1805c3a82d291451ce42?limit=30&contentsegment=ee9fe9a51cf2f1774e42f33abc9ca99c&shuffle=true
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1567085297
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
35.227.192.113 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
113.192.227.35.bc.googleusercontent.com
Software
lytics.io 910393fbafbb08c3ef4e7267ee4b5e65ce7f6385 /
Resource Hash
565aed5c64f0d17d906a6291a6bf1d1811790b3793914c5646d96afe4eefe26e

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:56 GMT
content-encoding
gzip
server
lytics.io 910393fbafbb08c3ef4e7267ee4b5e65ce7f6385
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Authorization, Cookie, *
status
200
access-control-allow-methods
GET
content-type
application/json
access-control-allow-origin
https://www.empr.com
alt-svc
clear
via
1.1 google
pathfora.min.css
c.lytics.io/static/
20 KB
3 KB
Stylesheet
General
Full URL
https://c.lytics.io/static/pathfora.min.css
Requested by
Host: c.lytics.io
URL: https://c.lytics.io/static/pathfora.min.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
58aa5964d6f5dc68b2180e943ea63b6031c0ba83e44d9815e724b10f2f615f9f

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

cf-ray
511636eaaa69599a-VIE
date
Thu, 05 Sep 2019 06:40:55 GMT
via
1.1 google
cf-cache-status
HIT
last-modified
Wed, 03 Jul 2019 23:03:58 GMT
server
cloudflare
age
1872
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
vary
Accept-Encoding
content-type
text/css; charset=utf-8
status
200
cache-control
public, max-age=7200
content-encoding
br
expires
Thu, 05 Sep 2019 08:40:55 GMT
config.js
c.lytics.io/api/program/campaign/config/43bffbce6f25564c8e2145a11836ff9f/
62 KB
8 KB
Script
General
Full URL
https://c.lytics.io/api/program/campaign/config/43bffbce6f25564c8e2145a11836ff9f/config.js
Requested by
Host: c.lytics.io
URL: https://c.lytics.io/api/tag/43bffbce6f25564c8e2145a11836ff9f/lio.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5465 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
71a43b5d3e261b0ff9a5c69c65592c17abee7c69cadd52a12d39e9c5b289e55e

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

cf-ray
511636f3af94599a-VIE
date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 google
cf-cache-status
HIT
server
cloudflare
age
999
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
vary
Accept-Encoding
content-type
application/javascript
status
200
cache-control
public, max-age=7200
content-encoding
br
expires
Thu, 05 Sep 2019 08:40:56 GMT
ads
securepubads.g.doubleclick.net/gampad/
4 KB
2 KB
XHR
General
Full URL
https://securepubads.g.doubleclick.net/gampad/ads?gdfp_req=1&pvsid=58798823753697&correlator=759639680399096&output=ldjh&callback=googletag.impl.pubads.callbackProxy1&impl=fif&adsid=NT&vrg=2019082701&guci=1.2.0.0.2.2.0.0&plat=1%3A32776%2C2%3A16809992%2C8%3A134250504&sc=1&sfv=1-0-35&ecs=20190905&iu=%2F5745%2Fmpr_us%2Fhome%2Fnews%2FOOP_prestitial&sz=1x1&ists=1&scp=pos%3DOOP_prestitial&eri=1&cust_params=pagetype%3Dpost%26sponsor%3D%26comp%3D%26author%3DSteve%2520Duffy%26postID%3D122761%26env%3Dlive%26sid%3DNews%26styleid%3D%26cat%3DMiscellaneous_Musculoskeletal_Disorders%252CMusculoskeletal_Disorders%26atype%3DMPR_Drug_News%26block%3Dmpr_basaglar042616%252CTest%26isnht%3Dfalse%26browser%3DChrome%252074%26amid%3D7ae510fe18e7431582eb749cfc8567497d75868fa53d079af4ef35f92eebbf33%26spr%3D448%26ssp%3D%26cpn%3Dpcp_md%252Cfp_md%252Cpcp_all%252Charvonitbg%252Cepclusalistb_jan2019%252Cepclusa_april_2019%26subid%3D0%26usrc%3Dhaymarket%26eid%3D4765f0213a10614f6c52b4556676d479ec4f181705feaedbccdcef78c850b74a%26LyticsSegments%3Dga_med_nomycme%252Cga_med_nht_false%252Cmycme_rheum_survey_audience%252C3_day_visitors_neuro_ca_empr%252Cblackfriday_notunknown%252Cactivity_5126_audience%252Cmycme_endofyearsale_noanonymous_nosdc%252Caudience_for_mlk_sale%252Cnot_unknown_5770%252Cmycme_activity_5762%252Cddw_opened_to_all%252Call%252Csmt_new%252Cly_reporting_from_email%252Cly_reporting_has_visited_web%252Cly_reporting_multi_session_visitor%252Cly_reporting_last_visit_within_day%252Cly_reporting_last_visit_within_week%252Cly_reporting_last_visit_within_month%252Cly_reporting_last_visit_within_3_months%252Cly_known_email%252Cly_repeat_visitor%252Cly_international_visitor%252Cly_uses_desktop%252Cly_from_email%252Cknown%252Call_time_visitors%252Cmycme_allergy_all_except_4797_completes%252Cmycme_hiv_all_except_4670_completes%252Cmycme_internal_med_all_except_4670_completes%252Cmycme_allergy_all_except_4744_completes%252Cmycme_psychiatry_all_except_4812_completes%252Cmycme_cardiology_all_except_cardiology_pas%252Cmycme_dermatology_all_except_4831_completes%252Cmycme_pediatrics_all_except_4354_completes%252Cmycme_acc_next_activity_promo_no_4523%252Cmycme_acc_next_activity_promo_no_4524%252Cmycme_acc_next_activity_promo_no_4525%252Cmycme_acc_next_activity_promo_no_4526%252Cmycme_acc_next_activity_promo_no_4593%252Cmycme_acc_next_activity_promo_no_4595%252Cmycme_acc_next_activity_promo_no_4710%252Cmycme_acc_next_activity_promo_no_4804%252Cmycme_acc_next_activity_promo_no_4834%252Cmycme_acc_next_activity_promo_no_4800%252Cmycme_acc_next_activity_promo_no_4792%252Cmycme_acc_next_activity_promo_no_4511%252Cmycme_acc_next_activity_promo_no_4529%252Cmycme_acc_next_activity_promo_no_4558%252Cmycme_acc_next_activity_promo_no_4634%252Cmycme_impact_next_activity_promo_no_4740%252Cmycme_impact_next_activity_promo_no_4757%252Cmycme_impact_next_activity_promo_no_4842%252Cmycme_impact_next_activity_promo_no_4816%252Cmycme_impact_next_activity_promo_no_4897%252Cmycme_impact_next_activity_promo_no_4727%252Cmycme_impact_next_activity_promo_no_4755%252Cmycme_impact_next_activity_promo_no_4791%252Cmycme_impact_next_activity_promo_no_47911%252Cmycme_impact_next_activity_promo_no_4826%252Cmycme_impact_next_activity_promo_no_4815%252Cce_excluding_mpr_print_subscribers%252Cce_excluding_ca_print_subscribers%252Cga_med_known%252Cmycme_homepage_ibs_town_wall_%252Cmycme_ddw_nash%252Cmycme_activity_5841_2%252Cmycme_pediatrics_activity_5591&cookie_enabled=1&bc=31&abxe=1&lmt=1567665655&dt=1567665655735&dlt=1567665654414&idt=208&frm=20&biw=1585&bih=1200&oid=3&adx=0&ady=3790&adk=1518026067&uci=1&ifi=1&u_tz=120&u_his=2&u_h=1200&u_w=1600&u_ah=1200&u_aw=1600&u_cd=24&u_sd=1&flash=0&url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&dssz=78&icsg=38070606888960&mso=67108864&std=0&vis=1&dmc=8&scr_x=0&scr_y=0&psz=1585x3791&msz=1585x1&blev=1&bisch=1&ga_vid=1629988481.1567665651&ga_sid=1567665656&ga_hid=927312587&fws=4&ohw=1585
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
216.58.210.2 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra16s07-in-f2.1e100.net
Software
cafe /
Resource Hash
e1e0803be994ab726b370a876bf287ca449192ea91deb049a3162bd933bdc8a1
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:55 GMT
content-encoding
br
x-content-type-options
nosniff
google-mediationgroup-id
-2
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
status
200
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
1984
x-xss-protection
0
google-lineitem-id
132788185
pragma
no-cache
server
cafe
google-mediationtag-id
-2
google-creative-id
138274708445
content-type
text/plain; charset=UTF-8
access-control-allow-origin
https://www.empr.com
cache-control
no-cache, must-revalidate
access-control-allow-credentials
true
timing-allow-origin
*
expires
Fri, 01 Jan 1990 00:00:00 GMT
pubads_impl_rendering_2019082701.js
securepubads.g.doubleclick.net/gpt/
66 KB
25 KB
Script
General
Full URL
https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
216.58.210.2 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra16s07-in-f2.1e100.net
Software
sffe /
Resource Hash
062aef80c07aa0f3d7ccffd31c292c44754798f065a72d6f21b00370e83811b4
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:55 GMT
content-encoding
gzip
x-content-type-options
nosniff
last-modified
Tue, 27 Aug 2019 11:19:55 GMT
server
sffe
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
private, immutable, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
25316
x-xss-protection
0
expires
Thu, 05 Sep 2019 06:40:55 GMT
container.html
tpc.googlesyndication.com/safeframe/1-0-35/html/
0
0

universal-tag.js
ads.spotible.com/tag/ Frame F036
4 KB
2 KB
Script
General
Full URL
https://ads.spotible.com/tag/universal-tag.js
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.197.62.58 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-34-197-62-58.compute-1.amazonaws.com
Software
/
Resource Hash
8a846df9c01f4d8d8b6e82c6e505069104280430b3b05d94a13a5b99d7c854aa

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:55 GMT
Content-Encoding
gzip
ETag
"5c736e518f66ceaaee6badc00016e1a5"
Vary
Accept-Encoding
Content-Type
application/javascript
Cache-Control
public, max-age=3600
Connection
keep-alive
Content-Length
1767
truncated
/ Frame F036
214 B
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
2d8c51a94ca93aebed2dcc257233dbe9474a099e5044fecbd1273e6004216648

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/png
osd.js
www.googletagservices.com/activeview/js/current/
76 KB
28 KB
Script
General
Full URL
https://www.googletagservices.com/activeview/js/current/osd.js?cb=%2Fr20100101
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:824::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
7b50f00b4ec8c413fdfcf5ccb596f9ae3f47f776ae7fd913eab6cdda0e1543e9
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:55 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
sffe
etag
"1567595695661868"
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
private, max-age=3000
accept-ranges
bytes
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43,39",quic=":443"; ma=2592000; v="46,43,39"
content-length
28441
x-xss-protection
0
expires
Thu, 05 Sep 2019 06:40:55 GMT
/
adtrackapi.haymarketmedia.com/adverttracking/
2 B
365 B
XHR
General
Full URL
https://adtrackapi.haymarketmedia.com/adverttracking/
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-adtracking-js/prod/adtracking.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:9000:20bb:5a00:16:bc48:4dc0:93a1 , United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
/
Resource Hash
44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-type
application/json

Response headers

date
Thu, 05 Sep 2019 06:40:56 GMT
via
1.1 7ff3248f5aef149847858a974cf62b00.cloudfront.net (CloudFront)
x-amz-cf-pop
FRA56
x-amzn-requestid
3c894751-9d9b-4054-9830-f71494003305
status
200
x-cache
Miss from cloudfront
content-type
application/json
access-control-allow-origin
*
x-amzn-trace-id
Root=1-5d70adf8-2249e3a38b38020d6da68af5;Sampled=0
x-amz-apigw-id
fiAe0FDDIAMFfFA=
content-length
2
x-amz-cf-id
L0v-vAl33KhsplSuXs4xz1T2lINisFEXDyJT_SX1JxV2yuZZJ7jCYg==
creative-delivery.js
ads.spotible.com/creative/bmMb/
58 KB
20 KB
Script
General
Full URL
https://ads.spotible.com/creative/bmMb/creative-delivery.js
Requested by
Host: ads.spotible.com
URL: https://ads.spotible.com/tag/universal-tag.js
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.197.62.58 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-34-197-62-58.compute-1.amazonaws.com
Software
/
Resource Hash
2df541ba2dac12759f5cc36999736a318e366452d683593b713ca1a53d1e27e5

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:56 GMT
Content-Encoding
gzip
ETag
"c1d949de721a6052e9634dc663595413"
Vary
Accept-Encoding
Content-Type
application/javascript
Cache-Control
no-cache
Connection
keep-alive
Content-Length
19905
MPR-lightbox_640x480-july19_Q.gif
cdn1.spotible.com/hashed/a0bb68f349c5a16009bb7cf6d5bab3bb/
685 KB
686 KB
Image
General
Full URL
https://cdn1.spotible.com/hashed/a0bb68f349c5a16009bb7cf6d5bab3bb/MPR-lightbox_640x480-july19_Q.gif
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
143.204.214.75 Seattle, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
server-143-204-214-75.fra53.r.cloudfront.net
Software
/
Resource Hash
ad15e0951b55982ad0447c99a54cc497669f65c84ac6b12616891fec5f51223c

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Tue, 02 Jul 2019 21:06:07 GMT
via
1.1 e0064d0a2437e206ed082e1fa1cdae61.cloudfront.net (CloudFront)
age
85207
etag
"a0bb68f349c5a16009bb7cf6d5bab3bb"
x-cache
Hit from cloudfront
status
200
cache-control
public, max-age=604800
x-amz-cf-pop
FRA53-C1
accept-ranges
bytes
content-length
701058
x-amz-cf-id
Hc3hsuJl0fQYxZHXjVsCyutd8klNE28laJUjuKfY72LuHfg0aOO4Tw==
ads
securepubads.g.doubleclick.net/gampad/
19 KB
6 KB
XHR
General
Full URL
https://securepubads.g.doubleclick.net/gampad/ads?gdfp_req=1&pvsid=58798823753697&correlator=759639680399096&output=ldjh&callback=googletag.impl.pubads.callbackProxy2&impl=fif&adsid=NT&eid=21064502&vrg=2019082701&guci=1.2.0.0.2.2.0.0&plat=1%3A32776%2C2%3A16809992%2C8%3A134250504&sc=1&sfv=1-0-35&ecs=20190905&iu=%2F5745%2Fmpr_us%2Fhome%2Fnews%2Fleaderboard_top&sz=728x90&scp=pos%3Dleaderboard_top&eri=1&cust_params=pagetype%3Dpost%26sponsor%3D%26comp%3D%26author%3DSteve%2520Duffy%26postID%3D122761%26env%3Dlive%26sid%3DNews%26styleid%3D%26cat%3DMiscellaneous_Musculoskeletal_Disorders%252CMusculoskeletal_Disorders%26atype%3DMPR_Drug_News%26block%3Dmpr_basaglar042616%252CTest%26isnht%3Dfalse%26browser%3DChrome%252074%26amid%3D7ae510fe18e7431582eb749cfc8567497d75868fa53d079af4ef35f92eebbf33%26spr%3D448%26ssp%3D%26cpn%3Dpcp_md%252Cfp_md%252Cpcp_all%252Charvonitbg%252Cepclusalistb_jan2019%252Cepclusa_april_2019%26subid%3D0%26usrc%3Dhaymarket%26eid%3D4765f0213a10614f6c52b4556676d479ec4f181705feaedbccdcef78c850b74a%26LyticsSegments%3Dga_med_nomycme%252Cga_med_nht_false%252Cmycme_rheum_survey_audience%252C3_day_visitors_neuro_ca_empr%252Cblackfriday_notunknown%252Cactivity_5126_audience%252Cmycme_endofyearsale_noanonymous_nosdc%252Caudience_for_mlk_sale%252Cnot_unknown_5770%252Cmycme_activity_5762%252Cddw_opened_to_all%252Call%252Csmt_new%252Cly_reporting_from_email%252Cly_reporting_has_visited_web%252Cly_reporting_multi_session_visitor%252Cly_reporting_last_visit_within_day%252Cly_reporting_last_visit_within_week%252Cly_reporting_last_visit_within_month%252Cly_reporting_last_visit_within_3_months%252Cly_known_email%252Cly_repeat_visitor%252Cly_international_visitor%252Cly_uses_desktop%252Cly_from_email%252Cknown%252Call_time_visitors%252Cmycme_allergy_all_except_4797_completes%252Cmycme_hiv_all_except_4670_completes%252Cmycme_internal_med_all_except_4670_completes%252Cmycme_allergy_all_except_4744_completes%252Cmycme_psychiatry_all_except_4812_completes%252Cmycme_cardiology_all_except_cardiology_pas%252Cmycme_dermatology_all_except_4831_completes%252Cmycme_pediatrics_all_except_4354_completes%252Cmycme_acc_next_activity_promo_no_4523%252Cmycme_acc_next_activity_promo_no_4524%252Cmycme_acc_next_activity_promo_no_4525%252Cmycme_acc_next_activity_promo_no_4526%252Cmycme_acc_next_activity_promo_no_4593%252Cmycme_acc_next_activity_promo_no_4595%252Cmycme_acc_next_activity_promo_no_4710%252Cmycme_acc_next_activity_promo_no_4804%252Cmycme_acc_next_activity_promo_no_4834%252Cmycme_acc_next_activity_promo_no_4800%252Cmycme_acc_next_activity_promo_no_4792%252Cmycme_acc_next_activity_promo_no_4511%252Cmycme_acc_next_activity_promo_no_4529%252Cmycme_acc_next_activity_promo_no_4558%252Cmycme_acc_next_activity_promo_no_4634%252Cmycme_impact_next_activity_promo_no_4740%252Cmycme_impact_next_activity_promo_no_4757%252Cmycme_impact_next_activity_promo_no_4842%252Cmycme_impact_next_activity_promo_no_4816%252Cmycme_impact_next_activity_promo_no_4897%252Cmycme_impact_next_activity_promo_no_4727%252Cmycme_impact_next_activity_promo_no_4755%252Cmycme_impact_next_activity_promo_no_4791%252Cmycme_impact_next_activity_promo_no_47911%252Cmycme_impact_next_activity_promo_no_4826%252Cmycme_impact_next_activity_promo_no_4815%252Cce_excluding_mpr_print_subscribers%252Cce_excluding_ca_print_subscribers%252Cga_med_known%252Cmycme_homepage_ibs_town_wall_%252Cmycme_ddw_nash%252Cmycme_activity_5841_2%252Cmycme_pediatrics_activity_5591&cookie_enabled=1&bc=31&abxe=1&lmt=1567665656&dt=1567665656455&dlt=1567665654414&idt=208&frm=20&biw=1585&bih=1200&oid=3&adx=193&ady=140&adk=2785330797&uci=2&ifi=2&u_tz=120&u_his=2&u_h=1200&u_w=1600&u_ah=1200&u_aw=1600&u_cd=24&u_sd=1&flash=0&url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&dssz=80&icsg=152282377224192&mso=67108864&std=0&vis=1&dmc=8&scr_x=0&scr_y=0&psz=1200x-1&msz=1200x-1&blev=1&bisch=1&psts=Ci8I2d-oP-gB3bfCjoMEggIVsbmAD9G59iGBw_Yh8e3PNLfIz49R0QJlE1_4V-o3hA&ga_vid=1629988481.1567665651&ga_sid=1567665656&ga_hid=927312587&fws=516&ohw=1585
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
216.58.210.2 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra16s07-in-f2.1e100.net
Software
cafe /
Resource Hash
50d6a2450daece08a66504b6bd7126046de8d0ee58231f39268cca2215d56cad
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:56 GMT
content-encoding
br
x-content-type-options
nosniff
google-mediationgroup-id
-2
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
status
200
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
5823
x-xss-protection
0
google-lineitem-id
5144421111
pragma
no-cache
server
cafe
google-mediationtag-id
-2
google-creative-id
138278274851
content-type
text/plain; charset=UTF-8
access-control-allow-origin
https://www.empr.com
cache-control
no-cache, must-revalidate
access-control-allow-credentials
true
timing-allow-origin
*
expires
Fri, 01 Jan 1990 00:00:00 GMT
FDA-HQ-1.jpg
www.empr.com/wp-content/uploads/sites/7/2019/04/
44 KB
44 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2019/04/FDA-HQ-1.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
3622b951ea76b210435cfe0389822bfbeb3c690133e6c6fd4724c335b594420a
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Sun, 28 Apr 2019 07:11:12 GMT
server
nginx
etag
"281477ab9f7eb60e6b7d1f61e45fe582"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
45105
expires
Sat, 05 Oct 2019 06:40:56 GMT
bloodtestforanalysisss489_1376274.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
28 KB
28 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/bloodtestforanalysisss489_1376274.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
95f0ba443cbab2ca6d72aa59c72eedb627345c3bd415d9c4d022d08dd61df8ee
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Wed, 20 Mar 2019 21:48:44 GMT
server
nginx
etag
"8c9e04782ba419465a52ccb8378f459c"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
28734
expires
Sat, 05 Oct 2019 06:40:56 GMT
talzennatalazoparib_1496086.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
14 KB
15 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/talzennatalazoparib_1496086.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
2a1624d75692bdf3b69455faad4e8d04557a26d3d8c6441a99eef350ec2ca48c
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Thu, 21 Mar 2019 03:52:14 GMT
server
nginx
etag
"57413adc9b504a7c8c647f92adb26c24"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
14602
expires
Sat, 05 Oct 2019 06:40:56 GMT
imfinzi_1215044.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
396 KB
396 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/imfinzi_1215044.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
397486cc51c9de9801c4edd9fb26b4ff81b25b770528ef43cd5ebebb6c541b13
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Wed, 20 Mar 2019 21:40:53 GMT
server
nginx
etag
"bcc532d51fe6cfece965d6933a3fb75f"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
405197
expires
Sat, 05 Oct 2019 06:40:56 GMT
supplementpillsbottlets_991666.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
188 KB
188 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/supplementpillsbottlets_991666.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
1680079026ea2e28d50b62db83178bdbee0839f530ac643f123aa78f19725c28
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Thu, 21 Mar 2019 01:55:51 GMT
server
nginx
etag
"6eb4aef7488248e4a25cf6bda86838c7"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
192499
expires
Sat, 05 Oct 2019 06:40:56 GMT
baxdelan_1245636.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
132 KB
133 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/baxdelan_1245636.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
3bfb4b4c34549039702c5c5e51ad79579ca9049ff0a6733cefcf6c54a157ec23
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Thu, 21 Mar 2019 02:01:18 GMT
server
nginx
etag
"e8f45f0a25e75bc347e3e397a3b216cc"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
135573
expires
Sat, 05 Oct 2019 06:40:56 GMT
blurredpostophospitalroom_1200787.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
129 KB
129 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/blurredpostophospitalroom_1200787.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
045f6ff8e99f41737a9712df79cc2d473194287623981689a1efe9384afd4a00
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Thu, 21 Mar 2019 02:11:29 GMT
server
nginx
etag
"decb997aad20cdb04ec26bd763061c1b"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
131962
expires
Sat, 05 Oct 2019 06:40:56 GMT
girlpatientg508857401_1498856.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
20 KB
21 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/girlpatientg508857401_1498856.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
6655dda7443b326bf955416e3c2c9ffb1cd0fd618a057129037b67a2a3cb0890
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Thu, 21 Mar 2019 02:10:46 GMT
server
nginx
etag
"fcdc2eb2a60cf6d5661049c96148f030"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
20724
expires
Sat, 05 Oct 2019 06:40:56 GMT
trintellixtakeda6916j_992245.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
47 KB
47 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/trintellixtakeda6916j_992245.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
cae869e477d18218e805e1fbc2260e7d3dd9601983b25430eb609def57f8a349
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Thu, 21 Mar 2019 01:46:53 GMT
server
nginx
etag
"4d76339ccaacb0d3076006cd329aea13"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
47908
expires
Sat, 05 Oct 2019 06:40:56 GMT
ezallor_capsule_artwork_contact-sheet_resized.jpg
www.thecardiologyadvisor.com/wp-content/uploads/sites/17/2019/07/
611 KB
612 KB
Image
General
Full URL
https://www.thecardiologyadvisor.com/wp-content/uploads/sites/17/2019/07/ezallor_capsule_artwork_contact-sheet_resized.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
2e497e5231e532fad481d8b7874822e1808d2ba6432a2f8436e57ccfdcdc2685
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Mon, 29 Jul 2019 07:11:15 GMT
server
nginx
etag
"429337dd1993d8a13e28c0a6834e6a8a"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
625396
expires
Sat, 05 Oct 2019 06:40:57 GMT
SYNCHRONY-cochlear-implant-systems.jpg
www.empr.com/wp-content/uploads/sites/7/2019/07/
15 KB
16 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2019/07/SYNCHRONY-cochlear-implant-systems.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
46ae0d1f4b96437615e4bf727595e12003e27746092a77ab69c6d3512142afc8
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Sun, 04 Aug 2019 07:11:37 GMT
server
nginx
etag
"912243172aa7fb2d79c9f15010341278"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
15861
expires
Sat, 05 Oct 2019 06:40:56 GMT
482253doctorlaptopcomputer_964351.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
31 KB
32 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/482253doctorlaptopcomputer_964351.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
d50a79836df0ebd32b0b0e885abd2b146a7bf523976656dc8c561ed8ea7163c5
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Wed, 20 Mar 2019 19:35:20 GMT
server
nginx
etag
"8d9af232e6e23b26ac923ab08bf2387d"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
32231
expires
Sat, 05 Oct 2019 06:40:56 GMT
retacritpfizer_1505798.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
25 KB
26 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/retacritpfizer_1505798.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
2e7c546d8aa4ea4e16bb14001faa63d27e0b72e2310e2befde2a69e2616d1150
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Wed, 20 Mar 2019 21:38:16 GMT
server
nginx
etag
"024842bb19fb42d1c3a3b0a6cd2eadbf"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
26048
expires
Sat, 05 Oct 2019 06:40:56 GMT
hedgehogg941863626_1526057.jpg
www.empr.com/wp-content/uploads/sites/7/2019/02/
31 KB
31 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2019/02/hedgehogg941863626_1526057.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
0fd9aa690754c17c3ca65594f8a39b39094e071a825d5bcd2852bb09ff883d6a
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Wed, 20 Mar 2019 09:12:51 GMT
server
nginx
etag
"0de3a1f593d389aa675aed55ba1820a4"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
31930
expires
Sat, 05 Oct 2019 06:40:56 GMT
breakthrough_1002211.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
168 KB
169 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/breakthrough_1002211.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
8c2303690ee0ee206f20c1f70c7b5eb29e1d592cebacb1cac0b3c7b3669e95ca
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Wed, 20 Mar 2019 21:42:13 GMT
server
nginx
etag
"45112d9354d777c4d33b6c67d062a807"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
172410
expires
Sat, 05 Oct 2019 06:40:56 GMT
depressionmddg728909107_1410912.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
14 KB
14 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/depressionmddg728909107_1410912.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
8ff24692e7395fae9138c4bb78c2bbb4d4923cae0d9f2720dee3a7e2d62d3a03
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:56 GMT
last-modified
Wed, 20 Mar 2019 21:42:15 GMT
server
nginx
etag
"223adb647bdda684b3b59babf32dd296"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
14347
expires
Sat, 05 Oct 2019 06:40:56 GMT
hospitalroomg536907565_1490839.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
29 KB
29 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/hospitalroomg536907565_1490839.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
a8a0e6b52ee335dc5282680c7a4d6aae56351925539dae786f4b8d32cdabe451
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Thu, 21 Mar 2019 03:46:37 GMT
server
nginx
etag
"ea42ecdc157f48c83d75569d2c4dc77c"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
29654
expires
Sat, 05 Oct 2019 06:40:57 GMT
imvexxy_1484185.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
17 KB
18 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/imvexxy_1484185.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
4ee3469c41e867b3ca0f3e2dd5f7373701b2401be742197b60adb914f0276573
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Wed, 20 Mar 2019 19:48:00 GMT
server
nginx
etag
"48f5f6470b63e31914e262c14eb4a9e3"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
17830
expires
Sat, 05 Oct 2019 06:40:57 GMT
painmanagementipad_1123350.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
222 KB
223 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/painmanagementipad_1123350.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
6003829935cc8575fbf4e925dace1c877be37ef8a64db4e4d36ba9cccb81ced8
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Wed, 20 Mar 2019 21:52:16 GMT
server
nginx
etag
"e10544aaa8142aad98c8f792023e6f75"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
227393
expires
Sat, 05 Oct 2019 06:40:57 GMT
manasleepns_975419.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
167 KB
168 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/manasleepns_975419.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
8a13016fab2d6fc9f1b512804ae42f585b20efd2d8cf59b9deae801bcb0509a4
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Thu, 21 Mar 2019 02:08:21 GMT
server
nginx
etag
"10a9b211e05a9bfc6a3ca54641b32b72"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
171173
expires
Sat, 05 Oct 2019 06:40:57 GMT
chronicidiopathicurticarias_1172801.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
144 KB
145 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/chronicidiopathicurticarias_1172801.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
992b8ea3c7b81f78c92cfe1ba96ac56f4f602c6428eadbd4522505b6cbdc2985
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Thu, 21 Mar 2019 00:04:14 GMT
server
nginx
etag
"92dea5a3b9a58f10ef2f568e71a44a1b"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
147659
expires
Sat, 05 Oct 2019 06:40:57 GMT
Tick_G_128600109.jpg
www.infectiousdiseaseadvisor.com/wp-content/uploads/sites/16/2019/06/
1 MB
1 MB
Image
General
Full URL
https://www.infectiousdiseaseadvisor.com/wp-content/uploads/sites/16/2019/06/Tick_G_128600109.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.1.34.120 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-1-34-120.compute-1.amazonaws.com
Software
nginx /
Resource Hash
364e86ec6ed159071ebd0ed63ee041968c529186719dc22e1cc4f39242132280
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Tue, 09 Jul 2019 07:15:46 GMT
server
nginx
etag
"cfde6a94b823d9d1976b7dede519f977"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
1289833
expires
Sat, 05 Oct 2019 06:40:57 GMT
FDA-logo-FI-1-1.png
www.empr.com/wp-content/uploads/sites/7/2019/04/
426 KB
427 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2019/04/FDA-logo-FI-1-1.png
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
92f43f03582b5fa6ab35f37ba18f5e9b532fe6105c262a7ad0879bd1b3a565c7
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Wed, 24 Apr 2019 07:11:37 GMT
server
nginx
etag
"ebd14b1e1b6d11a26972094f1799ed78"
x-frame-options
SAMEORIGIN
content-type
image/png
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
436575
expires
Sat, 05 Oct 2019 06:40:57 GMT
23andmelogo_1197939.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
44 KB
45 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/23andmelogo_1197939.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
28f256ee8a2014a400b83a1d0fc021e5a5f84b8d3c5e51ff86d8f9ccaca3c6c2
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Wed, 20 Mar 2019 19:48:14 GMT
server
nginx
etag
"2589dcb0cd927ff50e1eb301ad7051e2"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
45405
expires
Sat, 05 Oct 2019 06:40:57 GMT
gardasil9ns_1493571.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
27 KB
27 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/gardasil9ns_1493571.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
0200c19296d96ef2169886157ef011be3f0a92f5dd68acd12322422dedc8e2cc
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Thu, 21 Mar 2019 00:12:25 GMT
server
nginx
etag
"120dd5fde0f05ad39dbb2cd21d208df8"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
27767
expires
Sat, 05 Oct 2019 06:40:57 GMT
nasalsprayhandss655931212_1322132.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
14 KB
14 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/nasalsprayhandss655931212_1322132.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
13dc518c2c58ff68c8a35552bee7abe599c4ef1f103917fb8a0394a6c58f3d42
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Thu, 21 Mar 2019 01:59:49 GMT
server
nginx
etag
"a058988c1720ebc837f170a70885d6a3"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
14072
expires
Sat, 05 Oct 2019 06:40:57 GMT
mavyretpackage_1471497.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
18 KB
18 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/mavyretpackage_1471497.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
f7287232fe8ae205248d7e43f5d250c53143fd4cd92313ac6c1f702df2ffdd9c
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Thu, 21 Mar 2019 01:42:12 GMT
server
nginx
etag
"b6e645f1d003c46d2d337d808fb47dfb"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
18147
expires
Sat, 05 Oct 2019 06:40:57 GMT
angioedemalipss394597276_1170558.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
129 KB
129 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/angioedemalipss394597276_1170558.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
d0ba350f51daaad5b6aba1fe254ff69e7fb5a1093df1181351b5f177e3a1f6c8
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Wed, 20 Mar 2019 23:52:55 GMT
server
nginx
etag
"2b04f0fb16421861d24d79460712afce"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
131966
expires
Sat, 05 Oct 2019 06:40:57 GMT
adaceltdapvaccinesanofi_1523119.jpg
www.empr.com/wp-content/uploads/sites/7/2019/01/
18 KB
18 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2019/01/adaceltdapvaccinesanofi_1523119.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
3.225.154.29 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-225-154-29.compute-1.amazonaws.com
Software
nginx /
Resource Hash
f4f5a02002a24631ae4242e1de45bcf6d3c661b70eade3120ce2a1dc9459876b
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Thu, 05 Sep 2019 06:40:57 GMT
last-modified
Wed, 20 Mar 2019 09:08:51 GMT
server
nginx
etag
"869b89f11f74ec71e0f644c264866798"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
18496
expires
Sat, 05 Oct 2019 06:40:57 GMT
view
securepubads.g.doubleclick.net/pcs/ Frame 45FF
0
288 B
Fetch
General
Full URL
https://securepubads.g.doubleclick.net/pcs/view?xai=AKAOjstafsrw89xAr1SULU3OgtW8AFIlb7-P1kyx7T3_jGmidkpJz0jUlqTD2i3IbgC8Jsv6OirxEvM06HgpIRK2Pu2b5WCvwjl3CwyuuUggf4ZanJS2AEdXq_lPQKzo7ZHnFwxZoSzgjGTrfd9C1bzxcYnROzTOKK5nM624z7ER_jvo4oJwF8lMqZDb-Maecx_frNTW0I3zUBDoqOmwUFBagxkPYw8VcQFzguZukd1bs1PRKX_aenCrmJ7wxsLBRTGZw9pebOA7s326AcHoEsYQQxT9FZI&sai=AMfl-YST78OzqQ8AOoavY5sFrl9bQp3BfV5mmdfjyh9ZORO5CO0vdcZMIQLK4ScbYRY1ynutYGCY6YVsDEZhbwZr-Gv7qKKjPoIUc07zn3Uljw&sig=Cg0ArKJSzC_BVmAD0r1PEAE&adurl=
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
216.58.210.2 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra16s07-in-f2.1e100.net
Software
cafe /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

timing-allow-origin
*
date
Thu, 05 Sep 2019 06:40:56 GMT
x-content-type-options
nosniff
server
cafe
status
200
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
access-control-allow-origin
*
cache-control
private
content-type
image/gif
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
0
x-xss-protection
0
expires
Thu, 05 Sep 2019 06:40:56 GMT
window_focus.js
tpc.googlesyndication.com/pagead/js/r20190828/r20110914/client/ Frame 45FF
2 KB
1 KB
Script
General
Full URL
https://tpc.googlesyndication.com/pagead/js/r20190828/r20110914/client/window_focus.js
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:825::2001 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
6dd7e7ea596e944778e78ccd97a2e17837ef633d69cad2108842d4ddcb958b1c
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 30 Aug 2019 07:24:31 GMT
content-encoding
gzip
x-content-type-options
nosniff
age
515785
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
status
200
content-disposition
attachment; filename="f.txt"
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
1054
x-xss-protection
0
server
cafe
etag
18205873578609640656
vary
Accept-Encoding
content-type
text/javascript; charset=UTF-8
cache-control
public, max-age=1209600
timing-allow-origin
*
expires
Fri, 13 Sep 2019 07:24:31 GMT
osd_listener.js
www.googletagservices.com/activeview/js/current/ Frame 45FF
75 KB
28 KB
Script
General
Full URL
https://www.googletagservices.com/activeview/js/current/osd_listener.js?cache=r20110914
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:824::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
fa5aad043be6924981d5d8b2041376073fa1f630c77a1b327f153e56ab91d965
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:56 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
sffe
etag
"1567595695661868"
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
private, max-age=3000
accept-ranges
bytes
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43,39",quic=":443"; ma=2592000; v="46,43,39"
content-length
28589
x-xss-protection
0
expires
Thu, 05 Sep 2019 06:40:56 GMT
init-132dn9au2z77uqg0m5w.js
api.b2c.com/api/ Frame 45FF
12 KB
5 KB
Script
General
Full URL
https://api.b2c.com/api/init-132dn9au2z77uqg0m5w.js?AdUnitID_TopLevel=71146705&AdUnitID=21776212071&AdvertiserID=27496345&OrderID=415436905&LineItemID=5144421111&CreativeID=138278274851&CPN=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&sid=News
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:e914:8d8d:e7fd:f63e Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
972b4ec8e7b3f8ebf205921cd619ec7937af3f97654a8aadb03a5ab94b77595a

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:57 GMT
content-encoding
gzip
server
openresty
content-type
text/javascript
status
200
cache-control
no-cache, no-store, must-revalidate
expires
-1
15638570741095414737
tpc.googlesyndication.com/simgad/ Frame 45FF
30 KB
30 KB
Image
General
Full URL
https://tpc.googlesyndication.com/simgad/15638570741095414737
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:825::2001 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
892ff0b3166742d839aeb9027057d0bd3f0e9af48d70cbfa44f22952f9c1fcf0
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Wed, 28 Aug 2019 04:12:41 GMT
x-content-type-options
nosniff
age
700095
x-dns-prefetch-control
off
status
200
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
30632
x-xss-protection
0
last-modified
Wed, 07 Aug 2019 16:56:48 GMT
server
sffe
content-type
image/png
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
expires
Thu, 27 Aug 2020 04:12:41 GMT
ads
securepubads.g.doubleclick.net/gampad/
19 KB
6 KB
XHR
General
Full URL
https://securepubads.g.doubleclick.net/gampad/ads?gdfp_req=1&pvsid=58798823753697&correlator=759639680399096&output=ldjh&callback=googletag.impl.pubads.callbackProxy3&impl=fif&adsid=NT&eid=21064502&vrg=2019082701&guci=1.2.0.0.2.2.0.0&plat=1%3A32776%2C2%3A16809992%2C8%3A134250504&sc=1&sfv=1-0-35&ecs=20190905&iu=%2F5745%2Fmpr_us%2Fhome%2Fnews%2Fbox_1&sz=300x250%7C300x600&scp=pos%3Dbox_1%26lid%3D5144421111&eri=1&cust_params=pagetype%3Dpost%26sponsor%3D%26comp%3D%26author%3DSteve%2520Duffy%26postID%3D122761%26env%3Dlive%26sid%3DNews%26styleid%3D%26cat%3DMiscellaneous_Musculoskeletal_Disorders%252CMusculoskeletal_Disorders%26atype%3DMPR_Drug_News%26block%3Dmpr_basaglar042616%252CTest%26isnht%3Dfalse%26browser%3DChrome%252074%26amid%3D7ae510fe18e7431582eb749cfc8567497d75868fa53d079af4ef35f92eebbf33%26spr%3D448%26ssp%3D%26cpn%3Dpcp_md%252Cfp_md%252Cpcp_all%252Charvonitbg%252Cepclusalistb_jan2019%252Cepclusa_april_2019%26subid%3D0%26usrc%3Dhaymarket%26eid%3D4765f0213a10614f6c52b4556676d479ec4f181705feaedbccdcef78c850b74a%26LyticsSegments%3Dga_med_nomycme%252Cga_med_nht_false%252Cmycme_rheum_survey_audience%252C3_day_visitors_neuro_ca_empr%252Cblackfriday_notunknown%252Cactivity_5126_audience%252Cmycme_endofyearsale_noanonymous_nosdc%252Caudience_for_mlk_sale%252Cnot_unknown_5770%252Cmycme_activity_5762%252Cddw_opened_to_all%252Call%252Csmt_new%252Cly_reporting_from_email%252Cly_reporting_has_visited_web%252Cly_reporting_multi_session_visitor%252Cly_reporting_last_visit_within_day%252Cly_reporting_last_visit_within_week%252Cly_reporting_last_visit_within_month%252Cly_reporting_last_visit_within_3_months%252Cly_known_email%252Cly_repeat_visitor%252Cly_international_visitor%252Cly_uses_desktop%252Cly_from_email%252Cknown%252Call_time_visitors%252Cmycme_allergy_all_except_4797_completes%252Cmycme_hiv_all_except_4670_completes%252Cmycme_internal_med_all_except_4670_completes%252Cmycme_allergy_all_except_4744_completes%252Cmycme_psychiatry_all_except_4812_completes%252Cmycme_cardiology_all_except_cardiology_pas%252Cmycme_dermatology_all_except_4831_completes%252Cmycme_pediatrics_all_except_4354_completes%252Cmycme_acc_next_activity_promo_no_4523%252Cmycme_acc_next_activity_promo_no_4524%252Cmycme_acc_next_activity_promo_no_4525%252Cmycme_acc_next_activity_promo_no_4526%252Cmycme_acc_next_activity_promo_no_4593%252Cmycme_acc_next_activity_promo_no_4595%252Cmycme_acc_next_activity_promo_no_4710%252Cmycme_acc_next_activity_promo_no_4804%252Cmycme_acc_next_activity_promo_no_4834%252Cmycme_acc_next_activity_promo_no_4800%252Cmycme_acc_next_activity_promo_no_4792%252Cmycme_acc_next_activity_promo_no_4511%252Cmycme_acc_next_activity_promo_no_4529%252Cmycme_acc_next_activity_promo_no_4558%252Cmycme_acc_next_activity_promo_no_4634%252Cmycme_impact_next_activity_promo_no_4740%252Cmycme_impact_next_activity_promo_no_4757%252Cmycme_impact_next_activity_promo_no_4842%252Cmycme_impact_next_activity_promo_no_4816%252Cmycme_impact_next_activity_promo_no_4897%252Cmycme_impact_next_activity_promo_no_4727%252Cmycme_impact_next_activity_promo_no_4755%252Cmycme_impact_next_activity_promo_no_4791%252Cmycme_impact_next_activity_promo_no_47911%252Cmycme_impact_next_activity_promo_no_4826%252Cmycme_impact_next_activity_promo_no_4815%252Cce_excluding_mpr_print_subscribers%252Cce_excluding_ca_print_subscribers%252Cga_med_known%252Cmycme_homepage_ibs_town_wall_%252Cmycme_ddw_nash%252Cmycme_activity_5841_2%252Cmycme_pediatrics_activity_5591&cookie=ID%3Dd3ffe3dfdfd5d4bd%3AT%3D1567665656%3AS%3DALNI_MaAm-IjWDHfaassHCdFX4p4JvNhiw&cookie_enabled=1&bc=31&abxe=1&lmt=1567665656&dt=1567665656719&dlt=1567665654414&idt=208&frm=20&biw=1585&bih=1200&oid=3&adx=1053&ady=305&adk=204078694&uci=3&ifi=3&u_tz=120&u_his=2&u_h=1200&u_w=1600&u_ah=1200&u_aw=1600&u_cd=24&u_sd=1&flash=0&url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&dssz=79&icsg=152282377224192&mso=67108864&std=0&vis=1&dmc=8&scr_x=0&scr_y=0&psz=300x250&msz=300x250&blev=1&bisch=1&psts=Ci8I2d-oP-gB3bfCjoMEggIVsbmAD9G59iGBw_Yh8e3PNLfIz49R0QJlE1_4V-o3hA%2CCjAI98WGlRPoAaOOnJCDBIICFbG5gA_RufYhgcP2IfHtzzTnwNqPUdEClS48W5xUmUw&ga_vid=1629988481.1567665651&ga_sid=1567665656&ga_hid=927312587&fws=516&ohw=1585
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
216.58.210.2 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra16s07-in-f2.1e100.net
Software
cafe /
Resource Hash
bb608bfaf7b76546816de805fb8533c70cab8d228f56ece6cd6201175eedb0ff
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:56 GMT
content-encoding
br
x-content-type-options
nosniff
google-mediationgroup-id
-2
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
status
200
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
5461
x-xss-protection
0
google-lineitem-id
132783265
pragma
no-cache
server
cafe
google-mediationtag-id
-2
google-creative-id
116494027705
content-type
text/plain; charset=UTF-8
access-control-allow-origin
https://www.empr.com
cache-control
no-cache, must-revalidate
access-control-allow-credentials
true
timing-allow-origin
*
expires
Fri, 01 Jan 1990 00:00:00 GMT
truncated
/ Frame 45FF
217 B
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
0c562cce276bd9800e112331d4eaf2ab6bdbfcc4d67ff9de6f26b7f306edc414

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/png
report
ads.spotible.com/creative/bmMb/
43 B
191 B
Image
General
Full URL
https://ads.spotible.com/creative/bmMb/report?,1567665656,861001;UNIQUE_USER_GLOBAL!0,1,0;UNIQUE_USER_DAILY!0,1,0;UNIQUE_USER_HOURLY!0,1,0;IMPRESSION!0,1,0!2,1,0
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.197.62.58 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-34-197-62-58.compute-1.amazonaws.com
Software
/
Resource Hash
b1442e85b03bdcaf66dc58c7abb98745dd2687d86350be9a298a1d9382ac849b

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:57 GMT
Cache-Control
no-store
Connection
keep-alive
Content-Length
43
Content-Type
image/gif
view
securepubads.g.doubleclick.net/pcs/
0
67 B
Image
General
Full URL
https://securepubads.g.doubleclick.net/pcs/view?xai=AKAOjsurWluP11FO4thicAO-UzmoS_XhJHTWyq8CUlcNc99GyCpbqOVXWXCGrxQMMc0OSm_QXojQpU6xsUnxws9IwFNpDftBn9HD0spCkl4nVw--bPdsWQbwFOGdeAu8giLeTcy7KyFsYein85cfoJe74ULhQTf-QnLffNLbQfYQpyuIQYu8iLlGpukKwUWkaA3rJLT9soQJmW4Oxro-mRhDfKGYxBuOiLw_UtcVlIaDsyEqzPjkakIFSvELStBehmTAAFrLAyEmB1bpVNpBlPptXn_vRdcv_Y1JwemKrKFjvhjZX2jB2TzXzOWydJoHJQ&sai=AMfl-YRbifvGPZP7owoM-Y-ZHFaoK1EyS5Tq2Vn6lDTvq_dqNQNuF0AhxFNP1FNwgGs4jEWo4sIi8ujI1xZBcxUhu5s95mDZWSwXoIOEWvzj&sig=Cg0ArKJSzFSZo8DixIJwEAE&urlfix=1&adurl=
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
216.58.210.2 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra16s07-in-f2.1e100.net
Software
cafe /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

timing-allow-origin
*
date
Thu, 05 Sep 2019 06:40:57 GMT
x-content-type-options
nosniff
server
cafe
status
200
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
access-control-allow-origin
*
cache-control
private
content-type
image/gif
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
0
x-xss-protection
0
view
securepubads.g.doubleclick.net/pcs/ Frame 7ABA
0
67 B
Fetch
General
Full URL
https://securepubads.g.doubleclick.net/pcs/view?xai=AKAOjssZw4qbjnhrGnHl5kmoFButqZJRw-SiW23K2b8AdA_eOtAPjp8BDOlIRPE8KEFrFzKIB5fQ6GAXB1GxAw5kOGMEEdKrGzz5x5sl-6DeWsLhAG3U7upAgy4lhxa4s7snqChlHH6cQ3c1Jh-pk9dSx3rYW0345kblkiY3gEoAo52Jy5LVyYy9lRhTQNIE4ShGPEnF6n7givCQDz9xcYxXBkGtt2cVlfmO3Co3_V0Vorw5kaR7mmq850xeIfXgBlpQlze6epCOCOG3&sig=Cg0ArKJSzDd3wzYxlaouEAE&adurl=
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
216.58.210.2 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra16s07-in-f2.1e100.net
Software
cafe /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

timing-allow-origin
*
date
Thu, 05 Sep 2019 06:40:56 GMT
x-content-type-options
nosniff
server
cafe
status
200
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
access-control-allow-origin
*
cache-control
private
content-type
image/gif
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
0
x-xss-protection
0
window_focus.js
tpc.googlesyndication.com/pagead/js/r20190828/r20110914/client/ Frame 7ABA
2 KB
1 KB
Script
General
Full URL
https://tpc.googlesyndication.com/pagead/js/r20190828/r20110914/client/window_focus.js
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:825::2001 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
6dd7e7ea596e944778e78ccd97a2e17837ef633d69cad2108842d4ddcb958b1c
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 30 Aug 2019 07:24:31 GMT
content-encoding
gzip
x-content-type-options
nosniff
age
515786
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
status
200
content-disposition
attachment; filename="f.txt"
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
1054
x-xss-protection
0
server
cafe
etag
18205873578609640656
vary
Accept-Encoding
content-type
text/javascript; charset=UTF-8
cache-control
public, max-age=1209600
timing-allow-origin
*
expires
Fri, 13 Sep 2019 07:24:31 GMT
osd_listener.js
www.googletagservices.com/activeview/js/current/ Frame 7ABA
75 KB
28 KB
Script
General
Full URL
https://www.googletagservices.com/activeview/js/current/osd_listener.js?cache=r20110914
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:824::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
fa5aad043be6924981d5d8b2041376073fa1f630c77a1b327f153e56ab91d965
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:56 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
sffe
etag
"1567595695661868"
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
private, max-age=3000
accept-ranges
bytes
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43,39",quic=":443"; ma=2592000; v="46,43,39"
content-length
28589
x-xss-protection
0
expires
Thu, 05 Sep 2019 06:40:56 GMT
init-132dn9au2z77uqg0m5w.js
api.b2c.com/api/ Frame 7ABA
12 KB
5 KB
Script
General
Full URL
https://api.b2c.com/api/init-132dn9au2z77uqg0m5w.js?AdUnitID_TopLevel=71146705&AdUnitID=21776031401&AdvertiserID=27496345&OrderID=415436905&LineItemID=132783265&CreativeID=116494027705&CPN=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&sid=News
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:e914:8d8d:e7fd:f63e Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
5b582129b14659bc889ca240d18dd0a4246d500ed7276ab53b6e7f5417d92a23

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:57 GMT
content-encoding
gzip
server
openresty
content-type
text/javascript
status
200
cache-control
no-cache, no-store, must-revalidate
expires
-1
8299312168136675521
tpc.googlesyndication.com/simgad/ Frame 7ABA
90 KB
90 KB
Image
General
Full URL
https://tpc.googlesyndication.com/simgad/8299312168136675521
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:825::2001 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
e98ee80eff9057ec97269e5a00f640221bbdb5cbfbeebc82e09034cd36c32fb0
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Tue, 03 Sep 2019 23:35:10 GMT
x-content-type-options
nosniff
age
111946
x-dns-prefetch-control
off
status
200
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
92358
x-xss-protection
0
last-modified
Thu, 02 Feb 2017 14:20:51 GMT
server
sffe
content-type
image/jpeg
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
expires
Wed, 02 Sep 2020 23:35:10 GMT
ads
securepubads.g.doubleclick.net/gampad/
19 KB
6 KB
XHR
General
Full URL
https://securepubads.g.doubleclick.net/gampad/ads?gdfp_req=1&pvsid=58798823753697&correlator=759639680399096&output=ldjh&callback=googletag.impl.pubads.callbackProxy4&impl=fif&adsid=NT&eid=21064502&vrg=2019082701&guci=1.2.0.0.2.2.0.0&plat=1%3A32776%2C2%3A16809992%2C8%3A134250504&sc=1&sfv=1-0-35&ecs=20190905&iu=%2F5745%2Fmpr_us%2Fhome%2Fnews%2Fbox_2&sz=300x250&scp=pos%3Dbox_2%26lid%3D5144421111%2C132783265&eri=1&cust_params=pagetype%3Dpost%26sponsor%3D%26comp%3D%26author%3DSteve%2520Duffy%26postID%3D122761%26env%3Dlive%26sid%3DNews%26styleid%3D%26cat%3DMiscellaneous_Musculoskeletal_Disorders%252CMusculoskeletal_Disorders%26atype%3DMPR_Drug_News%26block%3Dmpr_basaglar042616%252CTest%26isnht%3Dfalse%26browser%3DChrome%252074%26amid%3D7ae510fe18e7431582eb749cfc8567497d75868fa53d079af4ef35f92eebbf33%26spr%3D448%26ssp%3D%26cpn%3Dpcp_md%252Cfp_md%252Cpcp_all%252Charvonitbg%252Cepclusalistb_jan2019%252Cepclusa_april_2019%26subid%3D0%26usrc%3Dhaymarket%26eid%3D4765f0213a10614f6c52b4556676d479ec4f181705feaedbccdcef78c850b74a%26LyticsSegments%3Dga_med_nomycme%252Cga_med_nht_false%252Cmycme_rheum_survey_audience%252C3_day_visitors_neuro_ca_empr%252Cblackfriday_notunknown%252Cactivity_5126_audience%252Cmycme_endofyearsale_noanonymous_nosdc%252Caudience_for_mlk_sale%252Cnot_unknown_5770%252Cmycme_activity_5762%252Cddw_opened_to_all%252Call%252Csmt_new%252Cly_reporting_from_email%252Cly_reporting_has_visited_web%252Cly_reporting_multi_session_visitor%252Cly_reporting_last_visit_within_day%252Cly_reporting_last_visit_within_week%252Cly_reporting_last_visit_within_month%252Cly_reporting_last_visit_within_3_months%252Cly_known_email%252Cly_repeat_visitor%252Cly_international_visitor%252Cly_uses_desktop%252Cly_from_email%252Cknown%252Call_time_visitors%252Cmycme_allergy_all_except_4797_completes%252Cmycme_hiv_all_except_4670_completes%252Cmycme_internal_med_all_except_4670_completes%252Cmycme_allergy_all_except_4744_completes%252Cmycme_psychiatry_all_except_4812_completes%252Cmycme_cardiology_all_except_cardiology_pas%252Cmycme_dermatology_all_except_4831_completes%252Cmycme_pediatrics_all_except_4354_completes%252Cmycme_acc_next_activity_promo_no_4523%252Cmycme_acc_next_activity_promo_no_4524%252Cmycme_acc_next_activity_promo_no_4525%252Cmycme_acc_next_activity_promo_no_4526%252Cmycme_acc_next_activity_promo_no_4593%252Cmycme_acc_next_activity_promo_no_4595%252Cmycme_acc_next_activity_promo_no_4710%252Cmycme_acc_next_activity_promo_no_4804%252Cmycme_acc_next_activity_promo_no_4834%252Cmycme_acc_next_activity_promo_no_4800%252Cmycme_acc_next_activity_promo_no_4792%252Cmycme_acc_next_activity_promo_no_4511%252Cmycme_acc_next_activity_promo_no_4529%252Cmycme_acc_next_activity_promo_no_4558%252Cmycme_acc_next_activity_promo_no_4634%252Cmycme_impact_next_activity_promo_no_4740%252Cmycme_impact_next_activity_promo_no_4757%252Cmycme_impact_next_activity_promo_no_4842%252Cmycme_impact_next_activity_promo_no_4816%252Cmycme_impact_next_activity_promo_no_4897%252Cmycme_impact_next_activity_promo_no_4727%252Cmycme_impact_next_activity_promo_no_4755%252Cmycme_impact_next_activity_promo_no_4791%252Cmycme_impact_next_activity_promo_no_47911%252Cmycme_impact_next_activity_promo_no_4826%252Cmycme_impact_next_activity_promo_no_4815%252Cce_excluding_mpr_print_subscribers%252Cce_excluding_ca_print_subscribers%252Cga_med_known%252Cmycme_homepage_ibs_town_wall_%252Cmycme_ddw_nash%252Cmycme_activity_5841_2%252Cmycme_pediatrics_activity_5591&cookie=ID%3Dd3ffe3dfdfd5d4bd%3AT%3D1567665656%3AS%3DALNI_MaAm-IjWDHfaassHCdFX4p4JvNhiw&cookie_enabled=1&bc=31&abxe=1&lmt=1567665656&dt=1567665656890&dlt=1567665654414&idt=208&frm=20&biw=1585&bih=1200&oid=3&adx=1053&ady=1176&adk=3917873969&uci=4&ifi=4&u_tz=120&u_his=2&u_h=1200&u_w=1600&u_ah=1200&u_aw=1600&u_cd=24&u_sd=1&flash=0&url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&dssz=79&icsg=152282377224192&mso=67108864&std=0&vis=1&dmc=8&scr_x=0&scr_y=0&psz=300x283&msz=300x250&blev=1&bisch=1&psts=Ci8IobmoP-gBuZfX_LEDggIVsbmAD9G59iGBw_Yh8e3PNKm9z49R0QIjpKQZUUnT8Q%2CCi8I2d-oP-gB3bfCjoMEggIVsbmAD9G59iGBw_Yh8e3PNLfIz49R0QJlE1_4V-o3hA%2CCjAI98WGlRPoAaOOnJCDBIICFbG5gA_RufYhgcP2IfHtzzTnwNqPUdEClS48W5xUmUw&ga_vid=1629988481.1567665651&ga_sid=1567665656&ga_hid=927312587&fws=516&ohw=1585
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
216.58.210.2 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra16s07-in-f2.1e100.net
Software
cafe /
Resource Hash
1623f1dc7a92d42de1ccd1e64962655cae56fbec01aaf244a652b496d0eb1fa8
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:57 GMT
content-encoding
br
x-content-type-options
nosniff
google-mediationgroup-id
-2
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
status
200
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
5639
x-xss-protection
0
google-lineitem-id
132783265
pragma
no-cache
server
cafe
google-mediationtag-id
-2
google-creative-id
116494043065
content-type
text/plain; charset=UTF-8
access-control-allow-origin
https://www.empr.com
cache-control
no-cache, must-revalidate
access-control-allow-credentials
true
timing-allow-origin
*
expires
Fri, 01 Jan 1990 00:00:00 GMT
truncated
/ Frame 7ABA
213 B
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
0abee5053b98cb54dc348eee6eb5c021b3ad5aaf331c0deadcde2a27aa4d8e4b

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/png
/
adtrackapi.haymarketmedia.com/adverttracking/
2 B
363 B
XHR
General
Full URL
https://adtrackapi.haymarketmedia.com/adverttracking/
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-adtracking-js/prod/adtracking.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:9000:20bb:5a00:16:bc48:4dc0:93a1 , United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
/
Resource Hash
44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-type
application/json

Response headers

date
Thu, 05 Sep 2019 06:40:57 GMT
via
1.1 7ff3248f5aef149847858a974cf62b00.cloudfront.net (CloudFront)
x-amz-cf-pop
FRA56
x-amzn-requestid
77337a57-aae3-4a81-b44a-f9b84d280ece
status
200
x-cache
Miss from cloudfront
content-type
application/json
access-control-allow-origin
*
x-amzn-trace-id
Root=1-5d70adf9-8acaf03429897910cf147c4e;Sampled=0
x-amz-apigw-id
fiAe_FncIAMF1qg=
content-length
2
x-amz-cf-id
2X6Ql03sq3TR0L5ZqKEzL1_8ee_bbUE8-YmKprA4EEy04AVThHp0RA==
view
securepubads.g.doubleclick.net/pcs/ Frame B52C
0
67 B
Fetch
General
Full URL
https://securepubads.g.doubleclick.net/pcs/view?xai=AKAOjsshMeFRAHxbB497GiiQC7KDZaz_16puvICoRQeJXe3xH4FTeVdEdnsFB1_IL0wjH1La2_IU-na9TsUMXmS1mzNFyBTV-DZkN7g3m3fkw-DDhQQN_AIVST_PT8lnzuqfH8G78LciUPu7eAt0JWUIXx2lx6wbAWvqvlabxYd2-O-NScVhofdGMIrbqs1sqd2O2z6ngA8tPeNXDV6_D_t_DfM2N7ncekJBagEtgwPhX5JVHeqWMjW6UcSEYAJ_gqQ3oNiomq7nvL_N&sig=Cg0ArKJSzLXInGypNbDKEAE&adurl=
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
216.58.210.2 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra16s07-in-f2.1e100.net
Software
cafe /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

timing-allow-origin
*
date
Thu, 05 Sep 2019 06:40:57 GMT
x-content-type-options
nosniff
server
cafe
status
200
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
access-control-allow-origin
*
cache-control
private
content-type
image/gif
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
0
x-xss-protection
0
window_focus.js
tpc.googlesyndication.com/pagead/js/r20190828/r20110914/client/ Frame B52C
2 KB
1 KB
Script
General
Full URL
https://tpc.googlesyndication.com/pagead/js/r20190828/r20110914/client/window_focus.js
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:825::2001 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
6dd7e7ea596e944778e78ccd97a2e17837ef633d69cad2108842d4ddcb958b1c
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 30 Aug 2019 07:24:31 GMT
content-encoding
gzip
x-content-type-options
nosniff
age
515786
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
status
200
content-disposition
attachment; filename="f.txt"
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
1054
x-xss-protection
0
server
cafe
etag
18205873578609640656
vary
Accept-Encoding
content-type
text/javascript; charset=UTF-8
cache-control
public, max-age=1209600
timing-allow-origin
*
expires
Fri, 13 Sep 2019 07:24:31 GMT
osd_listener.js
www.googletagservices.com/activeview/js/current/ Frame B52C
75 KB
28 KB
Script
General
Full URL
https://www.googletagservices.com/activeview/js/current/osd_listener.js?cache=r20110914
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:824::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
fa5aad043be6924981d5d8b2041376073fa1f630c77a1b327f153e56ab91d965
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 05 Sep 2019 06:40:57 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
sffe
etag
"1567595695661868"
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
private, max-age=3000
accept-ranges
bytes
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43,39",quic=":443"; ma=2592000; v="46,43,39"
content-length
28589
x-xss-protection
0
expires
Thu, 05 Sep 2019 06:40:57 GMT
l
www.google.com/ads/measurement/ Frame B52C
0
0
Image
General
Full URL
https://www.google.com/ads/measurement/l?ebcid=ALh7CaQy169_KgyoHQbxaBUGJqNh7xiT_c-yQ649JedCi7pNStreCA-6gtr0HYgmZxyavyYHAWsgf6hlKPbzyxPSiLd6X_gOag
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81c::2004 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
/
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

init-132dn9au2z77uqg0m5w.js
api.b2c.com/api/ Frame B52C
12 KB
5 KB
Script
General
Full URL
https://api.b2c.com/api/init-132dn9au2z77uqg0m5w.js?AdUnitID_TopLevel=71146705&AdUnitID=21776031404&AdvertiserID=27496345&OrderID=415436905&LineItemID=132783265&CreativeID=116494043065&CPN=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&sid=News
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:e914:8d8d:e7fd:f63e Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
4339beb536c6cc983ae8975879b02e10bcd4bf233306006bcc6c5d91750fb7f2

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:57 GMT
content-encoding
gzip
server
openresty
content-type
text/javascript
status
200
cache-control
no-cache, no-store, must-revalidate
expires
-1
17405305192067880125
tpc.googlesyndication.com/simgad/ Frame B52C
77 KB
77 KB
Image
General
Full URL
https://tpc.googlesyndication.com/simgad/17405305192067880125
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019082701.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:825::2001 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
8151ee77422a282f8c38e0cfd5ffdd7a3319ade37c8994d4007bf451c8dd6861
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 29 Aug 2019 02:26:11 GMT
x-content-type-options
nosniff
age
620086
x-dns-prefetch-control
off
status
200
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
79023
x-xss-protection
0
last-modified
Thu, 02 Feb 2017 14:43:31 GMT
server
sffe
content-type
image/jpeg
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
expires
Fri, 28 Aug 2020 02:26:11 GMT
truncated
/ Frame B52C
215 B
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
46b95476d9c70703dfc062fa578ae5c3c2845fd92cf421b9add675211ad223d3

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/png
/
adtrackapi.haymarketmedia.com/adverttracking/
2 B
365 B
XHR
General
Full URL
https://adtrackapi.haymarketmedia.com/adverttracking/
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-adtracking-js/prod/adtracking.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:9000:20bb:5a00:16:bc48:4dc0:93a1 , United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
/
Resource Hash
44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-type
application/json

Response headers

date
Thu, 05 Sep 2019 06:40:57 GMT
via
1.1 7ff3248f5aef149847858a974cf62b00.cloudfront.net (CloudFront)
x-amz-cf-pop
FRA56
x-amzn-requestid
9cd919f4-b839-4dd0-b86f-ad0dbaad428d
status
200
x-cache
Miss from cloudfront
content-type
application/json
access-control-allow-origin
*
x-amzn-trace-id
Root=1-5d70adf9-86735f5f64893b002d5d9490;Sampled=0
x-amz-apigw-id
fiAfCFoIoAMFQRA=
content-length
2
x-amz-cf-id
h4UEoWureFzG2lovzq5L9Hrk2pjuCev0KMkLPN6UnehnmG9STZc7TQ==
ad.gif
api-54-184-16-121.b2c.com/api/ Frame 45FF
43 B
233 B
Image
General
Full URL
https://api-54-184-16-121.b2c.com/api/ad.gif
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5802:ea78:47ca:ba3:8d5f Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:57 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Connection
keep-alive
Content-Length
43
Content-Type
image/gif
/
adtrackapi.haymarketmedia.com/adverttracking/
2 B
365 B
XHR
General
Full URL
https://adtrackapi.haymarketmedia.com/adverttracking/
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-adtracking-js/prod/adtracking.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:9000:20bb:5a00:16:bc48:4dc0:93a1 , United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
/
Resource Hash
44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-type
application/json

Response headers

date
Thu, 05 Sep 2019 06:40:58 GMT
via
1.1 7ff3248f5aef149847858a974cf62b00.cloudfront.net (CloudFront)
x-amz-cf-pop
FRA56
x-amzn-requestid
1677f228-87f8-4f88-957a-703c6ed659a8
status
200
x-cache
Miss from cloudfront
content-type
application/json
access-control-allow-origin
*
x-amzn-trace-id
Root=1-5d70adf9-00093b549fe9e3f8c8f16a30;Sampled=0
x-amz-apigw-id
fiAfDHoxoAMFiWA=
content-length
2
x-amz-cf-id
Ho9R1NlkZ4DCdImvUVVWIot0vZuVmfZdOuiLMIYTFOv38xkjjumz6w==
ad.gif
api-35-160-22-135.b2c.com/api/ Frame 7ABA
43 B
233 B
Image
General
Full URL
https://api-35-160-22-135.b2c.com/api/ad.gif
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:6019:4693:f458:2d4f Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:57 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Connection
keep-alive
Content-Length
43
Content-Type
image/gif
x
api-54-184-16-121.b2c.com/api/ Frame 45FF
0
382 B
XHR
General
Full URL
https://api-54-184-16-121.b2c.com/api/x?sEaYTw0KJW1qVIzS$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
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5802:ea78:47ca:ba3:8d5f Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:57 GMT
Server
openresty
Transfer-Encoding
chunked
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/plain
Access-Control-Allow-Origin
https://www.empr.com
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Expires
-1
4
api-54-184-16-121.b2c.com/api/ Frame 45FF
Redirect Chain
  • https://api-54-184-16-121.b2c.com/api/x?sEaYTw0KJW1qVIzS$bmF2aWdhdGlvbi10eXBlJDYkbmF2aWdhdGUiLCJnbG9iYWxzLXRpbWUkOSQwLjUzIiwiZ2xvYmFscyQxMCRhMzc1MjVhMyIsImRvY3VtZW50LXRpbWUkMTIkMC42NCIsImRvY3VtZW50...
  • https://api-54-184-16-121.b2c.com:444/api/4?sEaYTw0KJW1qVIzS
43 B
406 B
Other
General
Full URL
https://api-54-184-16-121.b2c.com:444/api/4?sEaYTw0KJW1qVIzS
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
54.184.16.121 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-54-184-16-121.us-west-2.compute.amazonaws.com
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:58 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
image/gif
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
43
Expires
-1

Redirect headers

Date
Thu, 05 Sep 2019 06:40:57 GMT
Server
openresty
Location
https://api-54-184-16-121.b2c.com:444/api/4?sEaYTw0KJW1qVIzS
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/html
Access-Control-Allow-Origin
https://www.empr.com
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
142
ad.gif
api-34-219-144-108.b2c.com/api/ Frame B52C
43 B
233 B
Image
General
Full URL
https://api-34-219-144-108.b2c.com/api/ad.gif
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:35b1:f17a:7da0:ec69 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:57 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Connection
keep-alive
Content-Length
43
Content-Type
image/gif
x
api-35-160-22-135.b2c.com/api/ Frame 7ABA
0
382 B
XHR
General
Full URL
https://api-35-160-22-135.b2c.com/api/x?gDQiv1XKhstcG1lx$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
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:6019:4693:f458:2d4f Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:58 GMT
Server
openresty
Transfer-Encoding
chunked
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/plain
Access-Control-Allow-Origin
https://www.empr.com
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Expires
-1
4
api-35-160-22-135.b2c.com/api/ Frame 7ABA
Redirect Chain
  • https://api-35-160-22-135.b2c.com/api/x?gDQiv1XKhstcG1lx$dGltZS1kb21JbnRlcmFjdGl2ZSQ1JDEiLCJ0aW1lLWRvbUNvbnRlbnRMb2FkZWRFdmVudFN0YXJ0JDUkMSIsInRpbWUtZG9tQ29udGVudExvYWRlZEV2ZW50RW5kJDUkMSIsInRpbWUt...
  • https://api-35-160-22-135.b2c.com:444/api/4?gDQiv1XKhstcG1lx
43 B
406 B
Other
General
Full URL
https://api-35-160-22-135.b2c.com:444/api/4?gDQiv1XKhstcG1lx
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
35.160.22.135 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-35-160-22-135.us-west-2.compute.amazonaws.com
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:58 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
image/gif
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
43
Expires
-1

Redirect headers

Date
Thu, 05 Sep 2019 06:40:58 GMT
Server
openresty
Location
https://api-35-160-22-135.b2c.com:444/api/4?gDQiv1XKhstcG1lx
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/html
Access-Control-Allow-Origin
https://www.empr.com
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
142
x
api-34-219-144-108.b2c.com/api/ Frame B52C
0
382 B
XHR
General
Full URL
https://api-34-219-144-108.b2c.com/api/x?ScvvlpZwtOqCJZY7$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
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:35b1:f17a:7da0:ec69 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:58 GMT
Server
openresty
Transfer-Encoding
chunked
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/plain
Access-Control-Allow-Origin
https://www.empr.com
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Expires
-1
4
api-34-219-144-108.b2c.com/api/ Frame B52C
Redirect Chain
  • https://api-34-219-144-108.b2c.com/api/x?ScvvlpZwtOqCJZY7$bmF2aWdhdGlvbi10eXBlJDIkbmF2aWdhdGUiLCJnbG9iYWxzLXRpbWUkNSQwLjQwNSIsImdsb2JhbHMkNSRhMzc1MjVhMyIsImRvY3VtZW50LXRpbWUkNyQwLjU2IiwiZG9jdW1lbnQ...
  • https://api-34-219-144-108.b2c.com:444/api/4?ScvvlpZwtOqCJZY7
43 B
406 B
Other
General
Full URL
https://api-34-219-144-108.b2c.com:444/api/4?ScvvlpZwtOqCJZY7
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.219.144.108 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-219-144-108.us-west-2.compute.amazonaws.com
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:58 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
image/gif
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
43
Expires
-1

Redirect headers

Date
Thu, 05 Sep 2019 06:40:58 GMT
Server
openresty
Location
https://api-34-219-144-108.b2c.com:444/api/4?ScvvlpZwtOqCJZY7
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/html
Access-Control-Allow-Origin
https://www.empr.com
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
142
activeview
pagead2.googlesyndication.com/pcs/ Frame 45FF
42 B
110 B
Image
General
Full URL
https://pagead2.googlesyndication.com/pcs/activeview?xai=AKAOjsvHQpDOh5USwJgcg5GRvXxv4IDKcPLgLD6sh7Jc9hlszQ57-ZcEw0Uxtv3IMFEvsSgod55WKNWKAEDveejbmAKDMbDSWOm06acImNL9Kww&sig=Cg0ArKJSzEecP6szx59yEAE&adk=2785330797&tt=-1&bs=1585%2C1200&mtos=1055,1055,1055,1055,1055&tos=1055,0,0,0,0&p=140,428.5,230,1156.5&mcvt=1055&rs=3&ht=0&tfs=964&tls=2019&mc=1&lte=1&bas=0&bac=0&met=0&avms=nio&niot_obs=885&niot_cbk=895&md=2&rst=1567665656714&rpt=36&isd=0&msd=0&lm=2&oseid=3&xdi=0&ps=1585%2C4110&ss=1600%2C1200&pt=-1&bin=1&deb=1-1-4-14-20-10-50-19-0-0-0&tvt=2015&r=v&id=osdim&vs=4&uc=11&upc=11&tgt=DIV&cl=1&cec=1&clc=1&cac=1&cd=728x90&itpl=3&v=20190904
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81b::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
ef1955ae757c8b966c83248350331bd3a30f658ced11f387f8ebf05ab3368629
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:57 GMT
x-content-type-options
nosniff
server
cafe
timing-allow-origin
*
status
200
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
access-control-allow-origin
*
cache-control
no-cache, must-revalidate
content-type
image/gif
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43,39",quic=":443"; ma=2592000; v="46,43,39"
content-length
42
x-xss-protection
0
expires
Fri, 01 Jan 1990 00:00:00 GMT
x
api-54-184-16-121.b2c.com/api/ Frame 45FF
0
382 B
Other
General
Full URL
https://api-54-184-16-121.b2c.com/api/x?sEaYTw0KJW1qVIzS$YWRibG9jayQ1NTYkMA
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5802:ea78:47ca:ba3:8d5f Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-Type
text/plain;charset=UTF-8

Response headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:57 GMT
Server
openresty
Transfer-Encoding
chunked
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/plain
Access-Control-Allow-Origin
https://www.empr.com
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Expires
-1
Cookie set rt=ifr
bcp.crwdcntrl.net/5/c=14413/rand=231707015/pv=y/ver=1.4/int=%23OpR%2396858%23Total%20Site%20Traffic%20%3A%20www.empr.com/int=%23OpR%2396859%23www.empr.com%20%3A%20Site%20Section%20%3A%20home/int=%2... Frame 6598
0
0
Document
General
Full URL
https://bcp.crwdcntrl.net/5/c=14413/rand=231707015/pv=y/ver=1.4/int=%23OpR%2396858%23Total%20Site%20Traffic%20%3A%20www.empr.com/int=%23OpR%2396859%23www.empr.com%20%3A%20Site%20Section%20%3A%20home/int=%23OpR%2396860%23www.empr.com%20%3A%20Site%20Section%20%3A%20home%20%20%3A%20news/int=%23OpR%2397492%23www.empr.com%20%3A%20Site%20Section%20%3A%20home%20%3A%20news%20%3A%20ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/med=%23OpR%2397539%23Article%20Tags%20%3A%20Miscellaneous%20Musculoskeletal%20Disorders%2CMusculoskeletal%20Disorders/rb=%7B%22url%22%3A%22https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653%22%7D/rt=ifr
Requested by
Host: tags.crwdcntrl.net
URL: https://tags.crwdcntrl.net/c/14413/cc.js?ver=1.4&ns=_cc14413
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
18.200.54.67 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-18-200-54-67.eu-west-1.compute.amazonaws.com
Software
/
Resource Hash

Request headers

Host
bcp.crwdcntrl.net
Connection
keep-alive
Pragma
no-cache
Cache-Control
no-cache
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
Sec-Fetch-Site
cross-site
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Accept-Encoding
gzip, deflate, br
Cookie
_cc_dc=1; _cc_id=ee7a9d3aee48e1c6fe2428dd33d051d0; _cc_cc="ACZ4nGNQSE01T7RMMU5MTTWxSDVMNktLNTIxskhJMTZOMTA1TDFgAILYgrU%2Fnvz%2F%2F5%2BfAQ4A3eEP0g%3D%3D"; _cc_aud="ABR4nGNgYGCILVj7gwEOAB2cAnM%3D"
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653

Response headers

Access-Control-Allow-Origin
*
Cache-Control
no-cache
Content-Encoding
gzip
Content-Type
text/html;charset=UTF-8
Date
Thu, 05 Sep 2019 06:40:58 GMT
Expires
0
P3P
CP=NOI DSP COR NID PSAa PSDa OUR UNI COM NAV
Pragma
no-cache
Set-Cookie
_cc_id=ee7a9d3aee48e1c6fe2428dd33d051d0;Path=/;Domain=crwdcntrl.net;Expires=Mon, 01-Jun-2020 06:06:00 GMT;SameSite=None _cc_cc="ACZ4nGNQSE01T7RMMU5MTTWxSDVMNktLNTIxskhJMTZOMTA1TDFgAILYgrW%2FHv3%2F%2F5%2BfAQZ4r89sUWQ8W8Dwn5GRoXc6gv1wzRY4%2B9RkhPjjmZvh7Okn1GHMB1N7GGHsj58tYczLz%2B%2FIwtiHF89hgbEvILEvnXrEBmPvX34Urh4A0uRI4Q%3D%3D";Version=1;Path=/;Domain=crwdcntrl.net;Expires=Mon, 01-Jun-2020 06:06:00 GMT;Max-Age=23328000;SameSite=None _cc_aud="ABR4nGNgYGCILVj7iwEGmBg4rtSCGBy3DwFJAFdsBXU%3D";Version=1;Path=/;Domain=crwdcntrl.net;Expires=Mon, 01-Jun-2020 06:06:00 GMT;Max-Age=23328000;SameSite=None
Vary
Accept-Encoding
X-Server
10.45.7.191
Content-Length
720
Connection
keep-alive
cs.js
sb.scorecardresearch.com/c2/21948019/
0
400 B
Script
General
Full URL
https://sb.scorecardresearch.com/c2/21948019/cs.js
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtm.js?id=GTM-5XFK9V6
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
23.5.97.37 , Netherlands, ASN16625 (AKAMAI-AS - Akamai Technologies, Inc., US),
Reverse DNS
a23-5-97-37.deploy.static.akamaitechnologies.com
Software
/
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:58 GMT
Content-Encoding
gzip
Last-Modified
Fri, 08 Apr 2011 23:11:26 GMT
ETag
"d41d8cd98f00b204e9800998ecf8427e:1349196464"
Vary
Accept-Encoding
Content-Type
application/x-javascript
Cache-Control
private, no-transform, max-age=259200
Connection
keep-alive
Content-Length
20
Expires
Sun, 08 Sep 2019 06:40:58 GMT
init-121b5si20pnxjymcwdz.js
api.b2c.com/api/
12 KB
5 KB
Script
General
Full URL
https://api.b2c.com/api/init-121b5si20pnxjymcwdz.js?isNHT=false
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:e914:8d8d:e7fd:f63e Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
2664112cbae00caff1a76a45586c82f9f83450297c45736d7d05e79e060d04e9

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:58 GMT
content-encoding
gzip
server
openresty
content-type
text/javascript
status
200
cache-control
no-cache, no-store, must-revalidate
expires
-1
up
insight.adsrvr.org/track/ Frame 77BF
0
0
Document
General
Full URL
https://insight.adsrvr.org/track/up?adv=wxli9bh&ref=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&upid=7fhq4wn&upv=1.1.0
Requested by
Host: js.adsrvr.org
URL: https://js.adsrvr.org/up_loader.1.1.0.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
54.194.184.41 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-54-194-184-41.eu-west-1.compute.amazonaws.com
Software
/
Resource Hash

Request headers

:method
GET
:authority
insight.adsrvr.org
:scheme
https
:path
/track/up?adv=wxli9bh&ref=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&upid=7fhq4wn&upv=1.1.0
pragma
no-cache
cache-control
no-cache
upgrade-insecure-requests
1
user-agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
sec-fetch-mode
nested-navigate
accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
sec-fetch-site
cross-site
referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
accept-encoding
gzip, deflate, br
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653

Response headers

status
200
date
Thu, 05 Sep 2019 06:40:58 GMT
content-type
text/html
cache-control
private,no-cache, must-revalidate
pragma
no-cache
x-aspnet-version
4.0.30319
p3p
CP="NOI DSP COR CUR ADMo DEVo PSAo PSDo OUR SAMo BUS UNI NAV"
ga-audiences
www.google.de/ads/
Redirect Chain
  • https://www.google-analytics.com/r/collect?v=1&_v=j79&a=927312587&t=event&ni=1&_s=1&dl=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-sp...
  • https://stats.g.doubleclick.net/r/collect?v=1&aip=1&t=dc&_r=3&tid=UA-1290429-2&cid=1629988481.1567665651&jid=1401154439&_gid=1250147468.1567665658&gjid=1015605570&_v=j79&z=688796880
  • https://www.google.com/ads/ga-audiences?v=1&aip=1&t=sr&_r=4&tid=UA-1290429-2&cid=1629988481.1567665651&jid=1401154439&_v=j79&z=688796880
  • https://www.google.de/ads/ga-audiences?v=1&aip=1&t=sr&_r=4&tid=UA-1290429-2&cid=1629988481.1567665651&jid=1401154439&_v=j79&z=688796880&slf_rd=1&random=1803167192
42 B
109 B
Image
General
Full URL
https://www.google.de/ads/ga-audiences?v=1&aip=1&t=sr&_r=4&tid=UA-1290429-2&cid=1629988481.1567665651&jid=1401154439&_v=j79&z=688796880&slf_rd=1&random=1803167192
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81e::2003 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
ef1955ae757c8b966c83248350331bd3a30f658ced11f387f8ebf05ab3368629
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:58 GMT
x-content-type-options
nosniff
server
cafe
timing-allow-origin
*
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
status
200
cache-control
no-cache, no-store, must-revalidate
content-type
image/gif
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
42
x-xss-protection
0
expires
Fri, 01 Jan 1990 00:00:00 GMT

Redirect headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:58 GMT
x-content-type-options
nosniff
server
cafe
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
status
302
content-type
text/html; charset=UTF-8
location
https://www.google.de/ads/ga-audiences?v=1&aip=1&t=sr&_r=4&tid=UA-1290429-2&cid=1629988481.1567665651&jid=1401154439&_v=j79&z=688796880&slf_rd=1&random=1803167192
cache-control
no-cache, no-store, must-revalidate
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
0
x-xss-protection
0
expires
Fri, 01 Jan 1990 00:00:00 GMT
collect
www.google-analytics.com/
35 B
109 B
Image
General
Full URL
https://www.google-analytics.com/collect?v=1&_v=j79&a=927312587&t=event&ni=1&_s=1&dl=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-dailydose-hay-20190905%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-66409-2303653&ul=en-us&de=UTF-8&dt=Ixekizumab%20Gains%20FDA%20Approval%20for%20Treatment%20of%20Active%20Ankylosing%20Spondylitis&sd=24-bit&sr=1600x1200&vp=1585x1200&je=0&ec=Scroll%20Depth&ea=%2Fhome%2Fnews%2Fixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis%2F&el=25%25&ev=25&_u=aCjAAAAjQ~&jid=&gjid=&cid=1629988481.1567665651&tid=UA-1290429-2&_gid=1250147468.1567665658&gtm=2wg8l25XFK9V6&z=1643566434
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81a::200e Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
Golfe2 /
Resource Hash
8337212354871836e6763a41e615916c89bac5b3f1f0adf60ba43c7c806e1015
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 29 Aug 2019 04:25:33 GMT
x-content-type-options
nosniff
last-modified
Sun, 17 May 1998 03:00:00 GMT
server
Golfe2
age
612925
status
200
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
alt-svc
quic=":443"; ma=2592000; v="46,43,39"
content-length
35
expires
Mon, 01 Jan 1990 00:00:00 GMT
activeview
pagead2.googlesyndication.com/pcs/ Frame 7ABA
42 B
110 B
Image
General
Full URL
https://pagead2.googlesyndication.com/pcs/activeview?xai=AKAOjssGGrTSWOnN2n3wKJ2IGZ_jBZSedmeCxl99wC46bC47dAxOpbOpq3RceXIBTw3OMHrbZeZe3bg2_MutGCzsm3QnZrTG8iCajyfn1nqMeyo&sig=Cg0ArKJSzL76d40qmphdEAE&adk=204078694&tt=-1&bs=1585%2C1200&mtos=1057,1057,1057,1057,1057&tos=1057,0,0,0,0&p=305,1052.5,905,1352.5&mcvt=1057&rs=3&ht=0&tfs=1170&tls=2227&mc=1&lte=1&bas=0&bac=0&met=0&avms=nio&niot_obs=1056&niot_cbk=1069&md=2&rst=1567665656885&rpt=36&isd=0&msd=0&lm=2&oseid=3&xdi=0&ps=1585%2C4110&ss=1600%2C1200&pt=-1&bin=1&deb=1-1-4-15-22-10-60-21-0-0-0&tvt=2220&r=v&id=osdim&vs=4&uc=11&upc=11&tgt=DIV&cl=1&cec=1&clc=1&cac=1&cd=300x600&itpl=3&v=20190904
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81b::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
ef1955ae757c8b966c83248350331bd3a30f658ced11f387f8ebf05ab3368629
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Thu, 05 Sep 2019 06:40:58 GMT
x-content-type-options
nosniff
server
cafe
timing-allow-origin
*
status
200
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
access-control-allow-origin
*
cache-control
no-cache, must-revalidate
content-type
image/gif
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43,39",quic=":443"; ma=2592000; v="46,43,39"
content-length
42
x-xss-protection
0
expires
Fri, 01 Jan 1990 00:00:00 GMT
x
api-35-160-22-135.b2c.com/api/ Frame 7ABA
0
382 B
Other
General
Full URL
https://api-35-160-22-135.b2c.com/api/x?gDQiv1XKhstcG1lx$YWRibG9jayQ1NTQkMA
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:6019:4693:f458:2d4f Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-Type
text/plain;charset=UTF-8

Response headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:58 GMT
Server
openresty
Transfer-Encoding
chunked
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/plain
Access-Control-Allow-Origin
https://www.empr.com
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Expires
-1
x
api-34-219-144-108.b2c.com/api/ Frame B52C
0
382 B
Other
General
Full URL
https://api-34-219-144-108.b2c.com/api/x?ScvvlpZwtOqCJZY7$YWRibG9jayQ1NDkkMA
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:35b1:f17a:7da0:ec69 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-Type
text/plain;charset=UTF-8

Response headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:58 GMT
Server
openresty
Transfer-Encoding
chunked
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/plain
Access-Control-Allow-Origin
https://www.empr.com
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Expires
-1
ad.gif
api-35-160-22-135.b2c.com/api/
43 B
233 B
Image
General
Full URL
https://api-35-160-22-135.b2c.com/api/ad.gif
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:6019:4693:f458:2d4f Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:40:58 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Connection
keep-alive
Content-Length
43
Content-Type
image/gif
x
api-35-160-22-135.b2c.com/api/
0
382 B
XHR
General
Full URL
https://api-35-160-22-135.b2c.com/api/x?sPGeg3fTMwdLiuIi$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
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:6019:4693:f458:2d4f Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:58 GMT
Server
openresty
Transfer-Encoding
chunked
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/plain
Access-Control-Allow-Origin
https://www.empr.com
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Expires
-1
4
api-35-160-22-135.b2c.com/api/
Redirect Chain
  • https://api-35-160-22-135.b2c.com/api/x?sPGeg3fTMwdLiuIi$dGltZS1kb21haW5Mb29rdXBFbmQkNyQyNTAiLCJ0aW1lLWNvbm5lY3RTdGFydCQ3JDI1MCIsInRpbWUtY29ubmVjdEVuZCQ3JDI1MCIsInRpbWUtcmVxdWVzdFN0YXJ0JDckMjUxIiwi...
  • https://api-35-160-22-135.b2c.com:444/api/4?sPGeg3fTMwdLiuIi
43 B
406 B
Other
General
Full URL
https://api-35-160-22-135.b2c.com:444/api/4?sPGeg3fTMwdLiuIi
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
35.160.22.135 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-35-160-22-135.us-west-2.compute.amazonaws.com
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Thu, 05 Sep 2019 06:40:58 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
image/gif
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
43
Expires
-1

Redirect headers

Date
Thu, 05 Sep 2019 06:40:58 GMT
Server
openresty
Location
https://api-35-160-22-135.b2c.com:444/api/4?sPGeg3fTMwdLiuIi
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/html
Access-Control-Allow-Origin
https://www.empr.com
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
142
close_button2.png
cdn1.spotible.com/hashed/74483a4bff0849849588dbf32a396fe9/
1 KB
2 KB
Image
General
Full URL
https://cdn1.spotible.com/hashed/74483a4bff0849849588dbf32a396fe9/close_button2.png
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
143.204.214.75 Seattle, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
server-143-204-214-75.fra53.r.cloudfront.net
Software
/
Resource Hash
f42e34b205a7c2ac4a0997e0b1eb2627e76ee8ae15ac7a15b05954827e186dd9

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Thu, 09 May 2019 21:30:55 GMT
via
1.1 e0064d0a2437e206ed082e1fa1cdae61.cloudfront.net (CloudFront)
age
511036
etag
"74483a4bff0849849588dbf32a396fe9"
x-cache
Hit from cloudfront
status
200
cache-control
public, max-age=604800
x-amz-cf-pop
FRA53-C1
accept-ranges
bytes
content-length
1429
x-amz-cf-id
86hDkZAean2x4dHYNRYG8o1OnRh-QOia5zMhkPYDF-2vnJ8R47juNw==
report
ads.spotible.com/creative/bmMb/
43 B
191 B
Image
General
Full URL
https://ads.spotible.com/creative/bmMb/report?,1567665656,861003;IMPRESSION!4,1,0!5,1,0
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.197.62.58 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-34-197-62-58.compute-1.amazonaws.com
Software
/
Resource Hash
b1442e85b03bdcaf66dc58c7abb98745dd2687d86350be9a298a1d9382ac849b

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/ixekizumab-gains-fda-approval-for-treatment-of-active-ankylosing-spondylitis/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-dailydose-hay-20190905&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-66409-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 05 Sep 2019 06:41:00 GMT
Cache-Control
no-store
Connection
keep-alive
Content-Length
43
Content-Type
image/gif

Failed requests

These URLs were requested, but there was no response received. You will also see them in the list above.

Domain
tpc.googlesyndication.com
URL
https://tpc.googlesyndication.com/safeframe/1-0-35/html/container.html

Verdicts & Comments Add Verdict or Comment

199 JavaScript Global Variables

These are the non-standard "global" variables defined on the window object. These can be helpful in identifying possible client-side frameworks and code.

number| pamEnabled object| hmAds object| dataLayer object| $ function| jQuery function| cookie object| _cc14413 object| LOTCC object| Digest function| UtilityMove object| core object| __core-js_shared__ object| global object| System function| asap function| Observable function| setImmediate function| clearImmediate object| regeneratorRuntime boolean| _babelPolyfill object| googletag object| ggeac object| closure_memoize_cache_ object| googleToken object| googleIMState object| google_js_reporting_queue function| processGoogleToken string| adTrackProxyPath string| advertTrackingApiUrl boolean| trackImpressionsViewable object| clickedAd boolean| isOverIFrame object| dfpRequests function| waitFor function| DataLayerExist function| AdSlotsRegistered function| TrackPassbackImpression function| TrackImpression function| TrackImpressionViewable function| AdClick function| checkDuplicateImpression function| callApi function| AmazonWebService function| createAdTrackingMessage function| getAJAXObject function| trackAdvert function| xdTrackAdvert function| getRenderedAd function| EventType function| getPageDetails function| getPageName function| getSection1 function| getPageType function| getDevice function| getValueFromTargets function| getPageTypeId function| getBrowser function| getUser function| getDfpTimestamp function| getCookies function| getTimeStamp function| ProcessMouseOut function| ProcessMouseOver function| processIFrameClick function| getDfpUrlFor function| getDfpUrls function| logAdvertRequested object| dataLayerService function| hmHeaderLoginState object| dfpAdSlots object| mapping object| adSlotsConfig object| allowedSlots string| hmHomeUrl string| hmAccountUrl object| hmRegisteredAds boolean| hmAdsLazyload number| hmAdsActiveRefresh boolean| hmAdsCommentsHouse boolean| hmDmdAimEnabled boolean| hmProclivityEnabled boolean| hmAdsActiveRefreshAll boolean| hmAdsBoxReposition boolean| hmAdsLytics object| adSlots number| adDebug object| hmProclivity string| cpn object| haymarketCustomEvents object| google_tag_manager string| GoogleAnalyticsObject function| ga object| _atrk_opts function| fbq function| _fbq function| retry function| isIE10OrLater function| detectPrivateMode string| redirect undefined| google_measure_js_timing boolean| google_DisableInitialLoad boolean| google_noFetch number| __google_ad_urls_id object| epas function| maropostInitTracking string| name_funnel function| _132350 string| name_funnel1 function| _13235 object| data object| ids object| epasAPI object| hm_localize object| hm_gated object| date function| isStorageSupported function| truncateItem function| storeData function| removeData function| retrieveData function| readStorage function| getExpiration object| google_tag_data object| gaplugins object| gaGlobal object| gaData object| CE2 string| __INDIVIDUAL_ONE_VERSION_ev-store_ENFORCE_SINGLETON undefined| __INDIVIDUAL_ONE_VERSION_ev-store object| TenUp object| liosetup object| jstag object| hmAuthNoncePromise function| disqus_config object| hmRegisterPrompt function| hmSetLyticsData function| atrk boolean| _atrk_fired object| ns_ object| adblockDetector object| pageVars object| wp function| hmOpenRegisterPrompt function| webpackJsonp function| __jstag_onload undefined| initObj string| ly_cid object| AIM object| _ml object| google_optimize string| set_domain function| domain_name function| deleteMaroClickScriptTag function| maroRecordClick function| anchor_event_add function| maroRecordTime function| maroTrackInit object| _0x2ea7 function| _0x5ec9 object| lio function| ttd_dom_ready function| TTDUniversalPixelApi function| HMIRegistration object| ssoLogin object| ssoRegister object| optimizely object| pathfora number| google_unique_id object| google_reactive_ads_global_state function| Goog_AdSense_getAdAdapterInstance function| Goog_AdSense_OsdAdapter object| __google_ad_urls object| ampInaboxIframes object| ampInaboxPendingMessages boolean| google_osd_loaded boolean| google_onload_fired function| Goog_Osd_UnloadAdBlock function| Goog_Osd_UpdateElementToMeasure function| google_osd_amcb object| prontoTags object| ProntoCE object| ProntoDOMEvents object| gtm string| string1 string| string2 string| string3 string| string4 string| string5 string| string6 string| string7 string| string8 string| string9 string| string10 number| lySegmentCounter string| result string| key function| checkForCPNSegments function| logit function| __$PP

11 Cookies

Domain/Path Name / Value
www.empr.com/ Name: PathforaTest_fbcdd6902623329bbdbacbed41b3575a
Value: 0.06983389282952723
www.empr.com/ Name: PathforaTest_845520b7c2ad6c7b2d753bf3b76b1546
Value: 0.9278776968891429
www.empr.com/ Name: PathforaTest_d32aacecfe87458780ba0a5b22e84019
Value: 0.02686167959284269
www.empr.com/ Name: PathforaTest_2c3134d8bbcf5fc7ef88d4f188d3d27a
Value: 0.952145967228853
www.empr.com/ Name: PathforaTest_eba13817e4cda2f9087c77f4803500dc
Value: 0.19503254627593924
www.empr.com/ Name: PathforaTest_16c648a7e9a8e384a49983317da2418c
Value: 0.695359391744756
www.empr.com/ Name: PathforaTest_c835c8fce5cb8c9ae765bcc82e287892
Value: 0.6444252667858894
.empr.com/ Name: __gads
Value: ID=d3ffe3dfdfd5d4bd:T=1567665656:S=ALNI_MaAm-IjWDHfaassHCdFX4p4JvNhiw
www.empr.com/ Name: PathforaTest_354ff931e1d1ba292afc8446d8447661
Value: 0.356921566133358
www.empr.com/ Name: PathforaTest_853e3ee5e01881b83ab49fe8c2eae359
Value: 0.7332704129541265
www.empr.com/ Name: PathforaTest_00a2fe23f73e4b2dcdcaba9058b0c8da
Value: 0.025856817102182017

78 Console Messages

Source Level URL
Text
console-api log URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=1.4.1(Line 2)
Message:
JQMIGRATE: Migrate is installed, version 1.4.1
console-api log URL: https://s3.amazonaws.com/haymarket-adtracking-js/prod/adtracking.js(Line 540)
Message:
interactive
console-api log (Line 2)
Message:
DMD AIM data:{}
console-api log URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/iab.min.js?ver=1567085297(Line 1)
Message:
[ABD] start beginTest
console-api log URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/iab.min.js?ver=1567085297(Line 1)
Message:
[ABD] adding bait node to DOM
console-api log URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/iab.min.js?ver=1567085297(Line 1)
Message:
[ABD] start beginTest
console-api log URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/iab.min.js?ver=1567085297(Line 1)
Message:
[ABD] adding bait node to DOM
console-api log (Line 8)
Message:
logit -ga_med_nomycme
console-api log (Line 8)
Message:
logit -ga_med_nht_false
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_rheum_survey_audience)
console-api log (Line 6)
Message:
checkForCPNSegments(3_day_visitors_neuro_ca_empr)
console-api log (Line 6)
Message:
checkForCPNSegments(blackfriday_notunknown)
console-api log (Line 6)
Message:
checkForCPNSegments(activity_5126_audience)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_endofyearsale_noanonymous_nosdc)
console-api log (Line 6)
Message:
checkForCPNSegments(audience_for_mlk_sale)
console-api log (Line 6)
Message:
checkForCPNSegments(not_unknown_5770)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_activity_5762)
console-api log (Line 6)
Message:
checkForCPNSegments(ddw_opened_to_all)
console-api log (Line 8)
Message:
logit -all
console-api log (Line 6)
Message:
checkForCPNSegments(all)
console-api log (Line 6)
Message:
checkForCPNSegments(smt_new)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_from_email)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_has_visited_web)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_multi_session_visitor)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_last_visit_within_day)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_last_visit_within_week)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_last_visit_within_month)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_last_visit_within_3_months)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_known_email)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_repeat_visitor)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_international_visitor)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_uses_desktop)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_from_email)
console-api log (Line 6)
Message:
checkForCPNSegments(known)
console-api log (Line 6)
Message:
checkForCPNSegments(all_time_visitors)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_allergy_all_except_4797_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_hiv_all_except_4670_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_internal_med_all_except_4670_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_allergy_all_except_4744_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_psychiatry_all_except_4812_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_cardiology_all_except_cardiology_pas)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_dermatology_all_except_4831_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_pediatrics_all_except_4354_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4523)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4524)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4525)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4526)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4593)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4595)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4710)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4804)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4834)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4800)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4792)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4511)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4529)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4558)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4634)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4740)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4757)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4842)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4816)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4897)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4727)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4755)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4791)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_47911)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4826)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4815)
console-api log (Line 6)
Message:
checkForCPNSegments(ce_excluding_mpr_print_subscribers)
console-api log (Line 6)
Message:
checkForCPNSegments(ce_excluding_ca_print_subscribers)
console-api log (Line 8)
Message:
logit -ga_med_known
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_homepage_ibs_town_wall_)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_ddw_nash)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_activity_5841_2)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_pediatrics_activity_5591)
console-api log (Line 5)
Message:
OK
console-api log URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/iab.min.js?ver=1567085297(Line 1)
Message:
[ABD] exiting test loop - value: false

Indicators

This is a term in the security industry to describe indicators such as IPs, Domains, Hashes, etc. This does not imply that any of these indicate malicious activity.

1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
accounts.haymarketmedia.com
ads.spotible.com
adservice.google.com
adservice.google.de
adtrackapi.haymarketmedia.com
api-34-219-144-108.b2c.com
api-35-160-22-135.b2c.com
api-54-184-16-121.b2c.com
api.b2c.com
api.lytics.io
bcp.crwdcntrl.net
c.lytics.io
cdn1.spotible.com
certify.alexametrics.com
connect.facebook.net
content.maropost.com
d31qbv1cthcecs.cloudfront.net
fonts.googleapis.com
fonts.gstatic.com
idsync.rlcdn.com
in.ml314.com
insight.adsrvr.org
js.adsrvr.org
link.email.empr.com
match.deepintent.com
ml314.com
mpct1.maropost.com
mt.sitomobile.com
pagead2.googlesyndication.com
pixel.mathtag.com
pixel.tapad.com
ps.eyeota.net
s3.amazonaws.com
sb.scorecardresearch.com
script.crazyegg.com
securepubads.g.doubleclick.net
sp.sitomobile.com
stats.g.doubleclick.net
subapi.haymarketmedia.com
sync.crwdcntrl.net
tags.bluekai.com
tags.crwdcntrl.net
tpc.googlesyndication.com
www.empr.com
www.facebook.com
www.google-analytics.com
www.google.com
www.google.de
www.googletagmanager.com
www.googletagservices.com
www.infectiousdiseaseadvisor.com
www.medtargetsystem.com
www.thecardiologyadvisor.com
tpc.googlesyndication.com
104.111.241.32
13.32.158.202
13.32.220.210
13.35.253.105
143.204.214.75
18.185.83.216
18.200.54.67
2.18.233.201
216.58.210.2
23.5.97.37
2600:1f14:e96:5800:35b1:f17a:7da0:ec69
2600:1f14:e96:5800:6019:4693:f458:2d4f
2600:1f14:e96:5800:e914:8d8d:e7fd:f63e
2600:1f14:e96:5802:ea78:47ca:ba3:8d5f
2600:9000:2057:aa00:1b:fadc:b780:93a1
2600:9000:20bb:5a00:16:bc48:4dc0:93a1
2606:4700:20::6819:5465
2606:4700::6813:9308
2a00:1450:4001:80b::200a
2a00:1450:4001:819::2008
2a00:1450:4001:81a::200e
2a00:1450:4001:81b::2002
2a00:1450:4001:81c::2004
2a00:1450:4001:81d::2003
2a00:1450:4001:81e::2003
2a00:1450:4001:824::2002
2a00:1450:4001:825::2001
2a00:1450:400c:c04::9d
2a03:2880:f01c:8012:face:b00c:0:3
2a03:2880:f11c:8083:face:b00c:0:25de
3.225.154.29
34.192.84.248
34.197.62.58
34.219.144.108
34.225.65.223
34.247.144.106
35.160.22.135
35.172.78.117
35.190.72.21
35.227.192.113
35.227.248.159
35.238.92.4
52.1.34.120
52.206.48.92
52.215.211.56
52.217.38.6
52.3.171.116
52.71.111.112
54.184.16.121
54.194.184.41
54.208.174.93
93.184.220.113
94.31.29.64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